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ABBREVIATIONS 
ADAM    a disintegrin and metalloprotease 
AP-1    activator protein 1 
Apaf-1    apoptotic protease activating factor-1 
AR    adrenergic receptor 
ASK    apoptosis signal-regulated kinase 
ATF    activating transcription factor 
Bcl2    B-cell follicular lymphoma 
BMK    big MAPK 
BSA    bovine serum albumin 
CalDAG-GEF calcium- and diacylglycerol-regulated guanine-
nucleotide exchange factor 
CaM    calmodulin 
CaMK    Ca2+/calmodulin-dependent kinase 
cAMP    cyclic AMP 
Cdc42    cell division cycle 42 
Crk    Cas-related kinase 
COS-7    Cercopithecus aethiops (monkey, African green) 
Csk    C-terminal Src kinase 
DAG    diacylglycerol 
ddH2O    bidestilled H2O 
DEPC    diethylpyrocarbonate 
ECL    enhanced chemiluminescence 
EDTA    ethylenediaminetetraacetic acid 
EF    helixE- and helixF-containing Ca2+ -binding protein 
EGFR    epidermal growth factor receptor 
EGTA ethylene glycol bis(2-aminoethylether)- N, N, N', N' -
tetraacetic acid 
ERK    extracellular signal-regulated kinase 
FADD    Fas-associated protein with death domain 
FAK    focal adhesion kinase 
FasL    Fas (APO1/CD95) ligand 
FSH    follicle stimulating hormone 
GAP    GTPase-activating protein 
GEF    guanine nucleotide exchange factor 
GFP    green fluorescent protein 
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GPCR    G protein-coupled receptor;  
Graf GTPase regulator associated with focal adhesion 
kinase 
Grb2    growth factor receptor-bound protein 2 
GRP    gastrin-releasing peptide 
GDP, GTP   guanosine-5` biphosphate, -triphosphate 
GST    glutathion-S-transferase 
HB-EGF   heparin-binding epidermal growth factor 
HEK    human embryonic kidney 
IGFR    insulin-like growth factor receptor 
IP3    inositol-1, 4, 5-trisphosphate 
IPTG    isopropyl-1-thio-ß-D-galactoside 
IQ motif   ilimaquinone motif 
IRS    insulin receptor substrate 
JNK/SAPK   c-jun N-terminal kinase/stress-activated kinase 
LH    luteinizing hormone 
LPA    lysophosphatidic acid 
M1R, M2R   muscarinic acetylcholine receptor 
MAPK    mitogen-activated protein kinase 
MAPKAPK   MAPK-activated protein kinase 
MEF    myocyte enhancer factor 
MEK    MAPK/ERK kinase 
MEKK    MEK kinase 
MLK    mixed lineage kinase 
MMP    matrix metalloproteinase 
Mnk    MAPK-interacting kinase 
Msk    mitogen- and stress-activated protein kinase 
MT-MMP   membrane type-MMP 
NF-κB    nuclear factor-κB 
Nir    Pyk2 N-terminal domain-interacting receptor 
p70S6K    p70 S6 kinase  
p130Cas   p130 Crk-associated substrate 
PAK    p21-activated kinase 
PBS    phosphate-buffered saline 
Pap    Pyk2 C-terminus associated protein 
PC12    pheochromocytoma cells 
PCR    polymerase chain reaction 
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PDGFR   platelet-derived growth factor receptor 
PI3K    phosphatidylinositol 3- kinase 
PIP2    phosphatidylinositol 4, 5-bisphosphate 
PLC    phospholipase C 
PKC    protein kinase C 
PKD    protein kinase D 
PKN    protein kinase N 
PMSF    phenylmethylsulphonyl fluoride 
POD    peroxidase 
Pyk2    proline-rich tyrosine kinase 
PSGAP   PH and SH3 domain containing GAP 
Rac    regulator of actin cytoskeleton 
Rap    Ras p21 protein 
RasGRF   Ras guanine nucleotide-releasing factor 
RasGRP   Ras guanine nucleotide-releasing protein 
Rb    retinoblastoma protein 
RBD    Ras-binding domain 
RGS    regulator of G protein signaling 
ROK    Rho-associated coiled-coil-forming protein kinase 
Rsk    p90 ribosomal S6 kinase 
RTK    receptor tyrosine kinase 
RT-PCR   reverse transcription-polymerase chain reaction 
SCLC    small cell lung cancer 
SDS    sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate - polyacrylamide gel electropho-
resis 
SH2 and SH3   Src homology domain 
Shc    SH2 domain-containing α2-collagen-related 
Sos    son-of-Sevenless 
Src    Retrovirus-associated DNA sequences 
Sprk Src homology 3 domain-containing proline-rich kinase/ 
MLK3 
TACE tumor necrosis factor α−converting enzyme 
TAK    TGFβ-activated kinase 
TAO    thousand-and-one amino acid protein kinase 
TBST    Tris base-buffered saline + Tween 20 
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TC21    R-Ras2 
TCF    ternary complex factor 
TEMED   N, N, N´, N´, -tetramethylethylenediamine 
TGFα    transforming growth factor alpha 
TIMP    tissue inhibitor of matrix metalloproteinase 
TMPS    triple membrane passing signal mechanism 
TNF    tumor necrosis factor 
TRADD   TNF receptor-associated protein with death domain 
TRAIL    TNF-related apoptosis inducing ligand 
TRP    transient receptor potential 
VGCC    voltage-gated calcium channel 
Vm    membrane potential 
VSMC    vascular smooth muscle cells 
wt    wild type 
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1. INTRODUCTION  
No cell lives in isolation. In all multicellular organisms, survival depends on an 
elaborate intercellular communication network that coordinates growth, differentiation 
and apoptosis of cells in diverse tissues and organs. Intercellular communication is 
accomplished by extracellular signaling molecules interacting with the cell by cell 
surface receptors. Binding of extracellular signaling molecules to cell surface 
receptors triggers intracellular pathways that ultimately modulate cellular 
development, differentiation, growth or metabolism. The multitude of cell surface 
receptors fall into four main classes:  Ligand-gated ion channels, receptors linked to 
cytosolic tyrosine kinases, receptor tyrosine kinases (RTKs) harboring intrinsic 
catalytic activity and G protein-coupled receptors (GPCRs) (Gether 1998, Ji 1998, 
Strader 1994).  
 
1.1. Signaling pathways emanating from G protein-coupled receptors 
(GPCRs) 
GPCRs constitute a family of receptors that mediate most of the cell-cell 
communication in humans and are encoded by the largest gene family in most 
animal genomes (Marinissen 2001, Neves 2002). This large receptor family includes 
light-activated receptors (rhodopsins) in the eye and odorant receptors in the 
mammalian nose, numerous receptors for various hormones, neurotransmitters as 
well as paracrine and autocrine factors (Gudermann 2000, Mombaerts 1999). All 
GPCRs contain seven transmembrane-spanning regions with their N-terminal 
segment on the exoplasmatic and their C-terminal segment on the cytosolic face of 
the plasma membrane. Although these receptors are activated by different ligands 
and may mediate different cellular responses, they all utilize similar signaling 
pathways.  
GPCRs signal by activating heterotrimeric signal transducing guanine nucleotide-
binding proteins (G proteins). Ligand binding to GPCRs activates a G protein, which 
then activates an effector enzyme to generate an intracellular second messenger. 
Trimeric G proteins are composed of three subunits, called α, β and γ. The α chain 
(Gα) binds and hydrolyzes GTP whereas the β and γ chains form a tight complex 
(Gβγ) tethering the α subunit to the plasma membrane. When stimulated by binding to 
a ligand-occupied receptor, Gα exchanges its GDP for GTP causing its dissociation 
from Gβγ . Both the GTP-bound α subunit as well as the βγ complex are capable of 
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transmitting messages to downstream targets. The GTPase cycle is completed when 
GTP is hydrolyzed to GDP by intrinsic GTPase activity of Gα (Neer 1995). The 
activating process is terminated when Gα-GDP reassociates with the βγ complex. 
GTPase activity of Gα is enhanced on the one hand by its target proteins, such as 
phospholipase Cβ (PLCβ), or on the other hand by regulator of G protein signaling 
(RGS) proteins. RGS proteins act as GTPase-activating proteins (GAPs). The 
activated receptor serves as a guanine nucleotide exchange factor (GEF) for the G 
protein by promoting GDP dissociation (Ishii 2003).  
GPCR signaling pathways have a wide spectrum of functions including regulation of 
cell proliferation and differentiation, promotion of cell survival and modulation of 
cellular metabolism (Gudermann 2000). Four distinct subfamilies of heterotrimeric G 
proteins are recognized todate: Gαq/11, Gαs, Gαi, Gα12/13 (Neves 2002, Fig. 1). 
Receptor stimulation of Gαq/11 proteins results in activation of PLCβ thereby 
generating two second messengers, diacylglycerol (DAG) and inositol- 1, 4, 5-tris-
phosphate (IP3), which activate protein kinase C (PKC) and elevate intracellular 
calcium concentrations ([Ca2+]i), respectively (Clapham 1995, Divecha 1995). The 
latter signaling molecules are central players coupling Gq/11 proteins to the extra-
cellular signal-regulated kinase (ERK) cascade (Grosse 2000b, Marais 1998, Wittau 
2000). Gαs proteins stimulate adenylyl cyclase resulting in increased concentrations 
of cyclic AMP (cAMP) (Houslay 1997, Hurley 1999). Activation of Gi proteins 
regulates cellular effects through both α and βγ subunits. Gαi couples to inhibition of 
adenylyl clyclase whereas Gβγ, e. g. is involved in activation of G protein-coupled 
inwardly rectifying potassium channels, adenylyl cyclase, PLC isoforms or phosphati-
dylinositol 3-kinase γ (PI3Kγ) (Camps 1992, Logothetis 1987, Stephens 1994, Tang 
1991). G12 and G13 proteins activate the monomeric GTPase Rho via GEFs. 
G12 activity leads to the induction of stress fibers and modulation of Na+/H+ 
exchanger. Activity of G13 results in actin cytoskeletal changes, modulation of Na+/H+ 
exchanger as well as activation of protein kinase D (PKD) and PI3K isoforms 
(DerMardirossian 2001).  
The termination of receptor function is achieved in a process called receptor desensi-
tization. It is usually controlled by receptor phosphorylation mediated by second-
messenger kinases, such as PKA or PKC, or by a distinct family of GPCR kinases 
(GRKs). “Heterologous” desensitization is realized by second messenger kinases 
and results in phosphorylation and desensitization of receptors which are not 
occupied by agonists (Zamah 2002). “Homologous” receptor desensitization is 
mediated by the GRK/β-arrestin (β-arr) system. Receptor phosphorylation by GRKs 
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leads to binding of β-arrestin proteins to the intracellular face of the receptor. 
β-Arrestin binding results in G protein-uncoupling of GPCRs by sterically hindering 
receptor/G protein interactions and mediates targeting of the GPCR for endocytosis 
in clathrin-coated pits. Several GPCRs internalize as a stable complex with β-arrestin 
and the stability of this complex appears to regulate whether the receptors are 
dephosphorylated in early endosomes and recycled back to the cell surface as fully 
functional receptors, retained in early endosomes or targeted for degradation in 
lysosomes (Seachrist 2003). 
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Figure 1. Mitogenic signal transduction emanating from G protein-coupled receptors. 
After agonist binding, GPCRs couple to their cognate G proteins. The mitogenic input is then 
transmitted via a plethora of different signaling cascades. The dashed line represents a 
putative relationship. β2-AR, β2-adrenergic receptor; CaM, calmodulin; CaMK, Ca2+/ cal-
modulin-dependent kinase; cAMP-GEF, cAMP-activated guanine nucleotide exchange factor; 
Crk, Cas-related kinase; EGFR, epidermal growth factor receptor; ERK, extracellular signal-
regulated kinase; FAK, focal adhesion kinase; GALR, galanin receptor; GnRHR, gonado-
tropin-releasing hormone receptor; Grb2, growth factor receptor-bound protein 2; LPAR, 
lysophosphatidic acid receptor; M1R, M2R, muscarinic acetylcholine receptor; MEK, mitogen-
activated protein kinase/ERK kinase; p130Cas, p130 Crk-associated substrate; PDGFR, 
platelet-derived growth factor receptor; PKA, protein kinase A; PKN, protein kinase N; Pyk2, 
proline-rich tyrosine kinase 2; Rap1, Ras p21 protein 1; RasGRF, Ras guanine nucleotide-
releasing factor; RasGRP, Ras guanine nucleotide-releasing protein; ROK, Rho-associated 
coiled-coil-forming protein kinase; RTK, receptor tyrosine kinase; Shc, SH2 domain-
containing α2-collagen-related; Sos, Son-of-sevenless, Src, Retrovirus-associated DNA 
sequences. 
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1.2. Mitogenic signaling by Gq/11-coupled receptors 
GPCRs transduce mitogenic signals by engaging the ERK cascade. p42 ERK 
(ERK1) and p44 ERK (ERK2) belong to the superfamily of mitogen-activated protein 
kinases (MAPKs) (Pearson 2001, Fig. 2). MAPKs are a family of serine/threonine 
kinases, which become activated in response to mitogens, growth factors, cellular 
stress and neurotoxic factors (Chen 2001). So far, four highly conserved MAPK 
subfamilies are known: ERKs, c-Jun N-terminal kinase/stress-activated kinase 
(JNK/SAPK), p38 mitogen-activated protein kinase (p38MAPK) and big MAPK 
(BMK1/ERK5) (Chen 2001). GPCRs activate MAPK cascades by a variety of 
mechanisms (Gudermann 2000, Marinissen 2001, Pearson 2001). An intensive 
cross-talk between different classes of receptors, e. g. GPCRs and receptor tyrosine 
kinases (RTKs), such as platelet-derived growth factor receptor (PDGFR), epidermal 
growth factor receptor (EGFR) or c-kit, contributes to an even wider range of cellular 
responses (Daub 1996, Herrlich 1998, Imokawa 2000). MAPKs are activated via a 
highly conserved kinase module consisting of three kinases (MEKK/MEK/MAPK, Fig. 
2) which sucessively phosphorylate and activate the downstream component 
(Pearson 2001). In addition to agonists acting on GPCRs, ERK1 and ERK2 are 
predominantly activated by growth factors, such as epidermal growth factor (EGF) or 
platelet derived growth factor (PDGF). Activation of ERK1 and ERK2 by ligand-bound 
EGFR has been the best studied MAPK signaling cascade so far (Gudermann 2000). 
The EGFR family of receptor tyrosine kinases is ubiquitously expressed and consists 
of four members: EGFR/ErB1, HER2/ErB2, HER3/ErB3 and HER4/ErB4 (Ullrich 
1984). Being activated by their six structurally related agonists- EGF, tumor growth 
factor α (TGFα), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin, 
betacellulin and epiregulin- the receptors promote pathways entailing proliferation 
and transformation. Activated EGFRs homo- or heterodimerize and subsequently 
autophosphorylation of cytoplasmic tyrosine residues is initiated. These 
phosphorylated amino acids represent docking sites for a variety of different proteins 
(Prenzel 2001). Phosphorylated EGFR recruits adaptor proteins like Shc and Grb2 
which become associated with the RasGEF Sos thus leading to GTP-loading of the 
small G protein Ras. The MEKK Raf is recruited to the plasma membrane by 
activated Ras and subsequently activates MEK eliciting p42 and p44 phosphorylation 
(Fig. 2). Activated ERKs target a diverse pool of proteins: they translocate to the 
nucleus activating transcription factors of the activator protein-1 (AP-1) family; 
phosphorylate a subset of protein kinases, e.g. Rsks, Mnks, Msks, MAPKAPKs, 
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which then activate downstream targets involved in transcriptional regulation or 
associate with cytoskeletal proteins (Pearson 2001, Reszka 1995, Shaulian 2002). 
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Figure 2. MAP kinase cascades.  
MAPK cascades are composed of a a three-step module consisting of three conserved 
kinases which sucessively phosphorylate the downstream kinase. The protein located 
upstream of MEKK2/3 leading to BMK1/ERK5 activation has not been identified so far. ASK, 
apoptosis signal-regulated kinase; ATF, activating transcription factor; Bcl2, B-cell follicular 
lymphoma; BMK1, big MAPK; Cdc42, cell division cycle 42; EGF, epidermal growth factor; 
ERK, extracellular signal-regulated kinase; IRS1, insulin receptor substrate; MAPK, mitogen-
activated protein kinase; MAPKAPK, MAPK-activated protein kinase; MEK, MAPK/ERK 
kinase; MEF, myocyte enhancer factor; MEKK, MEK kinase; Mnk, MAPK-interacting kinase; 
Msk, mitogen- and stress-activated protein kinase; PAK, p21-activated kinase; Rac, regulator 
of actin cytoskeleton; Sprk, Src homology 3 domain-containing proline-rich kinase/MLK3; Rsk, 
p90 ribosomal S6 kinase; TAK, TGFβ-activated kinase; TAO, thousand-and-one amino acid 
protein kinase; TCF, ternary complex factor. 
 
JNKs and p38MAPKs modulate cellular responses to a wide variety of extracellular 
stimuli including mitogens, inflammatory cytokines and stress stimuli (Chen 2001). In 
contrast to its ability to activate the ERK cascade, Ras only minimally affects JNK. 
However, overexpression of the constitutively activated mutants of the small G 
proteins, Rac and Cdc42, leads to robust stimulation of JNK activity (Coso 1995). 
The pathways leading to JNK activation mirror those seen for ERK with a variety of 
MEKs phosphorylating the various JNK isoforms (Pearson 2001, Fig. 2). As with 
ERKs, the end result of JNK activation is phosphorylation of certain transcription 
factors within their activation domains (Pearson 2001).  
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Increased BMK1 activity can be observed in response to growth factors and serum 
as well as stress stimuli (Chen 2001).  
As mentioned above, agonist stimulation of Gq/11-coupled receptors leads to 
activation of PLCβ isoforms (Rebecchi 2000). All four mammalian PLCβ isoenzymes 
are activated by Gq/11 proteins to various degrees. Under the control of the receptor, 
PLCβ hydrolyzes the membrane lipid phosphatidylinositol 4, 5-bisphosphate (PIP2) 
thereby generating two second messengers: diacylglycerol (DAG) and inositol- 1, 4, 
5-trisphosphate (IP3). DAG and IP3 stimulate distinct downstream signaling pathways.  
DAG remains associated with the plasma membrane where it directly activates 
PKCs, a family of serine/threonine kinases contributing essentially to growth control 
and differentiation (Divecha 1995). Even though PKC isotypes are considered key 
enzymes linking Gq/11-coupled receptors to activation of the Raf/MEK/ERK cascade, 
reports concerning PKC downstream events are still rather inconsistent. ERK 
activation by agonists acting on α1B adrenergic- and M1 muscarinic receptors 
proceeds by a pathway employing PKCα or PKCε, respectively, and Raf-1 - with 
PKCα and PKCε directly phosphorylating and activating Raf-1 (Hawes 1995, Kolch 
1993). Nevertheless, it was demonstrated that activation of PKC leads to activation of 
Ras and formation of Ras/Raf-1 complexes. Since a dominant-negative Ras mutant 
did not block Raf-1 activation, a distinct mechanism of Ras activation from that 
engaged by RTKs may exist (Marais 1998). Furthermore, Gq/11-mediated ERK 
activation can be achieved exploiting PKC activation or EGFR transactivation in 
parallel pathways (Adomeit 1999). It has been reported that neither Ca2+-release nor 
PKC activation are sufficient to induce ERK activation mediated by α1A adrenergic 
receptor activation in adrenal pheochromocytoma (PC12) cells (Berts 1999). 
On the contrary to DAG, IP3 diffuses into the cytoplasm regulating increases of 
[Ca2+]i. Rises in [Ca2+]i are realized by releasing Ca2+ from intracellular stores or by 
influx of extracellular Ca2+ through Ca2+-channels (Berridge 2000). Intracellular Ca2+-
binding proteins, such as calmodulin (CaM), act as calcium sensors decoding the 
information according to distinct increases in [Ca2+]i (Agell 2002).  
In this context, Ca2+-dependent proline-rich tyrosine kinase Pyk2 has been identified 
as an intermediate in Ca2+-regulated ERK activation. After complex formation with 
Src tyrosine kinases, the Pyk2/Src complex recruits the Grb2/Sos complex to the 
plasma membrane causing GTP-loading of Ras and subsequent engagement of the 
ERK/MAPK cascade (Dikic 1996, Lev 1995, Yu 1996). A more direct connection 
between Ca2+ and ERK activation is provided by two families of Ca2+-dependent 
RasGEFs, RasGRF and RasGRP, which can be differentiated by their cellular control 
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mechanisms (Cullen 2002, Table 1). Members of the RasGRF family are highly 
expressed in neurons. RasGRF proteins are IQ motif-containing GEFs with their 
activity being enhanced following binding of Ca2+-bound CaM. RasGRF1 is activated 
indirectly through CaM binding to its IQ motif whereas Ca2+ might exert an additional 
stimulatory effect on a closely related exchange factor RasGRF2. A dominant-
negative form of RasGRF1, GRFβ, is expressed in pancreatic β cells and seems to 
antagonize Ca2+-dependent signaling of RasGRF1. RasGRP/CalDAG-GEF proteins 
contain a calcium binding EF hand and a DAG binding site and are indeed activated 
following direct binding of Ca2+ and DAG. CalDAG-GEF I prefers Rap1a over N-Ras 
and a splice variant of the same exchange factor, RasGRP2, is inhibited rather than 
stimulated by Ca2+ when functioning as a RasGEF. The production of DAG is the key 
factor of the spatio-temporal regulation of RasGRP3 and RaGRP4 whereas elevation 
of [Ca2+]i does not affect the exchange activities of these GEFs (Arava 1999, Cullen 
2002, Ebinu 1998, Fam 1997, Farnsworth 1995). The net effect of Ca2+ on Ras/ERK 
signaling is not only determined by GEF activities but also by Ca2+-dependent 
deactivation utilizing GAPs. The two known directly Ca2+-triggered RasGAPs are 
calcium-promoted Ras inactivator (CAPRI) and a related protein, Ras GTPase-
activating-like (RASAL), preferentially expressed in endocrine tissue (Walker 2003). 
Furthermore, Ca2+-induced ERK/MAPK activation can be achieved via EGFR 
transactivation.  
Table 1. Ca2+-regulated Ras exchange factors. 
Name Modulator Effectors/effects 
Tissue 
expression 
RasGRF1 
Ca2+ ↑, 
Ca2+/CaM 
H-Ras, R-Ras, Rac1 
ERK/MAPK activation 
neurons,  
pancreatic β 
cells 
RasGRF2 
Ca2+ ↑, 
Ca2+/CaM 
H-Ras, Rac1 
ERK/MAPK activation ubiquitous 
mouse GRFβ  
dominant-negative regulator 
of RasGRF1 in β cells 
pancreatic β 
cells  
RasGRP/CalDAG-GEF II Ca2+ ↑, DAG↑↑ H-Ras, R-Ras forebrain 
CalDAG-GEF I Ca2+ ↑, DAG ↑ Rap1a forebrain 
RasGRP2 (splice variant 
of CalDAG-GEF I) Ca2+ ↑, DAG ↑ N-Ras, K-Ras brain 
RasGRP3/CalDAG-GEF III DAG ↑ 
H-Ras, R-Ras, TC21, M-
Ras, Rap1a, Rap2a 
ERK/MAPK activation 
glial cells of 
the brain, 
kidney  
RasGRP4 DAG ↑ H-Ras 
blood 
leukocytes, 
myeloid cell 
lines 
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1.2.1. Ca2+-mediated activation of Pyk2 
Proline-rich tyrosine kinase Pyk2, also known as cell adhesion kinaseβ (CAKβ), 
related adhesion focal tyrosine kinase (RAFTK) or calcium-dependent protein-
tyrosine kinase (CADTK), is a member of the focal adhesion kinase family of non-
receptor kinases and was cloned from a human brain cDNA library. Pyk2 is 
predominantly expressed in the central nervous system and in hematopoietic lineage 
as well as in liver epithelial and vascular smooth muscle cells (Lev 1995, Yu 1996). 
Pyk2 shares a high degree of sequence homology with focal adhesion kinase (FAK), 
especially in the kinase domain (~60%) and the C- and N-terminal domains (~40%) 
(Avraham 1995, Herzog 1996, Lev 1995, Yu 1996). The catalytic domain of Pyk2 is 
flanked by non-catalytic C- and N-termini with two proline-rich domains and a paxillin 
binding motif integrated in the C-terminus (Schlaepfer 1999, Fig. 3). Pyk2 lacks SH2 
and SH3 domains but contains sequences capable of binding to SH2 and SH3 
domains of other proteins as well as several tyrosine residues mediating specific 
protein-protein interactions (Dikic 1996, Qian 1997, Schlaepfer 1999). Tyrosine at 
position 402 has been identified as the major site for Pyk2 autophosphorylation and 
Src activation, with other tyrosine residues (579, 580 and 881) contributing to 
subsequent transphosphorylation and enhanced kinase activity (Schlaepfer 1999). 
Phosphorylation of tyrosine 881 creates a SH2 binding site for the adaptor protein 
Grb2 (Blaukat 1999). Pyk2 mutated at lysine 457 has been shown to be impaired in 
its ability to phosphorylate ion channels or glycogen synthase kinase 3β and is 
therefore appointed kinase-dead Pyk2 (Pyk2-PKM) (Hartigan 2001, Lev 1995). The 
two proline-rich motifs have been shown to be sites for SH3 domain-binding 
interactions, which are phosphorylation-independent. The SH3 domain of p130Cas is 
constitutively bound to Pyk2 via the first proline-rich domain. RhoGAPs, Graf and 
PSGAP, preferentially bind to the second proline-rich domain of Pyk2 (Astier 1997, 
Ohba 1998, Ren 2001).  
Pyk2 becomes activated in response to a variety of extracellular stimuli elevating 
[Ca2+]i and/or activating PKC, such as agonists of GPCR, growth factors, stress 
stimuli as well as integrin-induced signaling pathways (Avraham 2000, Lev 1995, Tai 
2002). Calcium signals responsible for Pyk2 activation can be generated by influx of 
extracellular calcium through calcium channels or through calcium release from 
intracellular stores (Lev 1995, Tokiwa 1996, Yu 1996). The proximal events coupling 
increases of [Ca2+]i or PKC to Pyk2 activation are not yet understood. In this context, 
Ca2+/CaM-dependent kinase II (CaMK II) has been implicated as an intermediate in 
Ca2+-dependent activation of Pyk2 in VSMCs (Ginnan 2002). Determined by cellular 
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environment and activation mode, Pyk2 is engaged in ERK-, JNK- and p38MAPK 
activation (Lev 1995, Sorokin 2001, Tokiwa 1996, Yu 1996).  
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Figure 3. Schematic drawing of Pyk2.  
Modified from Schlaepfer 1999. 
 
Interestingly, it has been reported that several fibroblastic and epithelial cell lines, 
e.g. rat-1, Swiss 3T3 or HEK293 cells transfected with Pyk2, undergo apoptosis, 
whereas no detectable cell death could be observed in cells expressing significant 
high levels of endogenous Pyk2, like PC12 cells (Xiong 1997). In this regard Pyk2 
has to be considered as a critical molecular switch in cell fate decisions.  
 
1.2.2. GPCR-dependent Epidermal Growth Factor receptor transactivation  
It had been noticed for quite some time that the EGFR became activated by stimuli 
other than its cognate ligands, namely agonists of GPCRs, cytokines, chemokines, 
other RTK agonists, cell adhesion elements as well as stress stimuli (Carpenter 
1999). Time course experiments revealed that GPCR-induced EGFR activation 
occurs within short periods after agonist challenge (Daub 1996). In addition, rapid 
ERK activation by these agonists is achieved in an EGFR-sensitive mode and seems 
Introduction 
   21
to mimic those of RTKs (Daub 1996, Grosse 2000). Taken together, these data 
implicated a distinct activation mechanism from the one engaged by RTKs and was 
therefore referred to as “receptor transactivation”. Transactivation of the EGFR has 
been reported for Gq-, Gi, G13- and recently for Gs-coupled receptors (Castagliuolo 
2000, Gohla 1998, Grosse 2000b, Piiper 2002).  
RTK transactivation was initially thought to be a ligand-independent pathway since 
several studies failed to detect released growth factors in culture media (Daub 1996, 
Eguchi 1998, Tsai 1997). However, in a seminal study, the involvement of 
metalloproteinase activity in the GPCR/EGFR cross-talk has been revealed (Prenzel 
1999). Blocking of metalloproteinases using a broad-spectrum metalloproteinase 
inhibitor as well as blockage of the EGFR ectodomain with an antibody abolished 
EGFR activation induced by GPCR agonists. Ligand-dependent EGFR 
transactivation can be viewed as operating through a “triple membrane-passing 
signal mechanism” (TMPS, Fig. 1 and 4). Therein, agonists acting on GPCRs induce 
a metalloproteinase activity which cleaves an EGFR ligand precursor. The secreted 
mature ligand then activates the EGFR by binding to its extracellular domain 
(Gschwind 2001, Wetzker 2003).  
EGFR agonists are commonly synthesized as membrane spanning pro-growth 
factors and are released through regulated metalloproteinase activity (Prenzel 2001). 
Enzymes which have been implicated in ectodomain shedding of growth factors 
mainly belong to two families: Matrix metalloproteinases (MMPs) and 
metalloprotease-disintegrin proteins/a disintegrin and metalloproteases 
(MDCs/ADAMs) (Massova 1998).  
MMPs are a family of currently known 26 zinc- and calcium-dependent 
endopeptidases secreted by cells. MMPs are synthesized as zymogens with a signal 
sequence and a propeptide segment being removed during activation. After 
activation, MMPs are secreted into the extracellular medium except for the 
membrane type (MT)-MMPs which are tethered to the cell surface by a hydrophobic 
transmembrane domain (Werb 1997). MMPs regulate cell-matrix composition by 
degrading components of the extracellular matrix and are divided into 5 subgroups 
according to their substrate specificity and structure:  collagenases, stromelysins, 
gelatinases, MT-MMPs and other MMPs. Physiologically, MMPs are implicated in a 
multitude of processes such as neurite growth, cell migration, bone elongation, 
wound healing, angiogenesis, ovulation, sperm maturation, menstruation, antigen 
processing and presentation and embryo implantation. Pathological processes 
involving MMPs include tumor growth and migration, fibrosis, arthritis, multiple 
sclerosis and infertility (Massova 1998). Endogenous regulators of MMP activities are 
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the tissue inhibitors of metalloproteinases (TIMPs). Four TIMPs are known so far 
harboring different inhibition efficiencies against MMPs. TIMPs have also been 
shown to inhibit ADAMs (Brew 2000). Synthetic MMP inhibitors are currently being 
developed and some have reached clinical trials as anti-cancer therapeutics 
(Wojtowicz-Praga 1996).  
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Figure 4. Triple membrane-passing signal mechanism of EGFR transactivation.  
GPCR activation leads to metalloproteinase-mediated proteolytic cleavage of EGF-like growth 
factor precursors. Mature growth factors activate the EGFR. This model for ligand-dependent 
inter-receptor communication encloses three membrane passages as indicated by the yellow 
arrows. 
 
The identity of the participating MMPs, their activation mechanism as well as their 
physiological relevance for GPCR-initiated signaling processes still remain elusive 
(Suzuki 1997). Recently, ADAM10, ADAM12 and ADAM17/tumor necrosis factor 
α−converting enzyme (TACE), three members of the ADAM family of proteases, 
have been claimed responsible for ectodomain shedding of EGF-like ligands 
resulting in EGFR transactivation. Platelet-activating factor receptor and ADAM10 
mediate responses to Staphylococcus aureus leading to mucin synthesis and 
ADAM10 induces bombesin-triggered EGFR transactivation in COS-7 cells. In a 
cardiac cell model, ADAM12 is responsible for HB-EGF shedding-induced EGFR 
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activation by some vasoactive molecules (Asakura 2002, Gschwind 2003, Lemjabbar 
2002, Yan 2002). In addition, ADAM9 (MDC9/meltrin-γ) has been identified as the 
protease responsible for the shedding of HB-EGF precursor in response to PKC 
activation (Asakura 2002, Gschwind 2003, Izumi 1998, Lemjabbar 2002, Yan 2002). 
However, GPCR-stimulated HB-EGF cleavage cannot be suppressed by dominant-
negative forms of ADAM9, indicating that yet another protease mediates EGFR 
activation in response to GPCR signaling. ADAMs are transmembrane proteins 
characterized by a zinc-dependent metalloproteinase-, an adhesion-, a fusion- and 
an intracellular signaling domain (Blobel 1997). Cleavage of pro-growth factors, 
cytokines and cell surface receptors is mediated by ADAMs. ADAM functions have 
been linked to mammalian sperm-egg fusion, ectodomain shedding and diverse 
functions in Drosophila development (Blobel 1997). ADAM17/TACE represents the 
best known ADAM family member and was the first ADAM to have a known 
physiological substrate. The close resemblance of the severe phenotype of the 
ADAM17/TACE-deficient mice with that of EGFR knock out mice uncovered 
ADAM17/TACE as the protease responsible for ectodomain shedding of 
TGFα (Peschon 1998). TGFα has been shown to be an intermediate in the cross-talk 
between the prostaglandin E2 receptor and the EGFR, suggesting that 
ADAM17/TACE might be the responsible metalloprotease (Pai 2002). Recently it was 
shown that ADAM17/TACE is responsible for cleavage of another EGFR-ligand, 
namely amphiregulin. Treatment of squamous cell carcinoma cells with LPA or 
carbachol induces ADAM17/TACE-dependent cleavage of proamphiregulin 
regulating proliferation and motility of this cancer model (Gschwind 2003). 
Nevertheless, depending on the cellular context, EGFR transactivation can also 
occur by ligand-independent signal transduction pathways. Thrombin-activated 
protease-activated receptor-1 generates an intracellular signaling cascade that leads 
to ligand-independent EGFR receptor activation (Sabri 2002).  
EGFR transactivation has been reported to be fully PKC-dependent, partially PKC-
dependent or PKC-independent. Cross-talk between purinergic P2Y2 receptors and 
the EGFR in PC12 cells has been shown to be achieved via PKC with contributions 
of rises in [Ca2+]i. In the same cell system, Ca2+-transients are sufficient to elicit 
EGFR activation after bradykinin challenge. Our laboratory has recently shown that 
the gonadotropin-releasing hormone receptor (GnRHR) transactivates the EGFR via 
a pathway solely depending on PKC in gonadotropic αT3-1 cells (Grosse 2000b, 
Soltoff 1998, Zwick 1997). The involvement of Src tyrosine kinases in the cross-
communication between GPCRs and EGFR is unquestioned but not without 
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controversy as far as the localization of this non-receptor tyrosine kinase is 
concerned. In COS-7 cells, LPA treatment leads to EGFR-dependent ERK activation. 
Inhibition of Src kinases by the specific inhibitor PP1 diminished ERK activation 
whereas EGFR phosphorylation was unaffected (Daub 1997). In addition, inhibition 
of EGFR kinase activity by the selective tyrphostin AG1478 decreased angiotensin II-
mediated Src phosphorylation in vascular smooth muscle cells (VSMCs) locating Src 
downstream of the EGFR whereas Src kinases acting upstream of the transactivated 
EGFR has been reported in the case of the β-adrenergic receptor in cardiac 
fibroblasts (Kim 2002, Touyz 2002).  
EGFR transactivation-triggered p38MAPK activation has been reported for a variety 
of stimuli. Thrombin activates p38MAPK by an EGFR-dependent mechanism via 
PKC and increases in [Ca2+]i in VSMCs (Kanda 2001). Angiotensin II-induced EGFR 
transactivation is required for p38MAPK stimulation in the same cell system (Eguchi 
2001). So far there are no reports on GPCR-induced EGFR transactivation involved 
in JNK and BMK1/ERK5 signaling. 
 
1.3. Neuropeptide-mediated ERK activation 
Neuropeptides are a structurally and functionally diverse group of molecular 
messengers that function as neurotransmitters, paracrine/autocrine regulators or 
systemic hormones in normal as well as cancerous cells (Rozengurt 2002). In the 
central nervous system, neuropeptides are responsible for regulating food intake, 
body temperature and behavioral responses. Throughout the organism they regulate 
exocrine and endocrine secretion, smooth muscle contraction, pain transmission, 
fluid homeostasis, blood pressure and inflammation (Rozengurt 2002). It is now well 
recognized that neuropeptides represent the most important growth factors in a 
variety of human cancers, most notably small cell lung cancer (SCLC) (Rozengurt 
1999).  
Receptors for neuropeptides belong to the large superfamily of heptahelical GPCRs 
(Gudermann 1997). It has been delineated that neuropeptide receptors couple to an 
assortment of G proteins. For example, in our laboratory the galanin receptor was 
shown to couple to Gq/11, Gi/0 and G12/13 proteins (Wittau 2000). Pathways initiated by 
neuropeptides resulting in mitogenic responses are primarily related to Gq proteins 
and are known to signal via the PLCβ pathway thereby activating PKC as well as 
increasing [Ca2+]i (Sethi 1992, 1993). Even though PKC plays a pivotal role in 
neuropeptide signal transduction, events downstream of PKC are still not well 
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understood. PKC, activated through neuropeptides, has been implicated in cell cycle 
events via the Raf/MEK/ERK as well as PKD pathways (Rozengurt 1998, Zhukova 
2001). In contrast, it was shown that neuropeptide-mediated Ca2+-transients are 
sufficient to trigger ERK activation in PC12 cells (Zwick 1997). Concordantly, a rise in 
[Ca2+]i was shown to be necessary and sufficient to elicit neuropeptide-induced ERK 
activation in small cell lung cancer cells besides PKC activation (Wittau 2000). 
 
1.3.1. The Gonadotropin-releasing hormone receptor utilizes PKC to activate 
the ERK/MAPK cascade 
Typically, heptahelical receptors couple to an assortment of different G proteins 
making it difficult to link resulting cell responses to a certain G protein-coupling 
propensity. We resorted to the gonadotropin-releasing hormone receptor (GnRHR) 
because of some of its noteworthy features. In transfected COS-7 and αT3-1 cells 
derived from the gonadotrope lineage, the GnRHR initiates multiple signaling 
pathways by exclusively coupling to Gq/11 proteins (Grosse 2000a). Furthermore, the 
GnRHR completely lacks a cytosolic C-terminus and therefore is not phosphorylated 
by GRK. Internalization of GnRHR occurs extremely slow not coinciding with agonist 
challenge, and expression of the GnRHR at the plasma membrane is regulated in a 
β-arrestin-independent fashion (Grosse 2000a, McArrdle 2002). As stated before, 
ERK activation following GnRH stimulation in gonadotropic cells is solely PKC-
dependent. Therefore, the GnRHR in αT3-1 cells served as a modell to investigate 
neuropeptide-mediated ERK activation via PKC. 
Gonadotropin-releasing hormone (GnRH) is a neuropeptide (pyroGlu-His-Trp-Ser-
Tyr-Gly-Leu-Arg-Pro-Gly-amide) which is produced in neurosecretory cells of the 
hypothalamus. After secretion into the hypophysal portal circulation, GnRH binds to 
its cognate high-affinity receptor on pituitary cells thereby initiating signaling 
cascades leading to regulation of GnRHR number, synthesis and secretion of the 
gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) 
(Pierce 1981). The gonadotropins act on ovaries and testes to stimulate 
steroidogenesis and gametogenesis. LH and FSH belong to the glycoprotein 
hormone family and display a heterodimer structure composed of a common α 
subunit and a hormone-specific β subunit with physiological specificity. Specific 
GnRH pulse frequencies are necessary for determination of LHβ or FSHβ gene 
activation (Kaiser 1997). Still, the mechanism as to how gonadotropes differentiate 
between GnRH pulse frequencies and subsequently differentially regulate the 
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expression of the LHβ and FSHβ genes remains yet to be determined. It was recently 
shown that GnRHR numbers on gonadotropic cells seem to play a critical role in this 
process (Bedecarrats 2003).  
The structural diversity of GnRH variants in vertebrates has been apparent for quite 
some time with 14 distinct peptides known so far (Kang 2003, Millar 2001). Among 
these, GnRH II, originally cloned from chicken brain, is expressed universally in 
mammals including humans (Kang 2003, Miyamoto 1984). By using a double-labeled 
histochemistry approach, it was revealed that the two GnRH types are expressed by 
two distinct populations of hypothalamic cells in mammals (Latimer 2000). The high 
expression of GnRH II outside the brain corroborates the belief that GnRH II might 
display functions distinct from those of GnRH (Lumpkin 1987, Okada 2003, 
Padmanabhan 2001). Recently, the GnRH II-receptor (GnRH II-R) has been cloned 
from monkeys and characterized which, in congruence to the GnRHR, is G protein-
coupled. The receptor is functional and specific for GnRH II in terms of inositol 
phosphate-, LH- and FSH production (Millar 2001, Neill 2001). However, it has not 
been possible so far to identify a full-length transcript of GnRH II-R in human tissues 
(Neill 2002).  
The majority of peptides mediate stimulation of cell growth with an essential 
contribution of ERK activity. However, GnRH-mediated stimulation of ERK activity in 
the pituitary is necessary for the maintenance of the gonadotropic phenotype (Kaiser 
1997). In gonadotropic αT3-1 cells, all four subfamilies of MAPKs are activated upon 
GnRH stimulation, and ERK activity is required for GnRH-induced expression of the 
common α subunit gene through a pathway critically involving PKC (Kaiser 1997, 
Naor 2000, Reiss 1997, Roberson 1995, Sundaresan 1996).  
Our laboratory has recently shown that GnRHR/Gq/11-coupling leads to rapid 
stimulation of ERK activity in transfected COS-7 and gonadotropic αT3-1 cells 
(Grosse 2000b). This effect can be fully mimicked by short-term phorbol ester (TPA) 
treatment. The involvement of PKC was further substantiated by inhibition of PKC 
using a specific inhibitor or by down-regulation of PKC by long-term TPA treatment 
leading to abrogation of GnRH-stimulated ERK activity. Elevation of [Ca2+]i did not 
have any influence on GnRH-induced ERK activation as demonstrated by the 
inability of calcium ionophores to induce or calcium chelators to block GnRH-
triggered ERK activity. ERK activation was sensitive to PP1 treatment and 
expression of Csk revealing Src as an intermediate signal transducer. Most notably, 
the kinetics and maximal response of ERK activation critically depends on EGFR 
transactivation (Grosse 2000b). 
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As described above, GnRH is the key hypothalamic signal peptide governing 
reproductive function. In addition to its “classical” hypophysiotropic action, GnRH has 
been implicated to modulate the activities of some extrapituitary tissues, such as 
brain, placenta, ovarian cells, myometrium and lymphoid cells as well as tumors 
arising from these tissues (Chegini 1996, Ho 1995, Kang 2003, Merz 1991, Peng 
1994). It has been suggested that GnRH functions as an autocrine/paracrine factor in 
these cells (Gruendker 2002, Kraus 2001). However, data concerning GnRHR 
expression, regulation and mode of action in pheripheral organs and tumor cells are 
controversial and not fully understood (Kang 2000, Nathwani 2000). Experiments 
using antisera against GnRH caused significant increases in cell proliferation of 4/6 
ovarian cancer cells, suggesting GnRH as a negative regulator of proliferation 
(Emons 2003, Voelker 2002). Nonetheless, opposing data exist for another ovarian 
cancer cell line, ES-2 cells, where GnRH acts as an autocrine growth factor 
(Arencibia 2000). GnRH II also has been shown to have an anti-proliferative effect on 
ovarian cancer cells (Choi 2001). The reason as to why GnRHR exploits different 
signal transduction pathways depending on the cell type remains to be discovered. It 
has been suggested that GnRHR might couple to pertussis toxin-sensitive Gi proteins 
in extrapituitary tissue leading to activation of phosphotyrosine phosphatases (PTPs). 
PTP might counteract the growth stimulatory properties of agonist-bound EGFR 
resulting in reversion of mitogenic signal transduction and cell proliferation 
(Gruendker 2001). Furthermore, NFκB as well as JunD are activated by GnRH in 
ovarian cancer cells protecting cells from apoptosis or leading to cell cycle arrest in 
G0/1 (Gruendker 2000, Gunthert 2002). One may speculate that GnRH enables the 
tumor cell to acquire repair mechanisms while proliferation as well as apoptosis are 
repressed.  
 
1.3.2. Galanin mediates growth of small cell lung cancer cells via rises in 
[Ca2+]i and ERK activation 
Due to over one million cases of lung cancer diagnosed every year, lung cancer is 
the leading cause of cancer death in the world (Parkin 2001). Human lung cancers 
are classified into two major groups, small cell lung cancer (SCLC) and non-small cell 
lung carcinoma (N-SCLC) with the latter consisting of several types (Travis 1995). 
Adenocarcinoma is the most frequent of the N-SCLC subtypes and is the most 
common in women and never smokers. On the contrary, SCLC is a neuroendocrine 
tumor that is strongly smoking-associated. Approximately 25% of all lung neoplasms 
are histologically classified as SCLC which is characterized by rapid growth and a 
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high metastatic potential. Despite initial radio- and chemosensitivity, SCLC 
possesses a 5-year survival rate of less than 5% (Clark 1998, Laskin 2003). Because 
SCLC tumors are seldom surgically resected, fresh tumor tissue is difficult to obtain 
and continuous cell lines are usually utilized for laboratory studies. Key events in the 
pathogenesis of SCLC are discrete mutations in tumor suppressor genes and 
chromosomal alterations like loss of heterozygosity of the short arm of chromosome 
3 (3p[14-25]) in 100% of the cases examined (Lindblad-Toh 2000). There is almost 
universal loss of the tumor suppressors p53 and Rb and frequent amplification of 
oncogenes such as myc and bcl2 in SCLC (Wistuba 2001). In contrast to N-SCLC, 
transforming Ras mutations or overexpression of RTKs are usually not encountered 
in SCLC, and the expression of GTPase-deficient Ras mutants in SCLC cells induces 
cell differentiation and growth arrest (Mabry 1988, 1989, Rozengurt 1999). 
Furthermore, overexpression of constitutively active Raf-1 leads to apoptosis in 
SCLC cells (Ravi 1998). On the contrary, fundamental evidence showed that broad-
spectrum antagonists acting on neuropeptide hormone receptors efficiently block the 
growth of SCLC cells (MacKinnon 1999, Maruno 1998, Seckl 1997, Sethi 1992). 
These findings lend credence to the notion that calcium-mobilizing neuropeptides, 
e.g. bombesin/gastrin-releasing peptide (GRP), bradykinin, neurotensin, vasopressin 
and galanin, acting through autocrine and paracrine loops, represent the main driving 
force for the growth and metastasis of this tumor entity (Rozengurt 1999, Gudermann 
2000). Neuropeptides are stored in cytoplasmic neurosecretory granules which are 
fused with the plasma membrane in response to Ca2+ stimuli. 
PLCβ is critically involved in neuropeptide-stimulated growth of SCLC cells since 
expression of the catalytically inactive enzyme results in inhibtion of ERK activity and 
cell growth (Beekman 1998). In addition, PKC became evident as a central molecule 
for SCLC cell growth and some effort has been made to identify critical downstream 
effectors of PKC (Paolucci 1999, Seufferlein 1996b). In this regard it was shown that 
one major role of PKC in SCLC cells is the activation of the ERK cascade, and 
downregulation of PKC isoforms was shown to inhibit both ERK activity and 
anchorage-independent growth (Seufferlein 1996a). There is evidence that 
neuropeptides like galanin or bombesin strongly activate PI3K and the downstream 
located ribosomal p70 S6 kinase (p70S6K), which has been implicated in regulation of 
translation, and that this pathway is important to maintain the anchorage-independent 
phenotype of SCLC cells (Moore 1998). It was further suggested that Src tyrosine 
kinases are not involved in this pathway, although no direct proof could be provided 
(Moore 1998). Our laboratory has recently shown that a rise of [Ca2+]i is necessary 
and sufficient to elicit galanin-induced ERK activation in SCLC cells (Wittau 2000). 
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Therefore we concluded that calcium mobilization, besides contributing to PKC 
activation, may regulate other targets to stimulate ERK activity in SCLC cells. 
Therefore, SCLC cells served to investigate the mechanism underlying neuropeptide-
induced ERK activation via rises of [Ca2+]i.  
Due to their neuroendocrine origin, SCLC cells express dihydropyridine-sensitive L-
type as well as dihydropyridine-insensitive P/Q-type and N-type voltage-gated 
calcium channels (VGCCs) (Watkins 2003, Williams 1997). Approximately 2-3% of 
SCLC patients present with Lambert-Eaton myasthenic syndrome (LES) caused by 
autoantibodies against P/Q-type VGCCs (Elrington 1991, Sutton 2002). LES is 
characterized by a generalized deficit of neurotransmitter release. Neurotransmitter 
release from presynaptic neurones at the neuromuscular junction and postganglionic 
sympathetic and parasympathetic neurones is mediated via depolarization of P/Q-
type VGCCs. Autoantibodies that interfere with neurotransmitter release by binding to 
presynaptic VGCCs have been found in sera of patients with LES and autoantibodies 
from patients affected by LES can precipitate these channels. These autoantibodies 
also block Ca2+ influx through VGCCs in SCLC cells and thereby inhibit tumor 
growth. In fact, SCLC patients with LES had a significantly longer median survival 
time from the diagnosis of SCLC when compared with SCLC-only patients (Maddison 
1999). 
Neuropeptide-dependent proliferation of SCLC cells critically relies on the fine-tuned 
activation of two parallel signaling pathways (Fig. 5): By way of Gq/11/PLCβ activation 
the Ras/Raf/MEK/ERK cascade is engaged in a PKC- and/or Ca2+-dependent 
manner. Amongst other effects, G12/13 proteins mediate activation of RhoGTPases 
which impinge on the dynamics of the actin cytoskeleton and may contribute to the 
recruitment of the JNK cascade. JNK, however, can also be activated via Gq/11-
dependent RhoGTPases. Selective engagement of the JNK pathway, for instance by 
biased neuropeptide receptor ligands, is invariably associated with apoptotic cell  
death (Chan 2002). Mechanistically, JNK-induced cell death of SCLC cells still 
remains enigmatic.  
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Figure 5. Current view of growth regulation of SCLC cells.  
Apart from VGCCs, SCLC cells express ligand-gated cation channels, store- and receptor-
operated as well as Ca2+-activated cation channels. Members of the transient receptor 
potential (TRP) family of cation channels are likely candidates for receptor-operated cation 
entry. Cation influx is required to depolarize the cell thereby leading to VGCC-mediated Ca2+ 
infllux. Neuropeptides are stored in cytoplasmic neurosecretory granules which are fused with 
the plasma membrane in reponse to Ca2+ stimuli. 
1.4. Apoptosis 
Apoptosis is a normal physiological process of programmed cell suicide which is 
important both in maintenance of adult tissues and in embryonic development. 
Apoptosis is the complementary mechanism to cell proliferation ensuring 
homeostasis of all tissues. In addition, programmed cell death provides a defense 
mechanism by which damaged and potentially dangerous cells can be eliminated for 
the well-being of the organism as a whole. Apoptosis can be triggered in mature cells 
by external stimuli such as growth factor depletion, loss of contact with neighboring 
cells or adhesion, glucocorticoids, radiation exposure or chemotherapeutics (Raff 
1998, Vaux 1999). Studies of cancer cells have shown that both uncontrolled cell 
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proliferation and failure to undergo programmed cell death can contribute to 
neoplasia and insensitivity to anti-cancer treatments (Reed 1999). 
Programmed cell death is characterized morphologically by blebbing of the plasma 
membrane, volume contraction, condensation of the cell nucleus and cleavage of 
genomic DNA by endogenous nucleases into nucleosome-sized fragments. Such 
apoptotic cells and cell fragments are phagocytosed by macrophages and 
neighboring cells, efficiently removing dead cells from tissues. In contrast, cells that 
die as a result of acute injury swell and lyse, releasing their contents into the 
extracellular space and causing inflammation. 
Three major apoptotic pathways have been elucidated todate all being orchestrated 
by caspases (Shivapurkar 2003). Caspases comprise a family of cysteine (C) 
proteases with high specificity for aspartatic residues (ASP) (Stennicke 2000). 
Caspases are expressed as inactive zymogens that can be activated by removal of 
the regulatory prodomain at the onset of apoptosis. Broadly, caspases can be divided 
into initiator (upstream) and effector (downstream) caspases (Shivapurkar 2003). 
Initiator caspases, such as caspases-8, -9 and –10 become activated by proapoptotic 
stimuli and subsequently activate effector caspases. “Executioner” caspases-3, -6 
and –7 are responsible for cleaving apoptotic target proteins including inhibitors of 
DNase, laminin or cytoskeletal proteins (Earnshaw 1999).  
One apoptotic pathway responds to death-inducing ligands such as TNF, FasL or 
TRAIL. After binding to their receptors, adaptor proteins FADD, TRADD and 
procaspase-8 are recruited to form a Death Inducing Signaling Complex (DISC). 
Recruitment of caspase-8 to the complex results in its proteolysis and subsequent 
activation of effector caspase-3 (Ashkenazi 1999). The closely related caspase-10 
has been shown to additionally participate in DISC formation and both caspases 
seem to further play important roles in apoptosis initiation (Kischkel 2001).  
The mitochondrial/cytochrome C pathway is largely mediated through Bcl2 family 
members. Release of cytochrome C from mitochondria results in formation of a 
complex called apoptosome containing adaptor protein Apaf-1 and procaspase-9 
(Adrain 2001). Procaspase-9 subsequently becomes activated resulting in caspase-3 
activation (Green 1998). Cytochrome C-mediated caspase-3 activation can be 
inhibited by inhibitor of apoptosis proteins (IAPs) which can be relieved by another 
mitochondrial protein, Smac/Diablo, by binding to the IAPs and releasing active 
caspases from their inhibitory influence (Du 2000, Verhagen 2000).  
Finally, granzyme B directly cleaves and activates several caspases resulting in cell 
death (Lord 2003). 
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2. OBJECTIVES 
Neuropeptides are responsible for a plethora of cellular functions in the central 
nervous system and in the periphery. They are also potent mediators for normal cell 
growth, differentiation and development. Furthermore, it is now well documented that 
neuropeptides play a crucial role in tumor growth via autocrine and paracrine growth 
loops. The most prominent example for a growth-stimulatory role of neuropeptides is 
represented by the growth regulation of small cell lung cancer cells.  
Neuropeptides bind to GPCRs with a wide coupling-spectrum. Mitogenic signaling of 
neuropeptides, however, is achieved via the Gq/11/PLCβ/Ras/ERK pathway. In this 
signaling cascade activated PLCβ generates two second messengers, DAG and IP3, 
which stimulate discrete downstream signaling pathways by activating PKC isoforms 
or regulating increases of [Ca2+]i, respectively.   
The aim of this work was to analyze differences between PKC- or Ca2+-mediated 
signaling cascades leading to ERK activation by neuropeptide stimulation.  
The receptor for the neuropeptide gonadotropin-releasing hormone has been 
delineated as an exclusively Gq/11-coupling receptor in gonadotropic αT3-1 and 
transfected COS-7 cells. In these cells, Gq/11 activation leads to PKC-mediated EGFR 
transactivation resulting in a rapid stimulation of ERK activity. The project intended to 
investigate the cellular mechanism underlying PKC-induced EGFR transactivation in 
αT3-1 cells.  
PLCβ-dependent elevation of [Ca2+]i is the key event to initiate ERK activation in 
SCLC causing cellular proliferation of this tumor entity. By means of the galanin and 
bradykinin receptors in SCLC cells, the project aimed at delineating Ca2+-dependent 
ERK activation in SCLC cells. Furthermore, Ca2+-regulated target proteins in SCLC 
cells were to be identified.  
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3. MATERIALS AND METHODS 
3.1. Materials 
3.1.1. Reagents 
Name Supplier
30% acrylamide/0.8% bisacrylamide  Roth
Bisbenzimide (Hoechst 33258) Boehringer Mannheim
ECL sytem Amersham Pharmacia Biotech
Expand™ High Fidelity   Boehringer Mannheim
jetPEI Polytransfection
Metafectene Biontex
poly-(L)-lysine Fluka
QuikChange® multi site-directed mutagenesis kit Stratagene
restriction endonucleases New England Biolabs
Roti Block Roth
SuperSript™ reverse transcriptase Gibco BRL
TOPO TA cloning® kit  Invitrogen
Trizol  Gibco BRL 
 All other reagents were purchased from Sigma. 
 
3.1.2. Cell Culture Supply 
Name Supplier
Dulbecco´s modified Eagle´s medium (DMEM), 
high glucose PAA
DMEM, low glucose PAA
fetal calf serum (FCS) PAA
gentamycin PAA
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Name Supplier
Ham´s F12 PAA
horse serum (HS) PAA
Phosphate-buffered saline (PBS) PAA
RPMI 1640 PAA
streptomycin/penicillin PAA
trypsin/EDTA PAA
 
3.1.3. Antibodies 
Name Supplier
anti-c-fos, rabbit polyclonal Santa Cruz Biotechnology
anti-c-jun, mouse monoclonal Transduction Laboratories
anti-c-src (B12), mouse monoclonal Santa Cruz Biotechnology
anti-c-src (Src2), rabbit polyclonal Santa Cruz Biotechnology
anti-EGFR (sc-03), rabbit polyclonal Santa Cruz Biotechnology
anti-ERK1/2 (K23), rabbit polyclonal Santa Cruz Biotechnology
neutralizing anti-HB-EGF R&D Systems
anti-MMP2 (SA103), rabbit polyclonal  Biomol
anti-MMP9 (SA106), rabbit polyclonal  Biomol
anti-mouse POD Sigma
anti-MT1-MMP, rabbit polyclonal Chemikon
anti-phosphoEGFR (Y845), rabbit polyclonal Biosource International
anti-phosphoERK, rabbit polyclonal New England Biolabs
anti-phosphoJNK, rabbit polyclonal Promega
anti-phosphop38, rabbit polyclonal New England Biolabs
anti-PI3K p85α (B-9), mouse monoclonal Santa Cruz Biotechnology
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Name Supplier
anti-PI3K p110α (H-201), rabbit polyclonal Santa Cruz Biotechnology
anti-PI3K p110β (N-20), rabbit polyclonal Santa Cruz Biotechnology
anti-phosphoSrc (Y418), rabbit polyclonal Biosource International
anti-phosphotyrosine (4G10), mouse monoclonal Upstate Biotechnology
anti-Pyk2, mouse monoclonal Transduction Laboratories
anti-rabbit POD Sigma
anti-Ras (pan-ras), mouse monoclonal Oncogene Research Products
 
3.1.4. Agonists and Drugs 
Name Supplier
AG1478 Calbiochem
BAPTA/AM Molecular Probes
batimastat (BB-94) Roche Diagnostics GmbH
bisindolylmaleimide II (GF109203X) Calbiochem
galanin, porcine Calbiochem
ionomycin Calbiochem
LY294009 Calbiochem
PD98059 Calbiochem
phorbol-12-myristoyl-13-acetate (TPA) Calbiochem
PP2 Calbiochem
Ro28-2653  Roche Diagnostics GmbH
Ro32-7315 Roche Diagnostics GmbH
All other reagents were purchased from Sigma. 
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3.1.5. Oligonucleotides 
Pyk2-1fwd 5´-GGCTGAGTGCTATGGGCTGAGGCTG-3´
Pyk2-1rev 5´-TCCCAAAGCAGATGCAGGAGAACTT-3´
Pyk2-2fwd 5´-AGGACATTGCCATGGAGCAAGAGA-3´
Pyk2-2rev 5´-CCCTGAGTGAGGAGTGCAAGAGGC-3´
rasGRF-fwd 5´-GCGGACAATGCCCACTGCTCT-3´
rasGRF-rev 5´-GTCCGCCACTGCCACCCATTTCT-3´
rasGRP-fwd 5´-GGACGCCAGCTTGACAGACAC-3´
rasGRP-rev 5´-CCCGGGCATAGGAAAGCTCATAGAT-3´
Pyk2-1818-F 5´-CCCGGTACATTGAGGACGAGGACTATTA-3´
Pyk2-3184-B 5´-GCAGAAGGCGGGGACGGACGGTA-3´
Pyk2-29-F 5´-GGGTGCCCGAGGAGTAGTCG-3´
Pyk2-2387-B 
5´-ATTGAGTGACGTGTGGGGTGGAGAGGTGG-
3´
 
3.1.6. Mutagenesis primer 
Pyk2-DN-F 5´-CGTCTCTGGCGACCTGCAAGAAAGACTG-3´
Pyk2-DN-B 5´-CAGTCTTTCTTGCAGGTCTCTGC-3´
Pyk2mut-402fwd 5´-AGTCAGACATCTTCGCAGAGATTCC-3´
Pyk2mut-402rev 5´-GGAATCTCTGCGAAGATGTCTGACT-3´
Pyk2mut-717fwd 5´-CCCCCACCCAAGGCCAGCCGACCTAAG-3´
Pyk2mut-717rev 5´-CTTAGGTCGGCTGGCCTTGGGTGGGGG-3´
Pyk2mut-859fwd 5´-CCGCCACAGAAGGCCCCGAGGCTGGGC-3´
Pyk2mut-859rev 5´-GCCCAGCCTCGGGGCCTTCTGTGGCGG-3´
 
3.1.7. Hammerhead ribozymes 
Rz-MMP2 
5´ - 
CCACAGUGCUGAUGAGUCCGUUUAGGGACGA
AACAUAGCG - 3´ 
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Rz-MMP9 
5 ´- 
ACGUCUGGCUGAUGAGUCCGUUAGGACGAAA
CACCACA – 3´ 
Rz-MMP12 
5` - 
UGAUGGUGCUGAUGAGUCCGUUAGGACGAAA
CUGCUAG - 3´ 
Rz-MT1-MMP 
5´- 
CUCAUUUUGCUGAUGAGUCCGUUAGGACGAA
ACAGUCCA - 3´ 
Rz-ADAM10  
5´- 
CAAUGACACUGAUGAGUCCGUUAGGACGAAA
CCCAUGA - 3´ 
Rz-FGF-BP 
5` - 
UUCCAAUACUGAUGAGUCCGUUAGGACGAAA
CUCUCU - 3´ 
 
3.2. Methods 
3.2.1. Cell culture and transient transfection 
3.2.1.1. SCLC cell lines 
SCLC cell lines NCI-H69 and NCI-H510 (hereafter referred to as H69 and H510) 
were a kind gift of E. Rozengurt (School of Medicine, University of California, Los 
Angeles, CA). SCLC cell lines were grown in RPMI 1640 medium supplemented with 
10% (v/v) FCS. The medium contained 50 units/ml penicillin, 50 µg/ml Streptomycin 
and 5 µg/ml L-glutamine. Cells were cultured in a humidified atmosphere of 5% 
CO2/95% air at 37°C. Approximately 3 x 104 cells were used for experimental 
purposes. Prior to stimulation, cells were grown in HITESA medium for 3-5 days. 
Stimulation of cells was performed as described in the figure legends and reactions 
were stopped by transferring cells on ice.  
Transient transfection of SCLC cells was carried out using Metafectene as a 
transfection reagent. Prior to transfection, SCLC cells were allowed to settle on poly-
(L)-lysine-coated coverslips in 6-well plates. 0.8 µg DNA was added to 50 µl serum-
free RPMI 1640 medium and mixed with 3 µl Metafectene prior diluted in 50 µl 
serum-free RPMI 1640 medium per well. To identify transfected cells, green 
fluorescent protein (0.2 µg peGFP-C1 in pcDNA3.1) was coexpressed as a marker. 
The mixture was incubated at room temperature for 15 min and subsequently added 
to the cells as indicated in the figure legends. Cells were incubated with the 
DNA/Metafectene mixture for 36 h and then subjected to fluorescence microscopy.  
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HITESA medium 
RPMI 1640 medium supplemented with  
10 nM hydrocortisone  10 nM estradiol 
5 µg/ml insulin 30 nM selenium 
10 µg/ml transferrin 0.25% BSA 
 
3.2.1.2. Gene transfer into SCLC cells by a viral approach using retroviruses 
Pyk2-wt, Pyk2-Y402F and Pyk2-PKM were cloned into the retroviral expression 
vector pLXSN (see 3.2.3.5.2.). Amphotrophic packaging cell line PA317 was 
transiently transfected with pLXSN, pLXSN-Pyk2-wt, pLXSN-Pyk2-Y402F or pLXSN-
Pyk2-PKM using the calcium phosphate precipitation procedure (Hitt 1995). PA317 
cells were exposed to the DNA precipitate until day 3 when the medium was 
aspirated and fresh medium was added. On day 4, the virus-containing medium was 
removed, centrifuged at 3000 x g for 5 min and virus titers of approximately 106/ml 
were utilized to infect H69 cells. Retrovirus-infected H69 cells were selected in G418 
(100 µg/ml)-containing RPMI medium. Viability of H69 cells was controlled every day 
by trypan blue staining. 
 
3.2.1.3. PC12W cells 
PC12W cells were a kind gift of S. Bottari (Transduction Laboratory, Medical School, 
Université de Grenoble I, France). PC12W cells were cultured in DMEM, low 
glucose/Ham´s F12 (1:1, v/v) supplemented with 10% (v/v) HS, 5% (v/v) FCS, 5 
µg/ml L-glutamine and 50 µg/ml gentamycin. Cells were cultured in a humidified 
atmosphere of 5% CO2/95% air at 37°C. Transient transfection of PC12W cells was 
carried out using jetPEI as a transfection reagent. Prior to transfection, cells were 
seeded into 6-well plates and grown to 80% confluency. 0.8 µg DNA was added to 50 
µl 150 mM NaCl pH 7.4 and mixed with 3 µl jetPEI prior diluted in 50 µl 150 mM NaCl 
pH 7.4 per well. To identify transfected cells, green fluorescent protein (0.2 µg 
peGFP-C1 in pcDNA3.1) was coexpressed as a marker. After vortexing, the mixture 
was incubated at room temperature for 15 min and subsequently added to the cells 
as indicated in the figure legends. Cells were incubated with the DNA/jetPEI mixture 
for 36 h and then subjected to fluorescence microscopy.  
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3.2.1.4. αT3-1 cells 
αT3-1 cells were a kind gift of P. L. Mellon (School of Medicine, University of 
California, San Diego, CA). αT3-1 cells were grown in DMEM, high glucose 
supplemented with 5% (v/v) FCS, 5% (v/v) HS, 50 units/ml penicillin, 50 µg/ml 
streptomycin and 5 µg/ml L-glutamine. They were cultured in a humidified 
atmosphere of 5% CO2/95% air at 37°C. Cells were seeded into 6-well plates and 
grown to 80% confluency. Prior to stimulation, cells were serum starved for 6 h. 
Experiments were performed in serum-free medium containing various substances 
as indicated in the figure legends. Basal values were determined in serum-depleted 
medium. 
Transient transfection of αT3-1 cells was performed using jetPEI as a transfection 
reagent. The indicated amount of ribozymal RNA was added to 50 µl 150 mM NaCl 
pH 7.4 and mixed with 3 µl jetPEI prior diluted in 50 µl 150 mM NaCl pH 7.4 per well. 
After vortexing, the mixture was incubated at room temperature for 15 min and 
subsequently added to the cells as indicated in the figure legends. Cells were 
incubated with the RNA/jetPEI mixture as specified and then cultured on serum-free 
medium for another 6 h before stimulation.  
 
3.2.1.5. LβT2 cells 
LβT2 cells were a kind gift of P. L. Mellon (School of Medicine, University of 
California, San Diego, CA). LβT2 cells were maintained in DMEM, high glucose 
supplemented with 10% (v/v) FCS, 50 units/ml penicillin, 50 µg/ml streptomycin and 5 
µg/ml L-glutamine. They were cultured in a humidified atmosphere of 5% CO2/95% 
air at 37°C. Cells were seeded into 6-well plates and grown to 80% confluency. Prior 
to stimulation, cells were serum starved for 18 h. Experiments were performed in 
serum-free medium containing various substances as indicated in the figure legends. 
Basal values were determined in serum-depleted medium. 
 
3.2.1.6. PC-3 cells 
PC-3 cells were purchased from the American Tissue Culture Collection. PC-3 cells 
were grown in RPMI 1640 medium supplemented with 50 mM Hepes, 10% (v/v) 
FCS, 50 units/ml penicillin, 50 µg/ml streptomycin and 5 µg/ml L-glutamine. They 
were cultured in a humidified atmosphere of 5% CO2/95% air at 37°C. Cells were 
seeded into 6-well plates and grown to 80% confluency. Prior to stimulation, cells 
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were serum starved for 36 h. Experiments were performed in serum-free medium 
containing various substances as indicated in the figure legends. Basal values were 
determined in serum-depleted medium. 
 
3.2.2. Biochemical Methods 
3.2.2.1. Standard procedures 
Detection of protein quantities Bradford 1976
SDS-PAGE Laemmli 1970
Western Blot Towbin 1979
 
3.2.2.2. Immunoprecipitation 
Cell stimulation was performed as indicated in the particular figure legends. For 
tyrosine phosphorylation of Pyk2 and coimmunoprecipitation experiments with Src 
kinases in SCLC cells, reactions were terminated by transferring cells on ice. After 
centrifugation at 300 x g, cells were lysed in 500 µl modified RIPA buffer for 15 min 
on ice. Lysates were cleared by centrifugation, supernatants diluted with 300 µl PBS 
and subjected to immunoprecipitation overnight at 4°C using the appropriate 
antibodies. Pyk2 was immunoprecipitated using monoclonal anti-Pyk2 antibody. For 
detection of coprecipitated Src kinases, monoclonal anti-Src antibodies were used. 
Subsequently, 100 µl of prewashed protein A-sepharose beads (12.5%, w/v) were 
added and the lysates incubated at 4°C at constant rotation for 2 h. Immune 
complexes were precipitated by centrifugation and washed three times with ice cold 
modified RIPA buffer. Precipitates were resuspended in 2x SDS-PAGE sample 
buffer, boiled for 3 min and resolved on 9% SDS-PAGE.  
For immunoprecipitation of the EGFR, αT3-1 cells were lysed in 500 µl ice cold lysis 
buffer for 15 min. Lysates were precleared by centrifugation and supernatants diluted 
with 500 µl lysis buffer containing 0.1% Triton X-100. The EGFR was 
immunoprecipitated using a polyclonal anti-EGFR (sc-03) at 4°C overnight. 
Subsequently, 100 µl of prewashed protein A-sepharose beads (12.5%, w/v) were 
added and the lysates incubated at 4°C at constant rotation for 2 h. Immune 
complexes were precipitated by centrifugation and washed three times with ice cold 
lysis buffer. Immuncomplexes were resuspended in 2x SDS-PAGE sample buffer, 
boiled for 3 min and resolved on 9% SDS-PAGE.  
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Modified RIPA buffer  
50 mM Tris-HCl, pH 7.5 1 mM Na3VO4 
150 mM NaCl 20 mM NaF 
0.3% deoxycholic acid 25 µM ZnCl2 
0.1% Nonidet P-40 1 mM PMSF 
1.5 mM MgCl2 10 µg/ml aprotinin 
1 mM EDTA 10 µg/ml leupeptin 
0.2 mM EGTA  
 
Lysis buffer  
50 mM Tris-HCl, pH 7.5 500 µM sodium orthovanadate 
100 mM NaCl 1% Triton X-100 
5 mM EDTA 1 mM PMSF 
1 mM dithiothreitol 1 µM leupeptin 
40 mM Na4P2O7 0.1 µM aprotinin 
 
3.2.2.3. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and 
Western blotting procedures  
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is used to 
separate complex protein mixtures by their molecular size. The standard Laemmli 
method (Laemmli 1970) is applied for discontinuous gel electrophoresis under 
denaturing conditions in the presence of SDS. Western blotting (immunoblotting) is 
applied to identify specific proteins (antigens) recognized by polyclonal or monoclonal 
antibodies. After separation by SDS-PAGE, the antigens are electrophoretically 
transferred onto nitrocellulose membranes. The transferred proteins are bound to the 
surface of the membrane providing access for immunodetection reagents. All 
remaining binding sites are blocked by immersing the membrane in a solution 
containg either a protein or a detergent-based blocking agent. After probing with the 
primary antibody, the membrane is washed and the antigen is identified by detection 
with a secondary horseraddish-specific peroxidase-conjugated anti-IgG antibody. 
Visualization of the antigen/antibody complex is carried out on x-ray film by enhanced 
chemiluminescence. Experimental terms for the antibodies used are enlisted in 
Table 2.  
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Table 2. Experimental terms for the used antibodies. 
 
Antibody, 
Supplier Blocking solution 
Solution for 
1st antibody  
Washing buffer 
system 
anti-c-fos;  
Santa Cruz Biotechnology Roti Block 5% milk/PBS PBS/PBST 
anti-c-jun;  
Transduction Laboratories Roti Block 5% milk/PBS PBS/PBST 
anti-c-src (B12), mouse 
monoclonal, Santa Cruz 
Biotechnology Roti Block 5% milk/PBS PBS/PBST 
anti-EGFR (sc-03),  
Santa Cruz Biotechnology Roti Block 5% milk/PBS PBS/PBST 
anti-ERK1/2,  
Santa Cruz Biotechnology Roti Block 5% milk/PBS PBS/PBST 
anti-MMP2,  
Biomol Roti Block 5% BSA/PBS PBS/PBST 
anti-MMP9,  
Biomol Roti Block 5% BSA/PBS PBS/PBST 
anti-MT1-MMP,  
Chemikon Roti Block 5% BSA/PBS PBS/PBST 
anti-phosphoEGFR (Y845), 
Biosource International 5% milk/PBS 5% BSA/PBS PBS/PBST 
anti-phosphoERK,  
New England Biolabs Roti Block 5% milk/PBS PBS/PBST 
anti-phosphoJNK,  
Promega Roti Block 5% milk/PBS PBS/PBST 
anti-phosphop38,  
New England Biolabs 5% milk/TBST 5% BSA/TBST TBST 
anti-PI3K p85α,  
Santa Cruz Biotechnology Roti Block 5% milk/PBS PBS/PBST 
anti-PI3K p110α,  
Santa Cruz Biotechnology Roti Block 5% milk/PBS PBS/PBST 
anti-PI3K p110β,  
Santa Cruz Biotechnology Roti Block 5% milk/PBS PBS/PBST 
anti-phosphoSrc (Y418),  
Biosource International 5% milk/PBS 5% BSA/PBS PBS/PBST 
anti-phosphotyrosine (4G10),  
Upstate Biotechnology  5% milk/PBS 5% BSA/PBS PBS/PBST 
anti-Pyk2,  
Transduction Laboratories Roti Block 5% milk/PBS PBS/PBST 
anti-Ras (pan-ras),  
Oncogene Research Porducts  Roti Block 5% milk/PBS PBS/PBST 
 
 
Stimulation of cells was carried out as indicated in the respective figure legends. In 
the case of SCLC lines, reactions were stopped by transferring cells on ice. Cells 
were centrifuged at 1000 rpm and resuspended in 2x SDS-PAGE sample buffer. For 
all other cell lines, reactions were stopped by washing cells once with ice cold PBS. 
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Cells were lysed by adding 2x SDS-PAGE sample buffer. Lysates were sonicated 
and boiled for 3 min at 95°C. Precleared lysates were resolved by SDS-PAGE.  
To control the amounts of detected proteins, blots were stripped in stripping buffer for 
2 h at 65°C and reprobed with the indicated antibodies. 
   
2x SDS-PAGE sample buffer 5X SDS electrophoresis buffer 
125 mM Tris-HCl, pH 6.8  0.125 M Tris base 
20% glycerol (v/v) 0.96 M glycine (w/v) 
4% SDS (w/v) 0.5% SDS (w/v) 
0.2% 2-mercaptoethanol (v/v)  
0.001% bromphenol blue (w/v)  
 
4x Tris-HCl/SDS pH 6.8 
0.5 M Tris base 
0.4% SDS (w/v) 
adjust to pH 6.8 with HCl 
 
4x Tris-HCl/SDS pH 8.8 
1.5 M Tris base 
0.4% SDS (w/v) 
adjust to pH 8.8 with HCl  
 
Stacking gel  
1 ml 30% acrylamide/0.8% bisacrylamide  
1.25 ml 4x Tris-HCl/SDS, pH 6.8  
3.05 ml ddH2O  
25 µl 10% APS (w/v)  
5 µl TEMED  
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Seperating gel 9% 15% 
30% acrylamide/0.8% bisacrylamide  4.50 ml 7.50 ml 
4x Tris-HCl/SDS, pH 8.8 3.75 ml 3.75 ml 
3.05 ml ddH2O 6.75 ml 3.75 ml 
25 µl 10% APS (w/v) 50 µl 50 µl 
5 µl TEMED 10 µl 10 µl 
 
Transfer buffer    Stripping buffer 
25 mM Tris-HCl, pH 8.3  100 mM 2-mercaptoethanol 
192 mM glycine (w/v) 2.5 mM Tris-HCl, pH 6.7 
0.02% SDS (w/v) 2% SDS (w/v) 
20% methanol (v/v)  
 
3.2.2.4. Src kinase activity assay 
Src kinase activity assays were performed as previously described (Rodriguez-
Fernandez 1996). Cells were lysed in 500 µl ice cold lysis buffer for 15 min. Lysates 
were cleared by centrifugation, supernatants diluted to 0.5% Triton X-100 with 500 µl 
HNTG buffer and subjected to immunoprecipitation overnight at 4°C by using a 
polyclonal anti-Src antibody. 100 µl prewashed protein A-sepharose beads (12.5%, 
w/v) were added, lysates were incubated at constant rotation for 2 h at 4°C and 
complexes precipitated by centrifugation. Precipitates were washed three times with 
ice cold HNTG buffer and subsequently washed twice with Src kinase buffer. After 
resuspension of the immune complexes in 35 µl Src kinase buffer, Src kinase 
reactions were performed in the presence of 10 mM MgCl2 and 100 µM Src-peptide 
(p-Ala-Glu-Glu-Glu-Ile-Tyr-Gly-Glu-Phe-Glu-Ala-Lys-Lys-Lys-Lys-NH2). Src kinase 
assay reactions were initiated by addition of 5 µl 100 µM ATP solution containing 2 
µCi [γ32-P]ATP. Peptide phosphorylation was carried out for 5 min at 30°C and 
terminated by the addition of 6 µl 10% phosphoric acid. Reaction mixtures were then 
spotted onto Whatman P81 chromatography paper squares and washed four times 
with 150 mM phosphoric acid. Incorporated radioactivity was determined by liquid 
scintilation spectrometry. All samples were performed in duplicates. 
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Src kinase-lysis buffer 
50 mM Hepes, pH 7.4 50 µM ZnCl2 
150 mM NaCl 25 mM NaF 
10% glycerol 1 mM Na3VO4 
1% Triton X-100 1 mM PMSF 
1 mM EDTA 10 µg/ml aprotinin 
1 mM EGTA 10 µg/ml leupeptin 
 
HNTG buffer 
20 mM Hepes, pH 7.5 10 mM NaF 
150 mM NaCl 1 mM Na3VO4 
0.1% Triton X-100 1 mM PMSF 
10% glycerol 10 µg/ml aprotinin 
 
Src kinase buffer 
50 mM Hepes, pH 7.5  
0.1 mM EDTA 
0.01% Brij 
 
3.2.2.5. ERK activity assay 
Endogenous ERK activity was determined as reported before (Grosse 2000). Cells 
were lysed in 500 µl ice cold Src kinase-lysis buffer (see above) for 15 min. Lysates 
were cleared by centrifugation, supernatants diluted to 0.5 % Triton X-100 with 500 µl 
HNTG buffer (see above) and subjected to immunoprecipitation overnight at 4°C by 
using a polyclonal anti-ERK2 antibody. 100 µl prewashed protein A-sepharose beads 
(12.5%, w/v) were added, lysates were incubated at constant rotation for 2 h at 4°C 
and complexes were precipitated by centrifugation. Precipitates were washed three 
times with ice cold HNTG buffer and afterwards twice with kinase buffer. Immune 
complexes were resuspended in 45 µl kinase buffer supplemented with 250 µg/ml 
myelin basic protein and 2 µM protein kinase A inhibitor, fragment 6-22 amide. The 
kinase assay reaction was initiated by addition of 5 µl 500 µM ATP solution 
containing 2 µCi [γ32-P]ATP. The reaction was performed for 30 min at room 
temperature and terminated by addition of 6 µl 88% formic acid. Reaction mixtures 
were then spotted onto Whatman P81 chromatography paper squares and washed 
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four times with 150 mM phosphoric acid. Incorporated radioactivity was determined 
by liquid scintilation spectrometry. All samples were performed in duplicates. 
 
Kinase buffer 
40 mM Hepes, pH 7.5 
5 mM magnesium acetate 
2 mM dithiothreitol 
1 mM EGTA 
200 µM Na3VO4 
 
3.2.2.6. Ras activation assay 
3.2.2.6.1. Preparation of GST fusion proteins containing the Ras-binding domain of 
Raf-1 
GST fusions proteins containing the minimal Ras-binding domain (RBD) of Raf-1 
(amino acids 51-131) were prepared as described (Herrmann 1995). Competent E. 
coli cells were transformed with the plasmid pGEX-2T/GST-RBD and were grown to 
an A600 of 0.8. Fusion protein expression was induced by addition of 0.1 mM IPTG. 
After 2 h, cells were collected by centrifugation at 7700 x g. The pellet was 
resuspended in 25 ml ice cold PBS. Lysates were sonicated on ice three times for 1 
min and Triton X-100 was added to a final concentrtion of 1%. After centrifugation, 
supernatants were incubated with prewashed glutathione-sepharose 4B for 30 min at 
room temperature. The fusion protein/sepharose preparation was washed three 
times in Ras-RIPA buffer and stored at 4°C for up to two weeks.   
 
PBS 
136 mM NaCl 0.5 mM MgCl2 
2.7 mM KCl 0.5 mM dithiothreitol 
8 mM Na2HPO4 0.1 µM aprotinin 
1.47 mM KH2PO4 1 µM leupeptin 
1.2 mM CaCl2 1 µM pepstatin A 
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Ras-RIPA buffer 
50 mM Tris-HCl, pH 8.0 0.1% SDS 
150 mM NaCl 1 mM PMSF 
0.5 mM MgCl2 0.1 µM aprotinin 
0.5% deoxycholic acid 1 µM leupeptin 
1% Nonidet P - 40  
 
3.2.2.6.2. Ras activation Assay 
Ras activity was determined as described before (de Rooij 1997). After termination of 
reactions, cells were lysed for 15 min in 500 µl ice cold Ras-RIPA buffer (see above). 
Lysates were cleared by centrifugation and incubated for 20 min at 4°C with GST-
RBD precoupled to glutathione-sepharose 4B. Sepharose beads were collected by 
centrifugation at 1000 rpm and washed three times with Ras-RIPA buffer on ice. 
Precipitates were dried up using a hamilton syringe, 2x SDS-PAGE sample buffer 
was added to the precipitates and GTP-loaded Ras was analysed by SDS-PAGE on 
15% gels followed by immunoblotting with an anti-Ras antibody. To demonstrate 
equal expression levels of Ras, aliquots of the same experiments were subjected to 
Western blotting. Western blots were probed with anti-Ras antibody. 
  
3.2.2.7. Gelatin zymography 
Zymography was performed according to a previously published method (Heussen 
1980). Cell culture media were concentrated using a concentration device (Centricon, 
Millipore, Schwalbach, Germany). Protein contents were determined using the 
Bardford method. Samples containing 15 µg protein were electrophoresed on 9% 
non-reducing SDS-PAGE gels containing 0.1% gelatin as a substrate. Gels were 
washed twice in 2.5% Triton X-100 for 15 min at room temperature. Subsequently, 
gels were preincubated in reaction buffer for 30 min and incubated in reaction buffer 
for 18 h at 37°C. Gels were incubated in Coomassie Blue solution for approximately 
30 min and afterwards destained in destaining solution. Gelatinolytic activity was 
visualized as clear areas in a Coomassie Blue-stained gel.  
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Reaction buffer Coomassie Blue staining solution 
50 mM Tris-HCl, pH 7.6 50% methanol (v/v) 
200 mM NaCl 10% acetic acid (v/v) 
5 mM CaCl2 40% H2O (v/v) 
1 µM ZnCl2 0.05% Coomassie brilliant blue (w/v) 
0.02% Brij-35  
 
Destaining solution 
5% methanol (v/v) 
7% acetic acid (v/v) 
88% H2O 
 
3.2.2.8. Colony formation assay 
Clonogenic assays were done as described before (Seufferlein 1996). SCLC cells 
were resuspended in HITESA medium and disaggregated by two passes through a 
19-gauge needle. 104 cells were mixed with HITESA medium containing 0.3% 
agarose and galanin or bradykinin in the presence or absence of PP2 and layered 
over a solid base of 0.5% agarose in HITESA medium with galanin or bradykinin in 
the presence or absence of PP2 in 6-well plates. The cultures were incubated in a 
humified atmosphere of 5% CO2/95% air at 37°C for 21 days and then stained with 
the vital stain nitro-blue tetrazolium. Colonies of >120 µm in diameter (~16 cells) 
were counted. 
 
3.2.2.9. Liquid growth assay  
Cells were resuspended in HITESA medium and disaggregated by two passes 
through a 19-gauge needle. At the density of 5 x 104 cells in 1 ml HITESA, cells were 
aliquoted in 24-well plates and treated as described in the figure legends. Cells were 
incubated in a humified atmosphere of 5% CO2/95% air at 37°C for 21 days. Viable 
cells were counted after staining with trypan blue.  
 
3.2.2.10. Detection of apoptosis 
For morphological analysis, cells were fixed with 3.7% formalin buffered in PBS 
containing 0.2% Triton X-100 for 1 h and permeabilized for 10 min with 1% Triton X-
100 in PBS supplemented with 0.25 µg/ml bisbenzimide (Hoechst 33258). After 
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washing with distilled water, single cells were analysed by fluorescence microscopy. 
Fluorescence microscopy was performed using a Polychrome II monochromator and 
an IMAGO CCD camera (Till Photonics, Martinsried, Germany) coupled to an 
inverted Zeiss Axiovert 100 microscope. Transfected cells were identified at 470 nm 
(excitation maximum of GFP) and apoptosis was analysed at 340 nm (excitation 
maximum of bisbenzimide). The percentage of apoptotic cells was determined for 
approximately 50 cells in multiple fields in each independent experiment.       
 
3.2.3. Molecular biological methods 
3.2.3.1. Standard procedures 
Agarose gel electrophoresis Aaij 1972
DNA sequencing Sanger 1977
Ethidium bromide staining of DNA Maniatis, 1982
Preparation of competent E. coli cells  Inoue 1990
Ligation of DNA fragments Maniatis, 1982
Phenol-chloroform extraction of DNA Maniatis, 1982
Plasmid preparation using DNA-binding columns Qiagen, 1993
RNA preparation Maniatis, 1982
Mutagenesis of DNA Kunkel 1985
Transformation of E. coli cells  Cohen 1972
 
3.2.3.2. Preparation of total RNA from αT3-1 and SCLC cells  
To prepare RNA from αT3-1 cells, cells were grown in a culture flask to 80% 
confluency. Cell culture medium was discarded and cells resuspended in 3 ml ice 
cold Trizol solution and incubated on ice for 15 min. Approximately 2 x 107 SCLC 
cells were pelleted by centrifugation at 300 x g to prepare RNA. Cells were 
resuspended in 1 ml ice cold Trizol solution and incubated on ice for 15 min. 
Afterwards 200 µl chloroform/ml Trizol solution was added, cells were shaked out 
and centrifuged at high speed for 10 min at 4°C. The organic phase including the 
protein-containing interphase was discarded. Total RNA was precipitated by adding 
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0.7-fold 2-propanol to the aqueous phase. After centrifugation at high speed for 30 
min at 4°C, the pellet was washed with 70% ethanol. The dried pellet was 
resuspended in 30 µl DEPC-treated ddH2O. 
   
3.2.3.3. RT-PCR of Pyk2 in SCLC cells 
Total RNA of SCLC cells was reverse transcribed using an oligo-d(T) primer and 
SuperSript™ reverse transcriptase according to the manufacturer´s instructions. After 
digestion with RNase H, PCR reactions to amplify Pyk2 were performed using sense 
primers Pyk2-1fwd, Pyk2-2fwd and antisense primer Pyk2-1rev, Pyk2-2rev, 
respectively. GAPDH was amplified as a control. The resulting PCR products were 
analysed on a 1% agarose gel and visualized by ethidium bromide staining and 
confirmed by DNA sequencing. 
 
3.2.3.4. RT-PCR of guanine nucleotide-releasing factors for Ras  
Total RNA of SCLC cells was reverse transcribed using an oligo-d(T) primer and 
SuperSript™ reverse transcriptase according to the manufacture´s instructions. After 
digestion with RNase H, PCR reactions were performed using sense primer 
RasGRF-fwd and antisense primer RasGRF-rev for RasGRF2 or sense primer 
RasGRP-fwd and antisense primer RasGRP-rev for RasGRP. GAPDH was amplified 
as a control. The resulting PCR products were analysed on a 1% agarose gel and 
visualized by ethidium bromide staining. Sequence confirmation as done by DNA 
sequencing. 
 
3.2.3.5. Molecular cloning strategies 
3.2.3.5.1. Cloning of Pyk2 and generation of Pyk2 mutants 
Wild type Pyk2 (Pyk2-wt) was cloned into expression vector pcDNA3.1 from human 
testis. The N-terminus of Pyk2 was amplified by PCR using forward primer Pyk2-29-F 
and reverse primer Pyk2-2387-B. The C-terminus was amplified by PCR using 
forward primer Pyk2-1818-F and reverse primer Pyk2-3184-B. Each PCR product 
was inserted into pcDNA3.1 by TOPO TA cloning. To generate full-length Pyk2-wt, 
both constructs were digested with BsmBI and XbaI, the resulting fragments were 
ligated and subcloned into pcDNA3.1 by TOPO TA cloning.  
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To introduce mutation K457A into the Pyk2-wt cDNA, a similar cloning strategy as 
described above was performed. Primer pairs Pyk2-DN-F/Pyk2-3184-B and Pyk2-
DN-B/Pyk2-29-F were utilized to generate PCR products from the N- and C-termini of 
Pyk2. Pyk2 mutants Pyk2-Y402F, Pyk2-P717A and Pyk2-P859A were produced 
using the QuikChange® multi site-directed mutagenesis kit with mutagenesis primer 
pairs Pyk2mut-402fwd/Pyk2mut-402-rev, Pyk2mut-717fwd/Pyk2mut-717rev and 
Pyk2mut-859fwd/Pyk2mut-859rev, respectively. All constructs were confirmed by 
DNA sequencing.  
 
3.2.3.5.2. Cloning of Pyk2 into the retroviral pLXSN vector 
To generate recombinant retroviruses, BamHI-XhoI fragments of pcDNA3.1-Pyk2-wt, 
pcDNA3.1-Pyk2-Y402F and pcDNA3.1-Pyk2-PKM cDNAs were inserted into the pSV 
control vector. EcoRI-XhoI fragments of these constructs were cloned into the pLXSN 
vector. All constructs were confirmed by DNA sequencing. 
 
3.2.4. Reproducibility of results 
All assays were performed independently at least three times. One representative 
experiment is shown. 
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4. RESULTS  
PKC and [Ca2+]i comprise the two major second messengers in neuropeptide-
mediated mitogenic signal transduction. Neuropeptides bind to their cognate 
receptors to stimulate PLCβ, thereby activating PKC as well as mobilizing [Ca2+]i. In 
this work mechanisms underlying control of cell proliferation induced by 
neuropeptides acting on Gq/11-coupled receptors were investigated. By means of 
GnRH in gonadotropic αT3-1 cells and of galanin and bradykinin in small cell lung 
cancer cells, differences could be revealed between Ca2+- and PKC-dependent 
signaling pathways.  
 
4.1. The gonadotropin-releasing hormone receptor utilizes PKC to activate 
the ERK/MAPK cascade 
4.1.1. GnRH-induced ERK activation depends on gelatinase activity in 
gonadotropic cells.  
The proteolytic production of EGF-like agonists by metalloproteases has recently 
been identified as the unifying principle governing EGFR transactivation in various 
cell systems (Prenzel 1999). To identify distinct proteolytic enzymes involved in 
GnRH-mediated signal transduction, we first chose a pharmacological approach. 
Since members of the gelatinase subfamily of MMPs (MMP2 and MMP9) are 
expressed in pituitary tumors and normal pituitary glands (Beaulieu 1999, Paez-
Pereda 2000, Turner 2000), we initially focussed on a potential involvement of MMP2 
and MMP9 in GnRH-dependent ERK activation in gonadotropes. 
Prior to GnRH challenge, αT3-1 cells were incubated with Ro28-2653 (5-biphenyl-4-
yl-5-[4-(4-nitro-phenyl)-piperazin-1-yl]pyrimidine-2,4,6-trione), a novel pyrimidine-
2,4,6-trion-based MMP inhibitor characterized by a high selectivity for MMP2 and 
MMP9 (Arlt 2002, Grams 2001, Lein 2002, Table 3) or the broad-spectrum MMP 
inhibitor batimastat (BB-94, [4-(N-hydroxyamino)-2R-isobutyl-3S-(thiopen-2-
ylthiomethyl)-succinyl]-L-phenylalanine-N-methyl-amide). Activated ERK1 and ERK2 
were detected by Western blotting with a phosphorylation-specific anti-p42/p44 
(pERK1/pERK2) antibody (Figure 6 A). GnRH-elicited ERK activation was almost 
completely blocked after pretreatment of cells with Ro28-2653 implicating a role for 
gelatinases in the cross-talk between GnRHR and EGFR, while batimastat had no 
inhibitory consequence in the concentration tested (10 µM) (Fig. 6 A). Ro28-2653- or 
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BB-94 treatment of unstimulated cells did not influence the basal phosphorylation 
status of ERKs (Fig. 6 A).  
Table 3. In vitro efficacy of Ro28-2653, batimastat and Ro32-7315. 
  Ro28-2653 Batimastat Ro32-7315 
MMP Common name IC50 [nM] IC50 [nM] IC50 [nM] 
MMP1 
interstitial collagenase, 
collagenase 1 16000 25 500 
MMP2 gelatinase A 12 32 250 
MMP3 stromelysin 1 1800 67 190 
MMP8 
neutrophil collagenase, 
collagenase 2  21 27 25 
MMP9 gelatinase B 16 23 100 
MMP12 human macrophage elastase 9 nd 11 
MMP14 MT1-MMP 10 19 nd 
 ADAM17 TACE >20000 nd 5 
 
Cited from Beck 2002, Grams 2001, In vitro efficacies were determined by a modified 
fluorescence assay. nd: not determined 
 
Batimastat has been reported to ablate bombesin-induced EGFR transactivation in 
PC-3 prostate cancer cells (Prenzel 1999). To control for the activity of the batimastat 
solution used, PC-3 cells were pretreated with batimastat and subsequently 
stimulated with bombesin. Bombesin-mediated EGFR and ERK activation was 
detected by Western blotting using phosphorylation-specific antibodies (Fig. 6 B, C). 
Batimastat abrogated bombesin-induced EGFR- (Fig. 6 B) and ERK phosphorylation 
(Fig. 6 C) demonstrating that the observed weak inhibitory property of batimastat 
(Fig. 6 A) was a characteristic feature of αT3-1 cells. Ro28-2653 also harbored 
inhibitory properties concerning bombesin-mediated EGFR- and ERK 
phosphorylation in PC-3 cells. These results indicate a predominant role of 
gelatinases for GPCR-induced ERK phosphorylation in gonadotropic cells. 
According to our previous findings in transfected COS-7 cells that stimulation of ERK 
activity by GnRH is mediated by PKC, short-term TPA challenge of αT3-1 cells 
resulted in ERK phosphorylation (Fig. 6 D). TPA-elicited ERK-activation was reduced 
to basal levels in Ro28-2653-treated cells (Fig. 6 D). Incubation of cells with 
batimastat did not yield an inhibitory effect on TPA-induced ERK phosphorylation 
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(Fig. 6 D). However, inhibition of EGFR tyrosine kinase activity by the specific 
tyrphostin AG1478 suppressed ERK activation (Fig. 6 D).  
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Figure 6. GnRH-induced ERK activation in gonadotropic cells depends on gelatinase 
activity.  
A: Upper panel, Serum-starved αT3-1 cells were pretreated with 10 µM Ro28-2653 or 10 µM 
batimastat (BB-94) for 30 min and stimulated with 1 µM GnRH for 5 min. Western blots of cell 
lysates were probed with an anti-phosphoERK antibody. Lower panel, Blots were reprobed 
with an anti-ERK1/2 antibody. B, C: Upper panels, Serum-starved PC-3 cells were 
preincubated with 10 µM Ro28-2653 or 10 µM batimastat (BB-94) for 30 min and 
subsequently stimulated with 1 µM bombesin (Bomb) for 5 min. Western blots of cell lysates 
were probed with an anti-phosphoEGFR (B) or an anti-phosphoERK antibody (C). Lower 
panels, Blots were reprobed with an anti-EGFR (B) or an anti-ERK1/2 antibody (C). D: Upper 
panel, Serum-starved αT3-1 cells were pretreated with 10 µM Ro28-2653 or 10 µM 
batimastat (BB-94) for 30 min and stimulated with 1 µM TPA for 5 min. Western blots of cell 
lysates were probed with an anti-phosphoERK antibody. Lower panel, Blots were reprobed 
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with an anti-ERK1/2 antibody. E: Upper panel, Serum-starved LIT2 cells were preincubated 
with 10 µM Ro28-2653, 10 µM batimastat (BB-94) or 100 nM AG1478 for 30 min and 
subsequently stimulated with 1 µM GnRH for 5 min. Western blots of cell lysates were probed 
with an anti-phosphoERK antibody. Lower panel, Blots were reprobed with an anti-ERK1/2 
antibody.  
 
We further extended our study on another gonadotropic cell line, LβT2 cells. LβT2 
cells express both the α and β subunit of LH as well as GnRHR. LβT2 cells probably 
arose later in ontogeny than αT3-1 cells and thus represent a more mature 
gonadotropic cell modell (Turgeon 1996). LβT2 cells were pretreated with the 
gelatinase inhibitor Ro28-2653, batimastat or AG1478 prior to GnRH treatment and 
stimulation of ERK activity was analysed with an antibody recognizing 
phosphorylation of ERK1 and ERK2  (Fig. 6 E). In LβT2 cells, GnRH-elicited ERK 
phosphorylation was blocked to basal levels following pretreatment with Ro28-2653 
as well as AG1478, whereas batimastat treatment did not have a bearing on GnRH-
mediated ERK phosphorylation (Fig. 6 E). 
To address the conundrum as to why batimastat at 10 µM had hardly any effect on 
Gq/11-mediated ERK phosphorylation in αT3-1 and LβT2 cells (Fig. 6 A, D, E), while 
completely abolishing bombesin-dependent EGFR transactivation and ERK 
phosphorylation in PC-3 cells (Fig. 6 B, C), concentration-response experiments for 
the two inhibitors, batimastat and Ro28-2653, with concentrations ranging from 0.1 – 
50 µM were carried out. Phosphorylation of ERK2 was quantified by densitometric 
scanning of the x-ray films. GnRH-mediated ERK2 phosphorylation without any 
inhibition was set as 100%. Data of at least three independent experiments were 
pooled. As shown in Fig. 6 F, batimastat treatment of αT3-1 cells with increasing 
concentrations up to 10 µM resulted only in an 18% ± 8.6% suppression of ERK2 
phosphorylation. Because of the poor water solubility of batimastat, the highest 
concentration tested was 50 µM. Even at such a high concentration, ERK2 
phosphorylation still amounted to 54% ± 16.6% of the reference value obtained in the 
absense of batimastat (Fig. 6 G). On the contrary, pretreatment of αT3-1 cells with 
Ro28-2653 brought about a concentration-dependent decrease of GnRH-mediated 
ERK2 phosphorylation (Fig. 6 H). At 10 µM Ro28-2653 suppressed Gq/11-dependent 
ERK2 activation by more than 70%. At higher inhibitor concentrations (up to 50 µM), 
ERK2 activation was reduced to about 10% of the initial control value (Fig. 6 I). The 
enhanced potency of Ro28-2653 compared to batimastat supported the concept that 
gelatinases represent the main mediators of GnRH-induced signal transduction in 
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αT3-1 cells, while additional MMPs besides MMP2 and 9 appear to be involved in 
PC-3 cells. 
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Figure 6. F, H: Upper panels, Serum-starved αT3-1 cells were pretreated with the indicated 
concentrations of batimastat (BB-94) (F) or Ro28-2653 (H) for 30 min and were subsequently 
stimulated with 1 µM GnRH for 5 min. Western blots of cell lysates were probed with an anti-
phosphoERK antibody. Lower panels, Blots were reprobed with an anti-ERK1/2 antibody. G, 
I: Serum-starved αT3-1 cells were pretreated with the indicated concentrations of batimastat 
(BB-94) (G) or Ro28-2653 (I) for 30 min and were subsequently stimulated with 1 µM GnRH 
for 5 min. Quantification of ERK2 phosphorylation was carried out by densitometry. Pooling of 
data was achieved by normalizing results to GnRH-mediated ERK2 phosphorylation without 
any inhibition (100%). Data shown are mean ± SEM of at least three independent 
experiments.  
 
To unequivocally define the role of gelatinases for the stimulation of ERK activity by 
GnRH, an independent and more specific ribozyme-based approach was applied 
(Aigner 2002). The efficiency of the transfection reagent jetPEI to transiently transfect 
αT3-1 cells was approximately 30 - 50% as assessed by fluorescence microscopy 
using enhanced green flourescent protein as a marker. Incubation of αT3-1 cells with 
the transfection preparation entailed no adverse effects on cell proliferation or 
morphology.  
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Beforehand, the kinetics and concentration-response of ribozyme-induced 
downregulation of MMP2 and MMP9 expression in αT3-1 cells were tested. To 
evaluate the amount of ribozyme needed to suppress GnRH-mediated ERK 
activation, αT3-1 cells were transfected with increasing amounts of ribozyme Rz-
MMP2 directed against MMP2 for an initial time of 6 h and ERK phosphorylation was 
measured after GnRH challenge as described above. As can be seen in Fig. 7 A, 
cells transfected with 0.5 µg/well Rz-MMP2 showed the most prominent decline in 
ERK phosphorylation (Fig. 7 A).  
 
Figure 7. GnRH-induced ERK activation in gonadotropic cells can be inhibited by 
ribozymes targeting MMP2 or MMP9.  
A: Upper panel, αT3-1 cells were transiently transfected with 0.1, 0.5 or 1 µg Rz-MMP2 for 6 
h. After serum-depletion, cells were stimulated with GnRH for 5 min. Western blots of cell 
lysates were probed with an anti-phosphoERK antibody. Lower panel, Blots were reprobed 
with an anti-ERK1/2 antibody.   
 
In the kinetic studies, ribozyme targeting of MMP12, human macrophage elastase 
belonging to the MMP subgroup of stromelysins, was included since Ro28-2653 
inhibits MMP12 apart from MMP2 and MMP9 (Grams 2001, Table 3). Cells were 
incubated with ribozymes Rz-MMP2, Rz-MMP9 or Rz-MMP12 for 6 h, 12 h, 18 h and 
24 h, and agonist-induced ERK activation was monitored (Fig. 7 B - E). Incubation of 
αT3-1 cells with ribozymes MMP2 or MMP9 for 6 h resulted in maximal suppression 
of GnRH-mediated ERK phosphorylation (Fig. 7 B) while longer incubation times had 
no further inhibitory effect (Fig. 7 C, D, E). Transfection of Rz-MMP12 did not yield 
any inhibition during the observation period. Basal values did not change significantly 
in cells transfected with either ribozyme compared to non-transfected cells (Fig. 7). In 
conclusion of the data obtained, ribozyme transfection was carried out using 0.5 
µg/well for 6 h.  
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Figure 7. B, C, D, E: Upper panels, αT3-1 cells were transiently transfected with ribozymes 
directed against MMP2 (Rz-MMP2), MMP9 (Rz-MMP9) or MMP12 (Rz-MMP12) for the 
indicated time periods. Serum-depleted cells were stimulated with 1 µM GnRH for 5 min. 
Western blots of cell lysates were probed with an anti-phosphoERK antibody. Lower panels, 
Blots were reprobed with an anti-ERK1/2 antibody.  
 
αT3-1 cells were transiently transfected with ribozymes directed against MMP2 (Rz-
MMP2), MMP9 (Rz-MMP9), and as controls against MMP12 (Rz-MMP12) or an 
unrelated fibroblast growth factor-binding protein (Rz-FGF-BP) and Western blots of 
cell lysates were probed with anti-pERK specific antibodies (Fig. 7 F). Basal values 
did not change significantly in cells transfected with either ribozyme compared to 
non-transfected cells (Fig. 7 F). In light of this finding and the previously observation 
shown in Fig. 6 A that basal values of ERK phosphorylation are not influenced by 
Ro28-2653- or batimastat pretreatment, inhibitor-treated unstimulated cells were not 
further included in our study. Cells transfected with Rz-MMP2 or Rz-MMP9 displayed 
a significant decline in GnRH-induced ERK phosphorylation, whereas transient 
expression of Rz-MMP12 or the unrelated Rz-FGF-BP did not interfere with GnRH-
dependent ERK activation. In summary, these data provide strong support for the 
concept that GnRH-mediated ERK activation is due to gelatinase-sensitive EGFR 
transactivation in gonadotropic cells.   
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Figure 7. F: Upper panel, αT3-1 cells were transiently transfected with ribozymes directed 
against MMP2 (Rz-MMP2), MMP9 (Rz-MMP9), MMP12 (Rz-MMP12) or FGF-BP (Rz-FGF-
BP). Serum-depleted cells were stimulated with 1 µM GnRH for 5 min. Western blots of cell 
lysates were probed with an anti-phosphoERK antibody. Lower panel, Blots were reprobed 
with an anti-ERK1/2 antibody. 
 
4.1.2. HB-EGF shedding is involved in GnRH-mediated ERK activation.  
Each of the known EGF-like mammalian gene products is synthesized as a 
transmembrane precursor protein subject to proteolytic cleavage of its ectodomain in 
order to release a soluble growth factor. So far, amphiregulin, HB-EGF and TGFα 
have been implicated in EGFR transactivation (Gschwind 2003, Pai 2002, Prenzel 
1999, Werneburg 2003). To identify the pertinent ligand involved in EGFR 
transactivation in gonadotropes, we first chose a pharmacological approach by 
applying a specific ADAM17/TACE inhibitor, Ro32-7315 ((E)-2(R)-[1(S)-(Hydroxy-
carbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydra-
zide, Beck 2002, Table 3) in αT3-1 cells. As mentioned above, ADAM17/TACE has 
been uncovered as being responsible for shedding of proamphiregulin leading to 
EGFR phosphorylation in squamous cancer cells (Gschwind 2003). Furthermore, 
TGFα has been shown to be an intermediate in GPCR-mediated EGFR 
transactivation suggesting ADAM17/TACE as the responsible protease (Pai, 2002, 
Peschon 1998).  
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Figure 8. HB-EGF shedding is involved in GnRH-mediated ERK activation in αT3-1 
cells.  
A: Upper panel, Serum-depleted αT3-1 cells were pretreated with 10 µM Ro32-7315 for 30 
min prior to stimulation with 1 µM GnRH or 1 µM TPA for 5 min. Western blots of cell lysates 
were probed with an anti-phosphoERK antibody. Lower panel, Blots were reprobed with an 
antibody detecting ERK1/2. B: Upper panel, Serum-starved αT3-1 cells were treated with 15 
µg/ml anti-HB-EGF antibody for 1 h and subsequently stimulated with 1 µM GnRH for 5 min. 
Western blots of cell lysates were probed with an anti-phosphoERK antibody. Lower panel, 
Blots were reprobed with an anti-ERK1/2 antibody. C: Upper panel, Serum-starved αT3-1 
cells were treated with 15 µg/ml anti-HB-EGF antibody for 1 h and subsequently stimulated 
with 10 ng/ml EGF for 5 min. Western blots of cell lysates were probed with an anti-
phosphoERK antibody. Lower panel, Blots were reprobed with an anti-ERK1/2 antibody. D: 
Total RNA was isolated from αT3-1 cells and RT-PCR was performed using primer pairs for 
ADAM10 and ADAM12. E: Upper panel, αT3-1 cells were transiently transfected with Rz-
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ADAM10. After serum-starvation, cells were treated with 1 µM GnRH for 5 min. Western blots 
of cell lysates were probed with an anti-phosphoERK antibody. Lower panel, Blots were 
reprobed with an anti-ERK1/2 antibody.  
 
In Fig. 8 A the effects of Ro32-7315 on GnRH- and TPA-mediated ERK 
phosphorylation are shown. Phosphorylation of ERKs by both agents did not diminish 
by Ro32-7315 pretreatment. These data clearly exclude ADAM17/TACE from being 
involved in GnRH-mediated ERK activation in gonadotropic cells. However, we 
cannot exclude TGFα or amphiregulin from being the relevant EGFR agonists in 
αT3-1 cells. Next, we focussed our attention to another EGF-like ligand, HB-EGF. 
HB-EGF-mediated EGFR transactivation has been reported for numerous GPCRs 
and cell systems (Prenzel 1999, Uchiyama-Tanaka 2001). To assess the contribution 
of HB-EGF shedding in GnRH-mediated ERK activation, αT3-1 cells were treated 
with neutralizing antibodies against HB-EGF. Scavenging of soluble HB-EGF with 
neutralizing antibodies completely prevented GnRH-elicited ERK activation (Fig. 8 B). 
On the contrary, ERK phosphorylation induced by exogenously added EGF was not 
affected by preincubation of cells with anti-HB-EGF (Fig. 8 C). 
As mentioned before, two additional disintegrin proteases, ADAM10 and ADAM12, 
have been shown to participate in RTK transactivation. ADAM12 has been implicated 
in HB-EGF shedding by vasoactive molecules (Asakura 2002). ADAM10 leads to 
EGFR transactivation in a variety of different cell systems, however, the precise 
EGFR agonist was not delineated (Lemjabbar 2002, Yan 2002). To analyse the 
possible involvement of ADAM10 and ADAM12 in GnRH-mediated EGFR 
phosphorylation, RT-PCR of total αT3-1 RNA using primer pairs for ADAM10 and 
ADAM12 were performed. This approach revealed ADAM10 as being expressed in 
this gonadotropic cell line (Fig. 8 D). αT3-1 cells were transfected with ribozymes 
targeting ADAM10. After GnRH challenge, Western blots of cell lysates were probed 
with anti-phosphoERK-specific antibodies. Downregulation of ADAM10 by ribozymes 
did not have any influence on GnRH-mediated ERK phosphorylation (Fig. 8 E). 
These data lead to the conclusion that ADAM10 or ADAM17/TACE do not participate 
in the GnRHR/EGFR cross-talk in αT3-1 cells. In gonadotropic cells, HB-EGF 
shedding induced by GnRH treatment leads to ERK phosphorylation.  
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4.1.3. Gelatinase activity is involved in GnRH-mediated EGF receptor 
transactivation in gonadotropic cells.  
To characterize the role of gelatinases in GnRH-initiated signaling events resulting in 
ERK activation in gonadotropic cells, we first studied the involvement of MMP2 and 
MMP9 in EGFR transactivation. 
For this reason, αT3-1 cells were incubated with Ro28-2653 or batimastat prior to 
GnRH challenge. Subsequent to agonist stimulation, the EGFR was 
immunoprecipitated and Western blots of immunoprecipitates were probed with an 
anti-phosphotyrosine antibody. As shown in Fig. 9 A, GnRH transactivated the EGFR 
in a Ro28-2653-sensitive manner. The unspecific MMP inhibitor batimastat (BB-94) 
had only a minor inhibitory effect on GnRH-mediated EGFR activation in αT3-1 cells 
at the concentration tested (10 µM). As mentioned above, GnRH-induced ERK 
activation in αT3-1 cells is preceded by EGFR transactivation (Gosse 2000b). Since 
ERK activation in these cells is dependend on Src activity, we chose antibodies 
specific for EGFRY845 to detect activated EGFR. Tyrosine 845 within the catalytic 
domain of the EGFR has been shown to be phosphorylated by Src and is involved in 
regulating receptor function (Biscardi 1999). GnRH challenge led to phosphorylation 
of tyrosine 845 of the EGFR which was inhibited by preincubation of the cells with 
Ro28-2653 (Fig. 9 B). Batimastat treatment had a less pronounced effect (Fig. 9 B). 
GnRH-induced tyrosine phosphorylation of EGFR was almost completely prevented 
by pretreatment of cells with 1, 10-phenanthroline (Phe), a chelator of bivalent ions 
such as zinc, thus lending additional support to the involvement of zinc-dependent 
endopeptidases.  
As a control, the effect of Ro28-2653 and batimastat on EGF-mediated EGFR 
activation in αT3-1 cells was examined (Fig. 9 C). As expected, EGF increased 
EGFR phosphorylation in a Ro28-2653-independent way while batimastat treatment 
showed no inhibition (Fig. 9 C).  
In order to strengthen the notion that gelatinases are specifically involved in GnRH-
induced EGFR activation in αT3-1 cells, the expression of distinct MMPs was 
targeted by transfection of ribozymes, and agonist-induced EGFR activation was 
monitored (Fig. 9 D). The most prominent inhibitory effect was observed when αT3-1 
cells were transfected with ribozyme Rz-MMP2. GnRH-mediated EGFR activation 
was also substantially blocked in cells transfected with ribozymes directed against 
MMP9. However, GPCR-induced EGFR phosphorylation was nearly unaffected in 
cells transfected with ribozyme Rz-MMP12. As a negative control, αT3-1 cells were 
transiently transfected with a ribozyme directed against FGF-BP, because this 
Results 
   63
binding protein is not involved in the receptor cross-talk under study. As expected, 
cells transiently expressing Rz-FGF-BP were not affected with regard to GnRH-
mediated EGFR tyrosine phosphorylation (Fig. 9 D).  
We again extended our study on gonadotropic LβT2 cells. LβT2 cells were pretreated 
with the gelatinase inhibitor Ro28-2653, batimastat or the EGFR-specific tyrphostin 
AG1478 prior to GnRH treatment and activation of EGFR was analysed with an 
antibody recognizing phosphorylation of tyrosine 845 (Fig. 9 E). Pretreatment of cells 
with Ro28-2653 resulted in a decline of EGFR phosphorylation to basal levels. 
Further, phosphorylation of EGFR was completely blocked by AG1478 pretreatment. 
Batimastat did not yield any inhibitory effect on GnRH-elicited EGFR phosphorylation 
(Fig. 9 E). 
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Figure 9. GnRH-induced EGFR transactivation in gonadotropic cells depends on 
gelatinase activity.  
A: Upper panel, Serum-starved αT3-1 cells were preincubated with 10 µM Ro28-2653 or 10 
µM batimastat (BB-94) for 30 min and subsequently stimulated with 1 µM GnRH for 5 min. 
After cell lysis, the EGFR was immunoprecipitated using a polyclonal anti-EGFR antibody and 
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EGFR phosphorylation was determined by an anti-phosphotyrosine (PY)-specific antibody. 
Lower panel, Blots were reprobed with an anti-EGFR antibody. B: Upper panel, Serum 
starved αT3-1 cells were preincubated with 10 µM Ro28-2653, 10 µM batimastat (BB-94) or 
1, 10-phenanthroline (Phe) for 30 min and subsequently stimulated with 1 µM GnRH for 5 
min. Western blots of cell lysates were probed with an anti-phosphoEGFR antibody. Lower 
panel, Blots were reprobed with an anti-EGFR antibody. C: Upper panel, Serum-starved αT3-
1 cells were preincubated with 10 µM Ro28-2653 or 10 µM batimastat (BB-94) for 30 min and 
subsequently stimulated with 10 ng/ml EGF for 5 min. Western blots of cell lysates were 
probed with an anti-phosphoEGFR antibody. Lower panel, Blots were reprobed with an anti-
EGFR antibody. D: Upper panel, αT3-1 cells were transiently transfected with ribozymes 
directed against MMP2 (Rz-MMP2), MMP9 (Rz-MMP9), MMP12 (Rz-MMP12) or FGF-BP 
(Rz-FGF-BP). After serum-depletion, cells were stimulated with 1 µM GnRH for 5 min. 
Western blots of cell lysates were probed with an anti-phosphoEGFR antibody. Lower panel, 
Blots were reprobed with an anti-EGFR antibody. E: Upper panel, Serum-starved LβT2 cells 
were preincubated with 10 µM Ro28-2653, 10 µM batimastat (BB-94) or 100 nM AG1478 for 
30 min and then stimulated with 1 µM GnRH for 5 min. Western blots of cell lysates were 
probed with an anti-phosphoEGFR antibody. Lower panel, Blots were reprobed with an anti-
EGFR antibody.  
 
To investigate whether gelatinases are activated in a GnRH-dependent manner, 
conditioned αT3-1 cell culture supernatants were concentrated, resolved by SDS-
PAGE and probed with anti-MMP2 or anti-MMP9 antibodies. A 5-min GnRH 
challenge resulted in enhanced release of MMP2 (Fig. 10 A, B, upper panels). 
Preincubation of αT3-1 cells with Ro28-2653 decreased MMP2 contents of the 
medium as did transfection with ribozymes targeting MMP2 (Fig. 10 A, B, upper 
panels). On the contrary, transfection of cells with Rz-MMP9, Rz-MMP12 or Rz-FGF-
BP had no impact on MMP2 levels (Fig. 10 B, upper panel). GnRH stimulation also 
led to an increase in MMP9 protein levels in the medium (Fig. 10 A, B, lower panels). 
The release of MMP9 was counteracted by preincubation of cells with Ro28-2653 
(Fig. 10 A, lower panel) or transfection with Rz-MMP9 (Fig. 10 B, lower panel). 
Targeting MMP2 via Rz-MMP2 entailed a decrease in MMP9 release (Fig. 10 B, 
lower panel) potentially indicating a role for MMP2 in MMP9 activation (Murphy 
1999). MMP12 or FGF-BP do not govern MMP9 activation since downregulation of 
these proteins did not inhibit MMP9 activation (Fig. 10 B, lower panel). 
To directly show that the enzymatic activity of gelatinases is subject to hormonal 
regulation in αT3-1 cells, cell culture media were analysed by gelatin zymography 
(Fig. 10 C). Under all conditions tested, we observed a gelatinolytic 72-kDa band 
corresponding to the proform of MMP2. An additional band migrating with a 
molecular mass of approximately 66 kDa was detected after GnRH stimulation of 
cells. It represents the active form of MMP2. Activated MMP2 was not demonstrable 
in conditioned media of cells pretreated with Ro28-2653. A gelatinolytic band with a 
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molecular mass of approximately 92 kDa corresponding to proMMP9 was noted in all 
samples. Yet, release of activated MMP9, which has a molecular mass of 
approximately 68 kDa, subsequent to GnRH treatment could not be readily observed 
(Fig. 10 C).  
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Figure 10. GnRH-mediated gelatinase activation is inhibited by Ro28-2653 as well as 
targeting gelatinases by ribozymes. MT1-MMP is activated in a GnRH-dependent 
manner in αT31- cells.  
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A: Serum-starved αT3-1 cells were preincubated with 10 µM Ro28-2653 for 30 min and 
subsequently stimulated with 1 µM GnRH for 5 min. Culture media were collected and 
concentrated. Western blots of samples containing 15 µg protein were probed with an anti-
MMP2 antibody (upper panel) or an antibody directed against MMP9 (lower panel). B: αT3-1 
cells weretransiently transfected with ribozymes directed against MMP2 (Rz-MMP2), MMP9 
(Rz-MMP9), MMP12 (Rz-MMP12) or FGF-BP (Rz-FGF-BP). After serum-depletion, cells were 
stimulated with 1 µM GnRH for 5 min. Culture media were collected and concentrated. 
Western blots of samples containing 15 µg protein were probed with an anti-MMP2 (upper 
panel) or an anti-MMP9 (lower panel) antibody. C: Serum-starved αT3-1 cells were 
preincubated with 10 µM Ro28-2653 for 30 min and subsequently stimulated with 1 µM GnRH 
for 5 min. Culture media were collected and concentrated. Samples containing 15 µg protein 
were subjected to gelatin zymography. Molecular weight markers are indicated at the right. D: 
Serum-starved αT3-1 cells were stimulated with 1 µM GnRH for 5 min. Western blots of cell 
lysates (upper panel) and concentrated culture medium containing 15 µg protein (lower panel) 
were probed with anti-MT1-MMP antibodies. E: αT3-1 cells were transfected with ribozymes 
directed against MT1-MMP (Rz-MT1-MMP). After serum-depletion, cells were stimulated with 
1 µM GnRH for 5 min. After concentration of culture media, Western blots of samples 
containing 15 µg protein were probed with an anti-MMP2 antibody. F: Upper panel, αT3-1 
cells were transiently transfected with ribozyme Rz-MT1-MMP. After serum-starvation, cells 
were stimulated with 1 µM GnRH for 5 min. Western blots of cell lysates were probed with an 
anti-phosphoEGFR antibody. Lower panel, Blots were reprobed with an anti-EGFR antibody.  
 
MT1-MMP plays a prominent role in the activation of gelatinases. MT1-MMP is 
anchored to the plasma membrane tethering secreted proMMP2 in a complex also 
containing TIMP2. As a result of activating stimuli, proMMP2 is cleaved and activated 
by MT1-MMP (Werb 1997, Westermarck 1999). Along these lines, αT3-1 cells were 
stimulated with GnRH and MT1-MMP was detected in cell lysates as well as 
concentrated conditioned medium (Fig. 10 D). As shown in Fig. 10 D, upper panel, a 
5-min stimulation of αT3-1 cells with GnRH resulted in a decrease of MT1-MMP in 
cell lysates, while agonist challenge led to secretion of MT1-MMP into the cell 
medium (Fig. 10 D, lower panel).  
To further show that MT1-MMP is not only rapidly activated by GnRH stimulation but 
is also responsible for MMP2 activation (Werb 1997), MT1-MMP was targeted with 
Rz-MT1-MMP and the protein level of MMP2 was detected in conditioned medium of 
αT3-1 cells 5 min after GnRH challenge (Fig. 10 E). Rz-MT1-MMP transfection 
reduced GnRH-mediated MMP2 levels in conditioned medium of αT3-1 cells (Fig. 10 
E). Finally, the involvement of MT1-MMP in GnRH-mediated EGFR phosphorylation 
was investigated. αT3-1 cells were transfected with ribozyme Rz-MT1-MMP and the 
phosphorylation status of EGFR was analysed after GnRH challenge (Fig. 10 F). 
Induction of EGFR phosphorylation by GnRH was markedly suppressed in cells 
transfected with Rz-MT1-MMP. In summary, our data show that the cross-talk 
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between GnRHR and EGFR proceeds via MT1-MMP and gelatinases. Furthermore, 
we provide evidence that MT1-MMP is involved in MMP2 activation in αT3-1 cells. 
 
4.1.4. HB-EGF shedding mediates EGF receptor phosphorylation in 
gonadotropic cells.  
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Figure 11. HB-EGF shedding is involved in GnRH-mediated EGFR transactivation in 
αT3-1 cells.  
A: Upper panel, Serum-starved αT3-1 cells were treated with 15 µg/ml anti-HB-EGF antibody 
for 1 h and subsequently stimulated with 1 µM GnRH for 5 min. Western blots of cell lysates 
were probed with an anti-phosphoEGFR antibody. Lower panel, Blots were reprobed with an 
anti-EGFR antibody. B: Upper panel, Serum-starved αT3-1 cells were pretreated with 10 µM 
Ro32-7315 for 30 min prior to stimulation with 1 µM GnRH or 1 µM TPA for 5 min. Western 
blots of cell lysates were probed with anti-phosphoEGFR antibody. Lower panel, Blots were 
reprobed with antibodies detecting EGFR. C: Upper panel, αT3-1 cells were transiently 
transfected with Rz-ADAM10. After serum-starvation, cells were treated with 1 µM GnRH for 5 
min. Western blots of cell lysates were probed with an anti-phosphoEGFR antibody. Lower 
panel, Blots were reprobed with an anti-EGFR antibody.  
 
We have shown that HB-EGF is the predominant ligand for transactivation-mediated 
ERK activation in αT3-1 cells. To test whether liberated HB-EGF serves to induce 
EGFR activation, lysates of αT3-1 cells preincubated with anti-HB-EGF prior to 
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GnRH challenge were probed with anti-phosphoEGFR antibodies. In line with our 
data obtained when monitoring ERK phosphorylation, trapping of HB-EGF strongly 
inhibited GnRH-mediated EGFR activation (Fig. 11 A). To elucidate the role of 
ADAM17/TACE-induced shedding in Gq/11-arbitrated EGFR activation, we applied 
Ro32-7315 in αT3-1 cells. In Fig. 11 B the effects of Ro32-7315 on GnRH- and TPA-
mediated EGFR activation are shown. GnRH transactivates EGFR in a 
ADAM17/TACE-independent fashion. Furthermore, TPA-elicited EGFR 
phosphorylation was not inhibited by Ro32-7315 treatment (Fig. 11 B). As performed 
on the ERK level before (Fig. 8 E), the involvement of ADAM10 in GnRH-induced 
EGFR phosphorylation was studied by transiently transfecting αT3-1 cells with Rz-
ADAM10. Phosphorylated EGFR was detected with an anti-phosphoEGFRY845-
specific antibody (Fig. 11 C). Ribozyme targeting of ADAM10 did not inhibit GnRH-
mediated EGFR phosphorylation (Fig. 11 C). In summary, these data elucidate that 
HB-EGF shedding induced by GnRH treatment leads to EGFR phosphorylation in 
gonadotropic cells.  
 
4.1.5. GnRH-mediated Src activation in αT3-1 cells depends on gelatinase 
activity.  
We have recently shown that inhibition of Src activity suppresses GnRHR-mediated 
GTP-loading of Ras and subsequent ERK activation in αT3-1 and transfected COS-7 
cells (Grosse 2000b). To directly address the role of Src kinases in GnRH-induced 
EGFR transactivation in αT3-1 cells, Src kinase activity was blocked by the specific 
Src inhibitor PP2. As shown in Fig. 12 A, preincubation of cells with PP2 resulted in 
diminished GnRH-mediated EGFR tyrosine phosphorylation. Likewise, pretreatment 
of cells with AG1478 abrogated EGFR activation stimulated by GnRH treatment (Fig. 
12 A). Furthermore, αT3-1 cells were pretreated with PP2 and AG1478 and activated 
Src was monitored in cell lysates with an antibody recognizing phosphorylation of 
tyrosine 424 (418 in human Src) located in the catalytic domain of Src. 
Phosphorylation of tyrosine 424 is necessary for full catalytic activity and SrcY424 has 
been shown to mediate phosphorylation of tyrosine 845 of the EGFR (Biscardi 1999). 
GnRH challenge led to increased Src phosphorylation which was not inhibited in cells 
pretreated with AG1478 whereas PP2 treatment resulted in reduced phosphorylation 
of Src (Fig. 12 B). Thus, EGFR tyrosine kinase activity is not required for Src 
phosphorylation at tyrosine 424 and Src appears to be located upstream of the 
EGFR in the cross-talk between the RTK and the GnRHR.  
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Figure 12. Src is involved in GnRH-mediated EGF receptor transactivation in αT3-1 
cells.  
A, B: Upper panels, Serum-depleted αT3-1 cells were preincubated with 1 µM PP2 or 100 nM 
AG1478 for 30 min and subsequently stimulated with 1 µM GnRH for 5 min. Western blots of 
cell lysates were probed with an anti-phosphoEGFR (A) or an anti-phosphoSrc (B) antibody. 
Lower panels, Blots were reprobed with an anti-EGFR (A) or an anti-Src (B) antibody. C: 
Upper panel, Serum-starved αT3-1 cells were preincubated with 10 µM Ro28-2653 or 10 µM 
batimastat (BB-94) for 30 min and subsequently incubated with 1 µM GnRH. Western blots of 
cell lysates were probed with an anti-phosphoSrc antibody. Lower panel, Blots were reprobed 
with an anti-Src antibody. D: Upper panel, αT3-1 cells were transiently transfected with 
ribozymes directed against MMP2 (Rz-MMP2), MMP9 (Rz-MMP9), MMP12 (Rz-MMP12) or 
FGF-BP (Rz-FGF-BP). After serum-depletion, cells were stimulated with 1 µM GnRH for 5 
min. Western blots of cell lysates were probed with an anti-phosphoSrc antibody. Lower 
panel, Blots were reprobed with an anti-Src antibody. 
 
To assess the contribution of MMPs in GnRH-mediated Src phosphorylation, 
gelatinases were blocked by preincubation with Ro28-2653 prior to GnRH stimulation 
(Fig. 12 C). GnRH-mediated Src phosphorylation was sensitive to inhibition of MMP2 
and MMP9 activities by Ro28-2653 as shown in Fig. 12 C, while batimastat had no 
inhibitory effect. This pharmacological approach indicates that gelatinases are 
located upstream of Src in the pathway emanating from GnRH coupling to its 
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cognate receptor. To further test this concept, MMP2 and MMP9 were downregulated 
by ribozyme transfection of αT3-1 cells as described above. Transfection with 
ribozymes against MMP2 or MMP9 confirmed the pharmacological inhibitor studies 
by suppressing GnRH-mediated Src activation (Fig. 12 D) while Rz-MMP12 or Rz-
FGF-BP did not show inhibitory properties. Considering that Src or EGFR blockage 
did not have any impact on the activation of MMP2 or MMP9 by GnRH (Fig. 12 E), 
we conclude that Src is interposed between activated gelatinases and the EGFR in 
αT3-1 cells.  
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Figure 12. E: Serum-starved αT3-1 cells were pretreated with 1 µM PP2 or 100 nM AG1478 
for 30 min and treated with 1 µM GnRH for 5 min. Culture media were collected and 
concentrated. Western blots of samples containing 15 µg protein were  probed with anti-
MMP2- (upper panel) or anti-MMP9 (lower panel) antibodies. F: Upper panel, Serum-depleted 
LβT2 cells were preincubated with 1 µM PP2 for 30 min and incubated with 1 µM GnRH for 5 
min. Western blots of cell lysates were probed with an anti-phosphoEGFR antibody. Lower 
panel, Blots were reprobed with an anti-EGFR antibody. G: Upper panel, Serum-depleted 
LβT2 cells were preincubated with 1 µM PP2, 100 nM AG1478 or 100 µM Ro28-2653 for 30 
min and incubated with 1 µM GnRH for 5 min. Western blots of cell lysates were probed with 
an anti-phosphoSrc antibody. Lower panel, Blots were reprobed with an anti-Src antibody.  
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Yet again, we extended our study on LβT2 cells to address the issue of Src 
localization. LβT2 cells were pretreated with PP2 and EGFR phosphorylation was 
detected. GnRH transactivated the EGFR in a PP2-dependent manner (Fig. 12 F). In 
addition, cells were treated with PP2 or AG1478 and Src phosphorylation was 
detected. Treatment of cells with PP2 led to inhibition of GnRH-mediated Src 
activation whereas AG1478 showed no inhibitory properties (Fig. 12 G). Gelatinases 
contribute to GnRH-induced Src phosphorylation since blockage of MMP2 and 
MMP9 by Ro28-2653 diminished GnRH-mediated Src phosphorylation (Fig. 12 G). 
 
4.1.6. GnRH-elicited Ras activation is dependend on EGF receptor 
transactivation and gelatinase activity in gonadotropic cells.  
Mitogenic signaling of GPCRs is realized via both Ras-dependent and –independent 
pathways (Gudermann 2000). GTP-loaded Ras subsequently engages the 
Raf/MEK/ERK cascade indistinguishable from the mechanism initiated by ligand-
bound RTKs. Interpretation of Ras activation by Gq-coupled receptors, however, is 
complicated by the fact that most heptahelical receptors concomitantly couple to an 
assortment of different G proteins and so GPCR-mediated Ras activation still is a 
rather contradictory subject (Gudermann 2000). We have shown recently that ERK 
activation in gonadotropic αT3-1 cells is accomplished via activation of Ras (Grosse 
2000b). To study the contribution of EGFR activation on GnRH-mediated GTP-
loading of Ras, αT3-1 cells were preincubated with AG1478 and subsequently 
treated with GnRH or TPA. A GST-fusion protein containing the minimal Ras-binding 
domain of Raf-1 was used to precipitate the activated form of Ras. GnRH challenge 
led to GTP-loading of Ras which was reduced substantially by preincubation of cells 
with AG1478 (Fig. 13 A). GnRH signaling to ERK can be fully mimicked by PKC 
activation induced by short-term TPA treatment (Fig. 13 A). TPA-elicited Ras activity 
was also substantially diminished by AG1478 pretreatment (Fig. 13 A). To define the 
roles of PKC and Src in GnRH-mediated Ras activation, both kinases were inhibited 
by specific inhibitors GF109203X or PP2, respectively (Fig. 13 B). As is clearly visible 
in Fig. 13 B, GnRH-mediated GTP-loading of Ras is attenuated by pretreatment of 
cells with GF109203X or PP2. To test whether gelatinase-mediated EGFR 
transactivation is a prerequisite for Ras activation by GnRH, αT3-1 cells were 
pretreated with Ro28-2653 or batimastat prior to GnRH or short-term phorbol ester 
treatment. Preincubation of cells with Ro28-2653 reduced the amounts of 
precipitated Ras proteins induced by both stimuli (Fig. 13 C, D). On the contrary, 
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pretreatment of cells with batimastat did not adversely affect GnRH- or TPA-
mediated activation of Ras. To summarize, our data demonstrate that MMP2 and 
MMP9 mediate GnRH activation of EGFR resulting in the engagement of a PKC- and 
Src-dependent Ras signaling pathway in αT3-1 cells.  
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Figure 13. Gq/11-mediated Ras activation involves MMP2 and MMP9 activities.  
A: Serum-starved αT3-1 cells were incubated with 200 nM GnRH or 100 ng/ml TPA for 5 min 
after pretreatment with 100 nM AG1478 for 20 min. Cell lysates were incubated with GST-
RBD precoupled to glutathione-sepharose at 4°C for 30 min. GTP-loaded Ras was analysed 
by SDS-PAGE followed by immunoblotting with an anti-Ras antibody. B: Serum-starved αT3-
1 cells were preincubated with 1 µM GF109203X or 1 µM PP2 for 20 min prior to 200 nM 
GnRH challenge. Cell lysates were incubated with GST-RBD precoupled to glutathione-
sepharose at 4°C for 30 min. GTP-loaded Ras was analysed by SDS-PAGE followed by 
immunoblotting with an anti-Ras antibody. C, D: Upper panels, Serum-depleted αT3-1 cells 
were preincubated with 10 µM Ro28-2653 or 10 µM batimastat (BB-94) for 30 min and then 
stimulated with 1 µM GnRH (C) or 1 µM TPA (D) for 5 min. Cell lysates were incubated with 
GST-RBD precoupled to glutathione-sepharose at 4°C for 30 min. GTP-loaded Ras was 
analysed by SDS-PAGE followed by immunoblotting with an anti-ras antibody. Lower panels, 
Aliquots of the used lysates were subjected to SDS-PAGE followed by immunoblotting with an 
anti-Ras antibody.  
4.1.7. EGF receptor tyrosine kinase and MMP activities are not required to 
mediate GnRH-induced activation of JNK and p38MAPK.   
p38MAPK has been implicated in being regulated by EGFR transactivation in a 
variety of different cell systems whereas GPCR/EGFR cross-talk has not been 
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reported to play a role in JNK activation (Eguchi 2001, Kanda 2001). Apart from 
engaging the ERK cascade, GnRH also stimulates the activities of all three stress-
related MAPKs (Naor 2000). We have previously shown that inhibition of EGFR by 
AG1478 retarded the onset of agonist-dependent ERK activation in αT3-1 cells 
(Grosse 2000b). To extend this experimental approach to the JNK and p38MAPK 
cascades, we monitored the time course of JNK and p38MAPK activation in αT3-1 
cells. Cells were pretreated with AG1478, Ro28-2653 or batimastat and subsequently 
stimulated with GnRH for multiple time points ranging from 5 min to 1 h. Western 
blots of cell lysates were performed with antibodies directed against phosphorylated 
JNK1/2 and p38MAPK (Fig. 14). 
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Figure 14. AG1478, Ro28-2653 or batimastat do not effect GnRH-induced JNK or 
p38MAPK activation in αT3-1 cells.  
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A: Serum-starved αT3-1 cells were stimulated with 1 µM GnRH for the indicated time periods. 
Western blots of cell lysates were probed with an anti-phosphoJNK antibody. B, C, D: Serum-
starved αT3-1 cells were stimulated with 1 µM GnRH for the indicated time periods. Prior to 
GnRH challenge, cells were incubated with 100 nM AG1478 (B), 10 µM Ro28-2653 (C) or 10 
µM batimastat (BB-94) (D) for 30 min. Western blots of cell lysates were probed with an anti-
phosphoJNK antibody. E: Serum-starved αT3-1 cells were stimulated with 1 µM GnRH for the 
indicated time periods. Western blots of cell lysates were probed with an anti-
phosphop38MAPK antibody. F, G, H: Serum-starved αT3-1 cells were stimulated with 1 µM 
GnRH for the indicated time periods. Prior to GnRH challenge, cells were incubated with 100 
nM AG1478 (F), 10 µM Ro28-2653 (G) or 10 µM batimastat (BB-94) (H) for 30 min. Western 
blots of cell lysates were probed with an anti-phosphop38MAPK antibody.   
 
In congruence with previous observations (Mulvaney 2000), an increase in the 
phosphorylation status of JNK1 and 2 was noted 5 min after GnRH challenge (Fig. 14 
A). JNK activation reached a maximum after 30 min and remained at a comparably 
high level throughout the observation period. The tyrosine kinase activity of the 
EGFR does not appear to be required for GnRH signaling to JNK, because 
preincubation of cells with AG1478 had no inhibitory impact (Fig. 14 B). Along these 
lines, application of Ro28-2653 (Fig. 14 C) or batimastat (Fig. 14 D) left GnRH-
induced JNK phosphorylation completely unaffected. According to previous studies in 
αT3-1 cells (Roberson 1999), GnRHR occupancy leads to p38MAPK activation 
commencing 15 min after agonist challenge and declining after 30 min (Fig. 14 E). 
Inhibition of EGFR as well as gelatinases by the specific inhibitors did not result in 
any decline of GnRH-mediated p38MAPK activation (Fig. 14 F, G). Furthermore, 
batimastat had no effect on GnRH-elicited p38MAPK activity (Fig. 14 H). In brief, 
gelatinase-triggered EGFR transactivation is not involved in activation of other 
MAPKs in αT3-1 cells. These findings further support the specificity of the inhibitors 
used. 
 
4.1.8. The induction of c-fos and c-jun depends on gelatinase activity and 
EGF receptor transactivation.  
GnRH stimulation of αT3-1 cells results in increased mRNA levels for the immediate 
early genes c-fos and c-jun (Cesnjaj 1994) as well as elevated c-fos and c-jun protein 
levels (Mulvaney 1999). The timing of c-fos and c-jun induction upon GnRH 
challenge, however, is discussed controversially. Hence, the time course of c-fos and 
c-jun induction in GnRH signaling was examined by stimulating αT3-1 cells with 
GnRH at multiple time points ranging from 5 min to 60 min. As depicted in Fig. 15 A, 
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B, a-60 min GnRH challenge resulted in a strong induction of c-fos and c-jun 
proteins. 
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Figure 15. Induction of c-fos and c-jun in αT3-1 cells depends on gelatinase-triggered 
EGFR transactivation.  
A, B: Serum-starved αT3-1 cells were stimulated with 1 µM GnRH for the indicated time 
periods. Western blots of cell lysates were probed with an anti-c-fos antibody (A) or an anti-c-
jun antibody (B). C, D: Serum-starved αT3-1 cells were pretreated with 10 µM Ro28-2653, 10 
µM batimastat (BB-94), 1 µM PP2 or 100 nM AG1478 for 30 min and subsequently treated 
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with 1 µM GnRH for 60 min. Western blots of cell lysates were probed with an anti-c-fos 
antibody (C) or an anti-c-jun antibody (D). E, F: αT3-1 cells were transiently transfected with 
ribozymes directed against MMP2 (Rz-MMP2), MMP9 (Rz-MMP9), MMP12 (Rz-MMP12) or 
FGF-BP (Rz-FGF-BP). Serum-depleted cells were stimulated with 1 µM GnRH for 60 min. 
Western blots of cell lysates were probed with an anti-c-fos antibody (E) or an anti-c-jun 
antibody (F).  
 
To address the issue as to whether gelatinase activation and subsequent EGFR 
transactivation are of cell physiological relevance or whether the latter events are 
dispensable for the complex GnRH action on gonadotropic cells, c-fos and c-jun 
induction in the presence of various pharmacological inhibitors was examined by 
stimulating αT3-1 cells with GnRH for 60 min. EGFR tyrosine kinase activity was 
blocked by AG1478, and cells were further preincubated with the gelatinase inhibitor 
Ro28-2653, batimastat and the Src kinase inhibitor PP2. After GnRH challenge, 
Western blots were performed with antibodies recognizing c-fos and c-jun proteins 
(Fig. 15 C, D). Pretreatment of cells with AG1478, Ro28-2653 or PP2 profoundly 
counteracted the induction of c-fos and c-jun. Incubation of cells with batimastat, 
however, had no effect on c-jun and c-fos protein levels.  
To confirm the role of MMP2 and MMP9 in GnRH-mediated c-fos and c-jun induction 
by an independent experimental approach, αT3-1 cells were transfected with 
ribozymes directed against MMP2, MMP9, MMP12 or FGF-BP. Cells treated with 
ribozyme Rz-MMP2 were characterized by a substantial suppression of c-fos and c-
jun protein levels in response to GnRH challenge (Fig. 15 E, F). Likewise, Rz-MMP9-
transfected cells displayed reduced c-fos and c-jun protein levels, although the 
inhibitory effect of the transfected ribozyme was less obvious when compared to Rz-
MMP2-mediated gene silencing. Transfection of αT3-1 cells with ribozymes directed 
against MMP12 or FGF-BP did not affect GnRH-mediated gene induction. 
 
4.2. Neuropeptides mediate growth of small cell lung cancer cells via rises 
in [Ca2+]i and ERK activation 
4.2.1. Neuropeptide-activated Pyk2 associates with Src kinases and PI3K in a 
[Ca2+]i–dependent way.  
One widely accepted hypothesis is that SCLC cells originate from neoplastic 
transformation of neuroendocrine cells of the neural crest (Watkins 2003, Williams 
1997). Many features of neuroendocrine cells, e.g. calcium-mediated synthesis and 
secretory release of neuropeptides and production of their cell surface receptors, 
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creating autocrine and paracrine growth loops (Rozengurt 1999, Williams 1997), are 
apparent in SCLC cells. We have previously demonstrated that galanin-induced ERK 
activation in SCLC cells critically depends on elevation of [Ca2+]i (Wittau 2000). 
Therefore, we concluded that intracellular Ca2+-levels besides contributing to PKC 
isoforms may regulate other targets to stimulate ERK activity in SCLC cells.  
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Figure 16. Neuropeptide-mediated Pyk2 activation is dependend on [Ca2+]i in SCLC 
cells.  
A: Western blots of H69 and H510 cell lysates (10 and 15 µg total protein) were probed with 
an anti-Pyk2 antibody. B, C: Upper panels, H69 cells (B) or H510 cells (C) were stimulated 
with 100 nM galanin (GAL), 1 µM bradykinin (BK) or 1 µM ionomycin (IONO) for 5 min. Pyk2 
was immunoprecipitated from cell lysates with an anti-Pyk2 antibody. The immunoprecipitated 
proteins were then subjected to immunoblotting with an antibody against phosphotyrosine 
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(PY). Lower panels, Blots were reprobed with anti-Pyk2 antibodies. D, E: Upper panels, H69 
cells (D) or H510 cells (E) were pretreated with 1 µM GF109203X or 1 µM BAPTA/AM for 30 
min and subsequently stimulated with 100 nM galanin (GAL) for 5 min. Pyk2 was 
immunoprecipitated from cell lysates with an anti-Pyk2 antibody. The immunoprecipitated 
proteins were then subjected to immunoblotting with an antibody against phosphotyrosine 
(PY). Lower panels, Blots were reprobed with an anti-Pyk2 antibody.  
 
Pyk2 is abundantly expressed in neuronal tissue and becomes activated in response 
to a number of extracellular stimuli including agonists acting on GPCRs thereby 
regulating ERK activation (Avraham 2000, Lev 1995). For this reason we tested 
whether Pyk2 was also expressed in SCLC cells by performing RT-PCR of H69 and 
H510 cell RNA. Two specific Pyk2 cDNA fragments were amplified using two 
different primer pairs of the Pyk2 coding region. The identity of the amplification 
products was confirmed by DNA sequencing (data not shown). To determine Pyk2 
expression at the protein level, lysates of H69 and H510 cells containing 10 and 15 
µg protein were analysed by immunoblotting with monoclonal anti-Pyk2 antibodies 
(Fig. 16 A). A specific band for both SCLC cell lines tested corresponding to the 
molecular weight of Pyk2 (116 kDa) is visible in Fig. 16 A. Next, we tested if 
neuropeptides like galanin or bradykinin induce Pyk2 phosphorylation in SCLC cells 
as assessed by increased tyrosine phosphorylation of immunoprecipitated Pyk2. 
Stimulation of H69 and H510 cells with either galanin (GAL) or bradykinin (BK) for 5 
min leads to a rapid increase in tyrosine phosphorylation of Pyk2 (Fig. 16 B, C). This 
effect could be fully mimicked by treatment of cells with the calcium ionophore 
ionomycin (IONO) (Fig. 16 B, C). Since increases of [Ca2+]i and/or active PKC are 
responsible for Pyk2 activation (Avraham 2000), SCLC cells were treated with the 
[Ca2+]i chelator BAPTA/AM or the specific PKC inhibitor GF109203X prior to galanin 
challenge and the phosphorylation status of immunoprecipitated Pyk2 was detected 
with an anti-phosphotyrosine-specific antibody (Fig. 16 D, E). We observed that 
galanin-mediated tyrosine phosphorylation of Pyk2 was abolished after loading of 
H69 and H510 cells with BAPTA/AM (Fig. 16 D, E). In contrast, blockage of PKC 
activity by GF109203X had no inhibitory effect on galanin-induced Pyk2 tyrosine 
phosphorylation in H69 cells (Fig. 16 D) and showed only a slight inhibitory effect in 
H510 cells (Fig. 16 E). Interestingly, we coprecipitated two additional tyrosine 
phosphorylated bands migrating at 60 and 85 kDa which were sensitive to 
BAPTA/AM pretreatment as well (Fig 17 A).  
It is well established that ERK activation via Pyk2 requires direct association with the 
SH2 domain of Src tyrosine kinases to recruit the Shc/Grb2 complex (Blaukat 1999, 
della Rocca 1997, Dikic 1996). Furthermore, immunoprecipitation analysis in different 
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cellular settings revealed complex formation between Pyk2 and PI3K (Hatch 1998, 
Rocic 2001). To test whether the 60-kDa fragment which was precipitated and 
tyrosine phosphorylated together with Pyk2 (Fig. 17 A) represents Src kinases, 
coprecipitation experiments were performed (Fig. 17 B). H69 cells were stimulated 
with galanin or treated with ionomycin for 5 min and Pyk2 was immunoprecipitated.  
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Figure 17. Pyk2 associates with Src tyrosine kinases and PI3K in a [Ca2+]i-dependent 
manner.  
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A: H69 cells were pretreated with 1 µM BAPTA/AM for 30 min and subsequently stimulated 
with 100 nM galanin (GAL). Pyk2 was immunoprecipitated from cell lysates with an anti-Pyk2 
antibody. The immunoprecipitated proteins were then subjected to immunoblotting with an 
anti-phosphotyrosine (PY) - specific antibody. B: H69 cells were stimulated with 100 nM 
galanin (GAL) or 1 µM ionomycin (IONO) for 5 min. Cell lysates were subjected to 
immunoprecipitation with anti-Pyk2 antibodies, immunoprecipitates were separated on 20 cm-
SDS-PAGE and detected with an antibody against Src tyrosine kinases. To demonstrate the 
specificity of the immunoprecipitating antibody, cell lysates were immunoprecipitated with 
protein A-sepharose alone (shown in first lane). C: H69 cells were stimulated with 100 nM 
galanin (GAL) for 5 min and Pyk2 was immunoprecipitated from cell lysates with an anti-Pyk2 
antibody. The immunoprecipitated proteins were then subjected to immunoblotting with an 
antibody against PI3K p110α (upper panel), PI3K p110β (middle panel) or PI3K p85α (lower 
panel). D: Upper panel, H69 cells were pretreated with 1 µM PP2 or 50 µM LY294002 for 30 
min and subsequently stimulated with 100 nM galanin (GAL) for 5 min. Pyk2 was 
immunoprecipitated from cell lysates with an anti-Pyk2 antibody. The immunoprecipitated 
proteins were then subjected to immunoblotting with an anti-phosphotyrosine (PY) antibody. 
Lower panel, Blots were reprobed with anti-Pyk2 antibodies.  
 
Coprecipitated Src tyrosine kinases were subsequently detected by immunoblotting 
with anti-Src antibodies. Fig. 17 B shows that Src specifically associated with Pyk2 in 
a galanin- or ionomycin-dependent manner. Since PI3K has been shown to be 
important for anchorage-independent growth of SCLC cells and immunoprecipitation 
experiments revealed the association of PI3K p85 subunit with Pyk2 in monocytic 
cells (Hatch 1998, Moore 1998), we were to examine if the 85 kDa-coprecipitating 
band corresponds to any PI3K subunit. By using specific PI3K p110α−, PI3K p110β− 
or PI3K p85α−antibodies,  the 85 kDa band was identified as the regulatory p85α 
subunit of PI3K (Fig. 17 C).  
To test whether neuropeptide-triggered Pyk2 phosphorylation in SCLC cells is 
dependent on Src kinase- or PI3K activities, H69 cells were incubated with the 
specific Src kinase inhibitor PP2 or the specific PI3K inhibitor LY294002 prior to 
galanin stimulation (Fig. 17 D). Inhibition of Src kinase activity resulted in diminished 
Pyk2 tyrosine phosphorylation to basal levels (Fig. 17 D). In addition, tyrosine 
phosphorylation of Pyk2 was completely blocked in cells pretreated with the PI3K 
inhibitor (Fig. 17 D).  
 
4.2.2. Galanin or elevation of [Ca2+]i stimulate Src activity in SCLC cells.  
In order to directly monitor Src kinase activity in SCLC cells, endogenous Src kinases 
were immunoprecipitated from H69 cell lysates and subsequently applied to an in 
vitro kinase assay using a synthesized Src-specific peptide substrate (Songyang 
1995). Basal Src kinase activities in samples of H69 cells were six times higher than 
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in COS-7 cells whereas values for samples treated without anti-Src antibodies were 
below 1% of basal values. Src kinase activity could hardly be detected in samples 
precipitated with protein A-sepharose alone, further demonstrating the specificity of 
the assay. Basal values were equated to one. Stimulation of H69 cells with galanin 
elicited a 1.9 ± 0.4-fold increase in Src kinase activity (Fig. 18 A) which was inhibited 
to basal levels by depletion of intracellular calcium with BAPTA/AM (Fig. 18 A). 
Treatment of cells with ionomycin alone was sufficient to activate Src kinases (Fig. 18 
A). [Ca2+]i-dependent activation of Src kinase activity was abolished by pretreatment 
of cells with the Src kinase inhibitor PP2 (Fig. 18 A). Similar results were obtained by 
stimulating Src kinase activity in H510 cells (Fig. 18 B). Treatment of H510 cells with 
galanin or ionomycin led to increased Src kinase activities which were sensitive to 
BAPTA/AM- or PP2 preincubation, respectively (Fig. 18 B). 
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Figure 18. Galanin or elevation of [Ca2+]i  stimulate Src activity in SCLC cells.  
A, B: Upper panels, H69 (A) or H510 (B) cells were stimulated with 100 nM galanin (GAL) or 
1 µM ionomycin (IONO) for 5 min in the presence or absence of 1 µM BAPTA/AM or 1 µM 
PP2, respectively. Src kinases were immunoprecipitated with an anti-src antibody and src 
kinase activity was measured in an in vitro kinase assay. The data are presented as ± SEM of 
at least three independent experiments performed in duplicates and are expressed as –fold 
stimulation relative to mean basal Src kinase activity. Lower panels, Aliquots of lysates used 
for Src kinase activity assays were subjected to immunoprecipitation with an anti-Src kinase 
antibody and blotted with an anti-Src kinase antibody. One representative blot is shown.  
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4.2.3. Neuropeptide-induced Ras activation is dependent on [Ca2+]i and Src 
kinase activity with RasGEFs not being involved.  
As explained before, ERK activation by agonists acting on Gq/11-coupled receptors 
can be accomplished via Ras-independent and –dependent pathways by direct 
phosphorylation of Raf-1 by PKC isoforms or GTP-loading of Ras, respectively 
(Gudermann 2000, Kolch 1993). A role for [Ca2+]i in the activation of Ras has been 
reported to proceed indirectly through activation of Pyk2 or Ca2+-dependent 
RasGEFs, RasGRF or RasGRP (Murasawi 1998, Zwartkruis 1999). RasGEFs are 
predominantly expressed in neuronal tissue with RasGRF2 also being highly 
expressed in lung tissue (Cullen 2002, Table 1). In order to decipher the expression 
of RasGEFs in SCLC cells, total RNA from H69 and H510 cells was isolated and RT-
PCR was performed using specific primer pairs for RasGRF2 and RasGRP/CalDAG-
GEF II (Fig. 19 A). Amplification products of the correct size were obtained only with 
oligonucleotides specific for RasGRF2 (Fig. 19 A). The identity of the PCR products 
was confirmed by DNA sequencing. Amplification of the housekeeping gene GAPDH 
was positive (Fig. 19 A).  
Activating ras mutations have not been described in SCLC (Mitsudomi 1991, Suzuki 
1990) and overexpression of inducable Raf-1 activity or constitutively active Ras in 
SCLC cells rather causes growth arrest or increased levels of endocrine 
differentiation markers, respectively (Mabry 1988, Ravi 1998). These data suggest 
that Ras activation may not award a growth advantage to SCLC cells. Furthermore, 
oncogenic Ras strongly activates JNK in SCLC cells whereas stimulation of ERK 
activity was only modestly affected (Xiao 2000). Given that the effect of neuropeptide 
stimulation on GTP-loading of Ras has not been investigated in SCLC cells, H69 
cells were stimulated with galanin or bradykinin for 5 min and the GTP-loaded form of 
Ras was precipitated by using a GST-fusion protein containing the minimal Ras-
binding domain of Raf-1 (Fig. 19 B, C). As shown in Fig. 19 B, C, both neuropeptides 
induced a rapid activation of Ras which was dependent on [Ca2+]i and Src kinase 
activity as assessed by pretreatment of cells with BAPTA/AM or PP2, respectively. 
To examine the involvement of RasGRF2 in Ca2+-dependent signaling to Ras, cells 
were incubated with the calmodulin antagonist calmidazolium chloride prior to galanin 
or bradykinin challenge (Fig. 19 B, C). Inhibition of calmodulin did not decrease 
neuropeptide-induced GTP-loading of Ras (Fig. 19 B, C).  
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Figure 19. Ras activity is induced by neuropeptides in a [Ca2+]i-dependend manner with 
Ras exchange factors not being involved in SCLC cells.  
A: Total RNA of H69 and H510 cells was isolated and RasGRF2, RasGRP and GAPDH 
cDNAs were amplified by RT-PCR. The DNA size is indicated at the left. B, C: H69 cells were 
pretreated with 1 µM BAPTA/AM, 1 µM calmidazolium chloride or 1 µM PP2 for 30 min and 
subsequently stimulated with 100 nM galanin (GAL; A) or 1 µM bradykinin (BK; B) for 5 min. 
Cell lysates were incubated with GST-RBD precoupled to glutathione-sepharose at 4°C for 30 
min. GTP-loaded Ras was analysed by SDS-PAGE followed by immunoblotting with an anti-
Ras antibody.  
4.2.4. Src kinase activity is required for neuropeptide-induced ERK activation 
and anchorage-independent growth of SCLC cells.  
Challenging H69 cells with galanin for 5 min leads to an increase in ERK activity 
(Wittau 2000). Since neuropeptide-mediated stimulation of ERK activity represents 
an essential mechanism for the growth of SCLC cells (Rozengurt 1999), we next 
addressed the role of Src kinase activity in mediating ERK activation in SCLC cells. 
Endogenous ERK activity of H69 cells was measured in an in vitro kinase assay 
using myelin basic protein as a substrate (Grosse 2000b). Experimental values of 
non-stimulated H69 cells were equated to one. Stimulation of H69 cells with galanin 
induced a 2.1 ± 0.3-fold increase of ERK activity (Fig. 20). Moderate stimulation of 
ERK activity was obtained by bradykinin treatment (Fig. 20). Neuropeptide-induced 
ERK activities were blocked by preincubating the cells with PP2 (Fig. 20).  
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Figure 20. ERK activity of H69 cells is dependent on Src kinase activity.  
Upper panel, H69 were pretreated with 1 µM PP2 for 30 min and subsequently treated with 
100 nM galanin (GAL) or 1 µM bradykinin (BK) for 5 min. ERK1/2 were immunoprecipitated 
with an anti-ERK1/2 antibody and ERK activity was measured in an in vitro kinase assay. The 
data are presented as ± SEM of three independent experiments performed in duplicates and 
are expressed as –fold stimulation relative to mean basal ERK kinase activity. Lower panel, 
Aliquots of lysates used for ERK activity assays were used for immunoblotting with an anti-
ERK1/2 antibody. One representative blot is shown. 
 
A well characterized marker for the transforming potential of cells is represented by 
the ability to grow anchorage-independently (Sethi 1991). Anchorage-independent 
growth can be analysed by means of colony formation in semisolid medium (soft 
agar). The invasiveness of the tumor in specimens taken from SCLC strongly 
correlates with generation of tumor cell colonies in agarose (Carney 1980). To 
elucidate the biological consequences of Src kinase inhibition on SCLC growth in soft 
agar, we examined the effect of PP2 on clonogenic growth of H69 and H510 cells. 
Initially, concentration-response experiments were performed. H69 cells were seeded 
in soft agar supplemented with galanin in the presence of PP2 in concentrations 
ranging from 10-3 – 1 µM. Colonies from at least three independent experiments 
including ten separate dishes were counted after 21 days. One representative 
experiment is shown in Fig. 21 A. Galanin stimulated enhanced clonogenic growth of 
H69 cells in soft agar (21 A). PP2 treatment resulted in a clear concentration-
dependent decrease in galanin-induced colony formation of H69 cells (IC50 = 10-2 µM, 
Fig. 21 A). As demonstrated in Fig. 21 B- E, PP2 inhibited basal growth of H69 and 
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H510 cells. The addition of galanin or bradykinin failed to overcome PP2-induced 
growth inhibition with the inhibitory effect being less pronounced in clonogenic 
assays with H510 cells whereas cells not treated with PP2 efficiently responded to 
neuropeptide-mediated growth (Fig. 21 B - E).  
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Figure 21. Colony formation of SCLC cells is dependent on Src kinase activity.  
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A: A single-cell suspension of H69 cells was plated in HITESA medium containing agarose at 
a density of 1x104 cells/dish in the presence or absence of 10-3 – 1 µM galanin and was 
incubated for 21 days. B, C: A single-cell suspension of H69 cells was plated in HITESA 
medium containing agarose at a density of 1x104 cells/dish in the presence or absence of 100 
nM galanin (GAL, B) or bradykinin (BK, C) and/or 1 µM PP2 and incubated for 21 days. D, E: 
A single-cell suspension of H510 cells was plated in HITESA medium containing agarose at a 
density of 1x104 cells/dish in the presence or absence of 100 nM galanin (GAL, D) or 1 µM 
bradykinin (BK, E) and/or 1 µM PP2 and incubated for 21 days. Columns, mean number of 
colonies formed on ten separate dishes, bars, SEM. In all cases, one reprensentative out of 
three independent experiments is shown.  
 
To further describe the inhibitory effect of PP2 under biological conditions, liquid 
culture assays of SCLC cells were performed (Fig. 22). Cells were incubated in 
culture medium and cell numbers were calculated after 7 days. The addition of PP2 
to H69 and H510 cells in liquid culture resulted in decreased cell numbers below 
basal levels (Fig. 22). Galanin or bradykinin added to the culture media did not result 
in increased cell numbers, in contrary to cell counts elicited by galanin or bradykinin 
alone (Fig. 22).  
 
0
20
40
60
80
C
el
l n
um
be
r (
x1
04
 p
er
 m
l)
basalbasal
+ PP2
GAL BK
+ PP2
BKGAL
+ PP2
H69
B
0
20
40
60
80
basalbasal
+ PP2
GAL BK
+ PP2
BKGAL
+ PP2
H510
C
el
l n
um
be
r (
x1
04
 p
er
 m
l)
A
C
el
l n
um
be
r (
x1
04
 p
er
 m
l)
C
el
l n
um
be
r (
x1
04
 p
er
 m
l)
 
 
Figure 22. Growth of SCLC cells in liquid culture is dependent on Src kinase activity.  
A, B: H69 (A) and H510 (B) cells were aliquoted in 24-well plates in HITESA medium in the 
presence or absence of 100 nM galanin (GAL) or 1 µM bradykinin (BK) and/or 1 µM PP2. Cell 
numbers were counted from a minimum of 3 wells per condition at day 7. Columns, mean 
number of cells, bars, SEM. In all cases, a reprensentative out of three independent 
experiments is shown.  
4.2.5. Overexpression of Pyk2 induces cell death in SCLC cells.  
To gain further insight into the signaling properties of Pyk2 in SCLC cells, we were to 
overexpress Pyk2 and various Pyk2 mutants in SCLC cells. The presence of 
potential SH2 and SH3 binding motifs as well as proline-rich regions mediates the 
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association of Pyk2 with a number of proteins (Schlaepfer 1999). Tyrosine 402 of 
Pyk2 represents the major autophosphorylation and binding site for the Src SH2 
domain (Schlaepfer 1999). Pyk2 mutants deficient in this residue have been shown 
to lack their ability to autophosphorylate as well as form complexes with Src kinases 
and cells overexpressing Pyk2-Y402F are impaired in stimulation of ERK activity 
(Blaukat 1999). Kinase-dead mutant Pyk2-K457A(PKM) has been shown to be 
unable of activating Src (Blaukat 1999). In cells transfected with Pyk2-PKM no 
Grb2/Sos association and ERK activation was detectable (Blaukat 1999, Lev 1995). 
Since the above mentioned domains link Pyk2 to the ERK cascade, we 
overexpressed Pyk2-wt, Pyk2-Y402F and Pyk2-PKM in SCLC cells. In initial 
experiments Pyk2-wt was subcloned into the retroviral expression vector pLXSN and 
recombinant retroviruses were produced. Unexpectedly, infection of SCLC cells with 
these viruses resulted in spontaneous cell death. On account of this, we chose a 
transient transfection approach. Because the transfection efficiency was below 10%, 
we were not able to perform biochemical assays with transfected SCLC cells. 
Therefore, the morphology of single cells was analysed by fluorescent microscopy 
using bisbenzimide as a fluorescent dye that binds to DNA in cell nuclei. Cells 
harboring characteristic features of apoptosis such as membrane blebbing, cell 
swelling or DNA degradation visible as apoptotic bodies were designated apoptotic. 
Initially time-course experiments were conducted. H69 cells were transfected with 
Pyk2-wt and cells were monitored 12 h, 24 h, 36 h and 48 h after transfection. An 
increased rate of apoptotic cells was first evident at about 36 h after transfection. 
Pyk2-wt transfected H69 cells showed characteristic morphological features of 
apoptosis (Fig. 23 A). Surprisingly, after 36 h 72.6% ± 18.2% of all cells expressing 
Pyk2-wt underwent apoptosis in contrast to 3.2% ± 6.7% mock (pcDNA3.1) 
transfected cells (Fig. 23 A, B). 65.8% ± 21.6% or 61.8% ± 21.4% cells expressing 
PYK2-PKM or PYK2-Y402F, respectively, were apoptotic (Fig. 23 A, B). In control 
experiments with PC12W cells, overexpression of Pyk2-wt (98.7% ± 5.2% viable 
cells), Pyk2-PKM (98.2% ± 4.5% viable cells) or Pyk2-Y402F (99.1% ± 2% viable 
cells) showed no induction of apoptosis (mock transfected cells 99.4% ± 2.1% viable 
cells, Fig. 23 C). Since Pyk2 mutated at tyrosine residue 881 has been shown to fully 
stimulate Src and ERK activities (Blaukat 1999), we did not include this Pyk2 mutant 
in our studies. 
In SCLC cells, besides coupling to G proteins of the Gq/11 family, neuropeptide 
receptors initiate the Rho pathway by coupling to G12/13 proteins (Wittau 2000). Graf 
and PSGAP are GAPs for RhoA and Cdc42 functioning as mediators for Pyk2 to 
regulate Rho-family GTPases (Hildebrand 1996, Ren 2001). Both GAPs associate 
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with Pyk2 by binding to the second proline-rich domain (Ohba 1998, Ren 2001). To 
examine the possible involvement of the Rho pathway in initiating an apoptotic cell 
response after overexpression of Pyk2, H69 cells were transfected with Pyk2-P859A 
(Ohba 1998). 58.9% ± 13.4% of H69 cells overexpressing Pyk2-P859A underwent 
apoptosis (Fig. 23 A, B) whereas no apoptosis was detectable in PC12W cells 
(100.0% ± 0.0% viable cells, Fig. 23 C).  
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Figure 23. Overexpression of Pyk2 leads to apoptosis in H69 cells.  
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H69 cells were transfected with plasmids encoding Pyk2-wt, Pyk2-Y402F, Pyk2-PKM, Pyk2-
P717A and Pyk2-P859A. Mock (pcDNA3) transfected cells served as controls. To allow 
detection of transfected cells, eGFP was cotransfected as a marker. A: After fixation, 
transfected cells were identified at 470 nm and cell morphology was examined at 340 nm 
using a fluorescence miscroscopy device.  
It has been reported that Pyk2 is involved in activation of the JNK pathway and the 
p130Cas/Crk complex specifically links Pyk2 to it (Astier 1997, Blaukat 1999, Dolfi 
1998, Yu 1996). Proline residue 717 located in the first proline-rich domain of Pyk2 
has been shown to mediate the association of Pyk2 with p130Cas (Ohba 1998). To 
determine whether the JNK pathway is involved in cell death observed after 
transfection of Pyk2-wt, Pyk2 mutated at proline 717, Pyk2-P717A (Ohba 1998), was 
transiently transfected in H69 cells (Fig. 23 A, B). Pyk2-P717A overexpression did 
not induce cell death in H69 cells (12.4% ± 11.7% apoptotic cells, Fig. 23 A, B). In 
control experiments with PC12W cells transfection of Pyk2-P717A showed no loss of 
cell viability (97.5% ± 4.5% viable cells, Fig. 23 C).  
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Figure 23. B: The percentage of apoptotic H69 cells (mean ± SEM) among positively 
transfected cells from at least three independent experiments are shown. C: The percentage 
of viable PC12W cells (mean ± SEM) among positively transfected cells from at least three 
independent experiments are shown.  
 
So far, JNK activation by neuropeptides has not been described for SCLC cells 
because JNK activation rather occurs successively to ultraviolet radiation in these 
cells (Butterfield 1997). Since our data indicate an involvement of the JNK pathway in 
Pyk2-induced cell death, H69 cells were treated with galanin ranging from 5 to 60 
min and phosphorylation of JNKs was determined in Western blot experiments with 
an anti-phosphoJNK-specific antibody. As shown in Fig. 23 D, H69 cells do not 
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exhibit any basal JNK activity. JNK phosphorylation started 5 min after galanin 
treatment and declined within 15 min reaching basal levels 60 min after galanin 
stimulation (Fig. 23 D). On the contrary, H69 cells display a high basal 
phosphorylation status of ERKs as assessed by Western blotting with an anti-
phosphoERK antibody (Fig. 23 E).  
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Figure 23. D, E: Upper panels, H69 cells were stimulated with 100 nM galanin (GAL) for the 
indicated time periods. Western blots of cell lysates were probed with an anti-phosphoJNK 
(D) or anti-phosphoERK (E) antibody. Lower panels, Blots were reprobed with anti-JNK1/2 
(D) or anti-ERK1/2 (E) antibodies.  
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5. DISCUSSION 
By binding to their cognate GPCRs, many potent mitogens such as neuropeptides, 
angiotensin II or lysophosphatidic acid stimulate cell proliferation via engaging the 
ERK/MAPK cascade. As mentioned before, agonists stimulating Gq/11-coupled 
receptors activate PLCβ isoforms thereby activating PKCs and elevating [Ca2+]i. 
These two second messengers represent key molecules for coupling Gq/11 proteins to 
the ERK/MAPK cascade. In this work, by means of GnRH in gonadotropic αT3-1 
cells and galanin or bradykinin in SCLC cells, different aspects of Gq/11-dependent 
mitogenic signaling pathways were revealed. Our findings together with previous 
reports underline the notion that signaling pathways emanating from Gq/11-coupled 
receptors are tightly regulated in a cell- and receptor-specific manner. 
 
5.1. Matrix metalloproteinases 2 and 9 mediate EGF receptor transactivation 
by gonadotropin-releasing hormone 
Previously, we have shown that GnRH-elicited EGFR transactivation in αT3-1 cells is 
required for Ras activation and accelerates the kinetics of GnRH-induced ERK 
activity (Grosse 2000b). In the present study, we extend our earlier observations and 
delineate the signal transduction pathway connecting the agonist-occupied GnRHR 
with the EGFR (Fig. 24). Recent work on the cross-talk between EGFR and GPCRs 
has suggested a pivotal contribution of MMPs to this kind of receptor cross-
communication. Using non-selective MMP inhibitors, it was shown that GPCR 
stimulation resulted in cleavage of EGFR ligand-precursors and production of 
diffusible growth factors which then activate the EGFR (Carpenter 2000a). LPA- and 
carbachol-induced EGFR activation in COS-7 cells as well as bombesin-mediated 
EGFR phosphorylation in PC-3 cells was found to be batimastat-sensitive (Prenzel 
1999). Prostaglandin E2-mediated activation of EGFR in gastric epithelial- and colon 
cancer cells was inhibited by another broad-spectrum metalloproteinase inhibitor, 
GM6001 (Pai 2002). While the principal involvement of MMPs in the EGFR 
transactivation process appears to be a rather undisputed issue, the identity of the 
proteolytic enzymes and their regulation via GPCR ligands still remains elusive. 
Recently, three members of the ADAM family of proteases, i. e. ADAM 10, ADAM12 
and ADAM17/TACE, have been claimed responsible for shedding of EGF-like ligands 
resulting in EGFR transactivation (Asakura 2002, Gschwind 2003, Lemjabbar 2002). 
While MMP3 has the potential to cleave HB-EGF precursors to release active growth 
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factors (Suzuki 1997), it has not been possible to conclusively ascribe a defined role 
in EGFR/GPCR cross-talk to distinct members of the MMP family.  
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Figure 24. Cross-communication between GnRHR and EGFR in gonadotropic cells. 
GnRHR-induced gelatinase and MT1-MMP activation leads to shedding of proHB-EGF 
resulting in EGFR transactivation. GnRHR/EGFR cross-communication engages the 
Ras/MEK/ERK cascade via Src kinases. It might be speculated that the agonist-occupied 
GnRHR regulates MT1-MMP function by a mechanism utilizing PKC as indicated by the 
dashed line.   
 
The expression of gelatinases MMP2 and MMP9 can be demonstrated in a variety of 
human tumors and a major impact of these enzymes on the acquisition of a 
malignant phenotype during multiple stages of tumor progression has been 
emphasized (McCawley 2000). For instance, upregulation of MMP2 and MMP9 has 
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been correlated with increased invasiveness of different tumors including pituitary 
adenomas and carcinomas (Paez-Pereda 2000). Elevated levels of gelatinases as 
well as of the membrane-spanning MT1-MMP and the endogenous MMP inhibitors 
TIMP1 and TIMP2 were noted in pituitary adenomas (Paez-Pereda 2000). 
Furthermore, MMP9 expression in pituitary tumors was related to aggressive 
biological behavior and the incidence of MMP9 secretion was found to be 
significantly higher in invasive pituitary adenomas and carcinomas as compared to 
non-invasive tumor species (Kawamoto 1996, Turner 2000). In light of these 
observations, we first concentrated on a specific gelatinase inhibitor, Ro28-2653, to 
dissect the signaling pathway linking the GnRHR to the ERK family of MAPKs in 
gonadotropic cells. Inhibition of MMP2 and MMP9 activities with Ro28-2653 
profoundly suppressed GnRH-induced mitogenic signaling events in αT3-1 cells 
including EGFR phosphorylation, phosphorylation of Src kinases, GTP-loading of 
Ras, stimulation of ERK activity and induction of transcription factors like c-fos and c-
jun. 
To unequivocally identify MMP2 and MMP9 as the relevant proteolytic enzymes 
involved in the cross-communication between GnRHR and EGFR in αT3-1 cells, we 
opted for a novel ribozyme approach to specifically ablate MMP2 and MMP9 
expression. A low molecular weight polyethylenimine (PEI) was used as a 
transfection reagent to stabilize and introduce unmodified bioactive all-RNA 
ribozymes into cells (Aigner 2002). In contrast to high molecular weight PEIs, low 
molecular PEIs display a far less cytotoxicity in combination with higher transfection 
efficiencies. PEIs are able to condense and compact ribozymal RNA into complexes 
which are then transported into the cell through endocytosis. We have recently 
shown in our laboratory that PEI-complexed ribozymes are bioactive intracellularly as 
demonstrated by efficient down-regulation of mRNA and protein levels of various 
gene products in vitro and in vivo (Aigner 2002). GnRH-induced EGFR 
phosphorylation was completely prevented in cells transiently transfected with 
ribozymes directed against MMP2. Rz-MMP9-loaded cells showed a substantial 
reduction of EGFR phosphorylation. Specificity of the experimental approach was 
demonstrated by using ribozymes directed against signaling components presumably 
unrelated to the signaling cascade under study, namely MMP12 and FGF-BP. The 
latter measure did not entail any inhibitory effect on GnRH-induced EGFR activation. 
Thus, the results obtained by ribozyme transfection were in perfect agreement with 
the conclusions drawn from pharmacological inhibition of MMPs. In contrast to our 
findings, the blockage of EGFR tyrosine kinase activity by the selective tyrphostin 
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AG1478 has been reported not to affect ERK activation via the GnRHR in the same 
cell line calling into question the relevance of EGFR transactivation for GnRH 
signalling to ERKs (Benard 2001). So far, the discrepancy between the two studies 
remains unresolved. Of note, GnRH-induced signaling to ERKs in hypothalamic 
neurons critically depends on EGFR transactivation (Shah 2003a).  
The exact mechanism and regulation of growth factor release resulting in EGFR 
transactivation is not fully understood. EGFR ligands are initially synthesized as 
membrane-bound precursor proteins which are subsequently processed by 
metalloproteinase activities yielding a secreted product. Conversion of insoluble 
precursors to soluble factors by enzymatic cleavage may constitute an important 
post-translational modification regulating growth factor activity and availability (Goishi 
1995, Sunnarborg 2002). In CHO cells, for instance, shedding of membrane-
anchored HB-EGF can effectively be induced by phorbolesters and subsequent PKC 
activation. However, the shedding process appears to be regulated by ERK, and time 
course experiments indicated that TPA/PKC-induced ERK activation precedes HB-
EGF release (Gechtman 1999). In gonadotropic cells examined by us, however, 
MT1-MMP secretion, gelatinase activation and HB-EGF shedding is a rapid process 
whose time course concurred with that of GnRH-dependent Ras and ERK activation. 
Here, we directly show for the first time MT1-MMP secretion and gelatinase 
activation as an immediate response to occupation of a Gq/11-coupled receptor by its 
agonist. Protein levels of active gelatinases in conditioned media were found to be 
elevated within 5 min of GnRH stimulation together with migration of MT1-MMP from 
cells to the cell culture media. Furthermore, gelatin zymography carried out with 
conditioned media of αT3-1 cells demonstrated increased MMP2 enzyme activity 
following short-term stimulation of cells with GnRH.  
At present, the activation mechanism of gelatinases in gonadotropic cells still 
remains elusive. MMP2 belongs to the most abundant MMP family and is 
constitutively secreted in a latent form by many cell types. MMP2 is set apart from 
other MMPs in that its proform is not activated by enzymatic digestion with 
exogenous proteinases, but requires the activity of MT-MMPs. The activation of 
proMMP2 is potentiated by the formation of a trimolecular complex, consisting of 
MT1-MMP, TIMP2 and proMMP2 thought to cause a sufficient local concentration of 
proMMP2 allowing activation by TIMP2-free MT1-MMP and ensuing autocatalytic 
processing to the fully active form (Butler 1998, English 2001). Data presented here 
show that downregulation of MT1-MMP or MMP2 results in diminished MMP2 or 
MMP9 activation, respectively. MT1-MMP has been identified as an ectoenzyme 
generated by cleavage at the cell surface. Data strongly support the existence of at 
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least three forms of MT1-MMP: membrane-associated, furin-processed and soluble. 
The latent soluble form of MT1-MMP has been ascribed fully active. Rapid elevation 
of MT1-MMP in culture media after GnRH challenge can be explained by MT1-MMP 
being processed at the cell surface, then complexed to TIMP2 and the complex 
released in the conditioned medium after proMMP2 activation (Kazes 1998, Sato 
1996, Toth 2002, Will 1996). MMP2 released from the cell surface is then assumed 
to convert proMMP9 into its active form (Westermarck 1999).  
There is considerable evidence supporting a role of Src family tyrosine kinases in the 
signaling pathways from GPCRs to RTKs (Grosse 2000b). In GnRHR-expressing 
GT1-7 neurons, it has recently been suggested that Src may act upstream of the 
transactivated EGFR (Shah 2003b). However, the contribution of the latter tyrosine 
kinase to EGFR activation by GPCRs is a highly contentious issue. In the present 
study, we show that GnRH-induced EGFR transactivation is clearly affected by PP2-
mediated Src blockage. Inhibition of gelatinase activities either by pharmacological or 
ribozymal strategies diminished phosphorylation of Src kinases after GnRH challenge 
whereas inhibition of EGFR kinase activity had no impact on the phosphorylation 
status of Src. These findings demonstrate that Src is involved in GnRH-mediated 
EGFR tyrosine phosphorylation and has to be placed downstream of gelatinases and 
upstream of the EGFR in the GnRH signaling cascade in αT3-1 cells. 
We have previously pointed out that GnRHR/Gq/11-induced ERK activation in αT3-1 
cells proceeds via activation of Ras GTPases. A dominant-negative Ras mutant 
overexpressed in COS-7 cells, interfered Gq/11-mediated ERK activation. Stimulation 
of Ras was dependend on PKC activity. By applying PP2 to αT3-1 cells, we were 
able to show the participation of Src kinases in GnRH-induced GTP-loading of Ras. 
This was additionally underlined by overexpression of Csk in COS-7 cells transiently 
transfected with the GnRHR resulting in diminished GTP-loading of Ras (Grosse 
2000b). In the present work we provide evidence that MMP2/MMP9 activities are 
necessary for GTP-loading of Ras in αT3-1 cells. Gelatinase inhibitor Ro28-2653 
reduced the levels of Ras-GTP raised by GnRH- or TPA challenge. These data 
indicate that GnRH-induced Ras activation in αT3-1 cells proceeds via a gelatinase-
dependent pathway. 
The gelatinase inhibitor Ro28-2653 exemplifies a new class of pyrimidine-2,4,6-trione 
MMP inhibitors. Batimastat is a hydroxamic acid derivative exhibiting broad-spectrum 
inhibitory activity and was the first metalloproteinase inhibitor to enter clinical testing 
(Wojtowicz-Praga 1996). As opposed to Ro28-2653, batimastat at concentrations up 
to 50 µM displayed only minor inhibitory effects on metalloproteinase-mediated 
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mitogenic signaling in gonadotropic cells. An optimized specificity of Ro28-2653 for 
gelatinases in vivo may offer one explanation for these discrepancies. Both 
batimastat and Ro28-2653 chelate the zinc ions in the catalytic core of 
metalloproteinases, but Ro28-2653 additionally forms four hydrogen bonds yielding a 
nearly perfect fit towards MMP2 and MMP9 (Grams 2001). Furthermore, batimastat 
is characterized by an exceptionally poor water solubility, thus favoring the access to 
cells of more soluble compounds such as Ro28-2653. Thirdly, gelatinases which 
belong to the most abundant MMPs in a variety of tissues, may in fact represent the 
vast majority of MMPs secreted by αT3-1 cells.  
To address the issue of specificity of the pharmacological approach of gelatinase 
inhibition, we turned our attention to other members of the MAPK family known to be 
activated by GnRH (Naor 2000):  p38MAPK and JNK are primarily known to be 
stimulated by environmental stress and inflammatory cytokines (Shaulian 2002). Our 
data using AG1478, Ro28-2653 or batimastat show that gelatinase-triggered EGFR 
activation is not involved in GnRH-induced p38MAPK or JNK activation in αT3-1 
cells. Furthermore, the pharmacological tools used allow for selective targeting of 
GnRH-dependent ERK activation without unspecifically affecting other MAPK 
cascades.  
So far, the physiological consequences of GnRH-mediated EGFR transactivation 
have not been investigated. Agonist occupation of the GnRH receptor in αT3-1 cells 
results in MAPK activation and increased mRNA and protein levels of the immediate 
early gene products c-jun and c-fos (Cesnjaj 1994, Mulvaney 1999) as well as in 
transcriptional activation of the common α subunit gene through a pathway involving 
PKC (Reiss 1997, Roberson 1995, Sundaresan 1996). In congruence with our data, 
c-fos induction has been reported to occur 1 h after agonist challenge in 
gonadotropic αT3-1 cells and LβT2 cells (Liu 2002, Mulvaney 1999). In the present 
study, we show that GnRH-mediated EGFR activation is an indispensable step in the 
induction of c-fos and c-jun and that MMP2 and MMP9 play a pivotal role in GnRH-
dependent gene induction.  
In microarray studies (Wurmbach 2001, Yuen 2002), c-jun and c-fos together with a 
select array of other transcription factors were among those genes found to be 
robustly induced by GnRH after 1 h. At present we do not know whether the induction 
of transcription factors other than c-jun and c-fos is also influenced by EGFR 
transactivation in gonadotropes. The relative contribution of different MAPK cascades 
engaged by the GnRH receptor and of different transcription factors to gonadotropin 
expression in the pituitary is discussed controversially and appears to differ 
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depending on the cell model under study (Harris 2002, Liu 2002, Mulvaney 1999, 
Naor 2000).  
The results presented herein define a new role for gelatinases in the endocrine 
regulation of the pituitary. We show for the first time that gelatinases are activated via 
an inside-out signaling mechanisms by Gq/11-coupled receptors and thus we identify 
hitherto unknown signaling components of the EGFR transactivation cascade. Apart 
from their matrix-degrading abilities, MMP2 and MMP9 seem to be essential for 
GnRH-induced EGFR transactivation and gene induction in gonadotropes. 
Considering that gelatinases are also abundantly expressed in many human tumors, 
our results may shed new light on the mechanism by which agonists acting on other 
Gq/11-coupled receptors can promote tumor growth. 
 
5.2. Pyk2 represents a cellular point of convergence by regulating 
neuropeptide-mediated cell proliferation or apoptosis of small cell lung 
cancer cells. 
Neuropeptide-mediated engagement of the ERK cascade has been shown to play a 
crucial role for SCLC cell growth (Beekman 1998, Seufferlein 1996b). However, the 
mechanism underlying ERK activation via Gq/11-coupling neuropeptide hormone 
receptors in SCLC cells is far from being understood. We have previously shown that 
galanin-stimulated ERK activity solely depends on [Ca2+]i, thus Ca2+ represents the 
central second messenger for ERK activation in SCLC cells (Wittau 2000). In this 
context we have identified Pyk2, known to be abundantly expressed in neuronal 
tissue, as an intermediate in Ca2+-mediated ERK stimulation in SCLC cells 
(Schlaepfer 1999).  
A rise in [Ca2+]i is a characteristic signaling event that can be observed in 
neuropeptide-stimulated H69 or H510 cells (Sethi 1991). Treatment of SCLC cells 
with the calcium ionophore ionomycin leads to profound tyrosine phoshporylation of 
Pyk2, further indicating that activation of Pyk2 can be induced by elevations of [Ca2+]i 
alone, independent of PKC activity. Pyk2 signaling has been connected to activation 
of the ERK, JNK and p38MAPK pathways. One of the main functions of Pyk2 is to 
serve as as precisely localized adaptor platform for the assembly of signaling 
complexes. A p130Cas/Crk protein complex formed at the N-terminal of two proline-
rich domains specifically links Pyk2 with the activation of JNK (Blaukat 1999, Dikic 
1996, Sorokin 2001, Tokiwa 1996). So far, it is unknwon how the cell manages to 
transmit a Pyk2-dependent signal either through the ERK or the JNK cascade by 
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means of a common initial calcium stimulus. However, direct association of Src 
tyrosine kinases with Pyk2 appears to be essential for both signaling pathways 
(Blaukat 1999). We observed that galanin or ionomycin efficiently induced the 
specific formation of a Pyk2/Src complex in H69 cells. Galanin or ionomycin also 
rapidly stimulated Src tyrosine kinase activity in H69 cells in a [Ca2+]i-dependent 
manner, further indicating a functional role for Pyk2/Src complex formation in SCLC 
cells. Nevertheless, it was recently postulated that Src tyrosine kinases are not 
participating in the transforming phenotype of SCLC, although direct proof was not 
provided (Moore 1998). Our findings do not support the latter idea, because 
neuropeptides like galanin were found to stimulate Src tyrosine kinases, and Src 
tyrosine kinase activity was required for neuropeptide-mediated GTP-loading of Ras, 
stimulation of ERK activity and anchorage-independent proliferation of SCLC cells. 
Furthermore, basal Src tyrosine kinase and ERK activities in SCLC cells were high 
compared to assays in COS-7 cells. 
In addition we found that the regulatory p85α subunit of PI3K was tyrosine 
phosphorylated and coprecipitated with Pyk2 in a Ca2+-dependent manner. 
Moreover, we found PI3K activity to be a prerequisite for galanin-induced tyrosine 
phosphorylation of Pyk2. These results provide evidence for a direct interaction of 
Pyk2 with the regulatory subunit of PI3K in H69 cells.  
Tyrosine phosphorylation of p85 was reported to regulate PI3K activity by several 
stimuli such as bradykinin or tyrosine kinases, e.g. vascular endothelial growth factor 
receptor and Src-like kinases (Kavanaugh 1994, Thakker 1999, von Willebrand 1998, 
Xie 2000). It was demonstrated that the p85 subunit was specifically coprecipitated 
with activated Pyk2 in monocytic cells and blood-derived macrophages. Furthermore, 
Pyk2 was shown to mediate bradykinin-induced NF-κB activation via PI3K in HeLa 
cells. These data suggest a tight synchronous functional regulation of these two 
kinases (Hatch 1998, Shi 2001). This is in agreement with the fact that Pyk2 contains 
a putative binding site for the p85 subunit of PI3K (Chen 1994, Lev 1995). Our data 
support a concept with PI3K and elevations of [Ca2+]i leading to tyrosine 
phosphorylation of Pyk2 to regulate Src activity. Src-like tyrosine kinases have been 
demonstrated as upstream activators of the PI3K/Akt pathway in several cell systems 
(Craxton 1999; Datta 1996, Dong 2000, Liu 1998). Interestingly, it was shown that 
the PI3K/Akt pathway is constitutively activated in SCLC cells (Moore 1998). Thus, 
one conceivable model could be that Pyk2 functions as a multiprotein docking 
molecule for PI3K and Src in SCLC cells. Once Src is bound to Pyk2, it could then 
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stimulate PI3K for Akt activation or/and ERK activation through the Shc/Grb2 
complex (Rocic 2001).  
Neuropeptide-mediated ERK activation proceeds via activated Ras in cardiac 
fibroblasts (Murasawa 1998). Ca2+-dependent RasGEFs are able to directly activate 
Ras (Cullen 2002). To investigate the involvement of RasGEFs in neuropeptide-
mediated ERK activation RT-PCR using primer pairs for RasGRF2 and RasGRP was 
carried out. We focussed on these two RasGEFs because RasGRF2 is highly 
expressed in lung besides neuronal tissue and RasGRP/CalDAG-GEF II displays 
Ras preference as compared to CalDAG-GEF I (Cullen 2002, Table 1). RT-PCR 
yielded RasGRF2 as being expressed in SCLC cells. Since the calmodulin inhibitor 
calmidazolium did not show any inhibitory effect on neuropeptide-mediated GTP-
loading of Ras, the direct activation of Ras via RasGRF2 after neuropeptide 
stimulation in SCLC cells can be expelled. By inhibiting Src activity with PP2, we 
showed that GTP-loading of Ras depends on Src kinase activity. In addition, Ras 
activation showed [Ca2+]i dependence. Our data provide first evidence that RasGEFs 
are not involved in neuropeptide-induced Ras activation in SCLC cells and strongly 
indicate that Pyk2 phosphorylation and Pyk2/Src association precede GTP-loading of 
Ras in SCLC cells. 
Cell death after overexpression of wild type Pyk2 has been observed in fibroblastic 
and epithelial cell lines before, while neuroendocrine PC12 cells were resistant to 
Pyk2 expression (Xiong 1997). Therefore we were surprised to monitor cell death of 
neuroendocrine H69 cells after overexpression of Pyk2-wt by a preliminary viral as 
well as a transient transfection approach. Furthermore, H69 cells underwent 
apoptosis when transfected with Pyk2-Y402F, kinase-deficient Pyk2-PKM and Pyk2-
P859A. H69 cells overexpressing Pyk2-P717A retained their viability. Pyk2 can be 
regarded as a multidocking adaptor for a variety of different proteins including Src 
kinases, the Grb2/Sos complex, paxillin, p130Cas, Graf, PSGAP and Hic-5 
(Hildebrand 1996, Matsuya 1998, Ohba 1998, Ren 2001, Salgia 1996). In H69 cells, 
kinase activity and autophosphorylation of Pyk2 as well as association with Src 
kinase are not responsible for induction of cell death as demonstrated by 
overexpression of Pyk2-Y402 and Pyk2-PKM. These observations strengthen our 
previous concept of autophosphorylation of Pyk2, activation of Src kinases and 
Pyk2/Src complexation upon neuropeptide stimulation as necessary prerequisites for 
SCLC cell survival. Previously mentioned, tyrosine 402 of Pyk2 is a putative PI3K 
binding site (Chen 1994, Lev 1995) and as shown above, Pyk2 forms a complex with 
PI3K after neuropeptide stimulation indicating that PI3K aids to cell survival of SCLC 
cells by an effector system not yet identified. In congruence with our data, it has been 
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shown that coexpression of Pyk2-wt with either active Src, Akt or PI3K rescues 
fibroblasts from Pyk2-induced apoptosis (Xiong 1997). As reported above, a 
constitutively activated PI3K/Akt pathway has been described in SCLC cells (Moore 
1998), further supporting our concept.  
In SCLC cells, neuropeptide hormone receptors are capable to activate G proteins of 
the Gq/11- and G12/13 families (Wittau 2000). It has been shown that neuropeptide 
receptor antagonists lead to death of SCLC cells engaging the JNK pathway via 
heterotrimeric G12/13 proteins in the way of “biased agonists” (Chan 2002). Pyk2 
signaling has been revealed as a part of the Rho pathway and RhoGAPs Graf and 
PSGAP have been suggested as mediators (Wu 2002). Graf mediates the cross-talk 
between FAK and Rho family members, but a function for Graf in Pyk2 signaling has 
not been described so far (Hildebrand 1996). It was suggested that PSGAP may be 
an essential protein for regulation of cytoskeletal organization by Pyk2 via 
RhoGTPases (Ren 2001). Graf and PSGAP interact with Pyk2 via its second proline-
rich domain (Ohba 2001, Ren 2001). Our results indicate that the G12/13/Rho pathway 
does not contribute to Pyk2-induced apoptosis since Pyk2-P859A, interrupted in the 
second proline-rich domain, did induce apoptotic cell death in H69 cells.  
The fact that cells transfected with Pyk2 mutants deficient in proline 717 remained 
viable, points out that proteins interacting with the first proline-rich domain of Pyk2 
might be involved in pathways leading to apoptotic cell death. Galanin triggered JNK 
activation in SCLC cells, indicating a causal link of neuropeptide-mediated Pyk2 
stimulation with JNK phosphorylation. Since an inhibitor specific for Pyk2 does not 
exist and SCLC cells are not amenable to high efficiency transfection, we were not 
able to supply a direct evidence. In support with our notion, it has been shown that 
Pyk2 activation leads to stimulation of JNK activity by a pathway emanating from 
elevation of [Ca2+]i in rat liver epithelial cells (Yu 1996). In transfection experiments 
with dominant interferring mutants of Crk and p130Cas, Pyk2-induced JNK activation 
was inhibited (Blaukat 1999). Pull-down experiments revealed that Pyk2 
constitutively binds p130Cas via its first proline-rich domain with activated Pyk2 being 
capable of enhancing phosphorylation of p130Cas (Ohba 1998, Salgia 1996). 
Therefore, we conclude that overexpression of Pyk2 leads to apoptosis by means of 
activation of the p130Cas/Crk/JNK pathway. One could hypothesize that the JNK 
pathway leading to cell death via Pyk2 is rather quiescent in SCLC cells and 
becomes activated in response to overexpression of Pyk2. This hypothesis is 
emphasized by the fact that SCLC cells display basal ERK phosphorylation being 
responsible for anchorage-independent growth, whereas JNK activity under 
unstimulated conditions is not detectable.  
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5.3. Conclusions, implications and perspectives 
It is reasonable to assume that the basic cellular equipment in each cell is essentially 
identical. However, each cell type harbors e. g. cell type-specific isoforms of different 
proteins, some proteins are expressed ubiquitously whereas others are restricted to a 
specific cell type. By comparing neuropeptide/Gq/11-induced mitogenic signaling 
pathways in SCLC and gonadotropic αT3-1 cells, distinct pathways downstream of 
Gq/11 were revealed. In this context, PLCβ can be viewed as a point of bifurcation by 
generating PKC and [Ca2+]i as two second messengers. PKC and [Ca2+]i then convey 
signals to the ERK/MAPK cascade via different tracks.  
Engagement of the ERK/MAPK signaling pathway by GnRH in gonadotropic cells 
proceeds via PKC as a second messenger. The temporal pattern and maximal 
response of ERK activity critically depends on gelatinase-triggered EGFR 
transactivation. Here we have shown for the first time that MT1-MMP shedding and 
gelatinase activation are immediate responses to occupation of GnRHR by its ligand. 
It is an attractive hypothesis to assume that the agonist-occupied GnRHR regulates 
MT1-MMP function by an intracellular mechanism employing PKC. Further studies on 
the regulation of MT1-MMP activity in gonadotropic cells will be enlightening in this 
regard. 
On the contrary, galanin- or bradykinin-induced activation of the ERK/MAPK cascade 
solely depends on [Ca2+]i as a second messenger in SCLC cells. Herein, the Ca2+-
dependent non-RTK Pyk2 has been characterized as the key component in 
neuropeptide-mediated ERK/MAPK activation. Furthermore, our data provide first 
evidence for Pyk2 representing a cellular point of convergence determining the fate 
of SCLC cells. Neuropeptide-elicited rises in [Ca2+]i mediate Pyk2 phosphorylation, 
Pyk2/Src association and stimulation of ERK activity leading to anchorage-
independent growth. Overexpression of Pyk2 in SCLC cells however results in 
apoptotic cell death. This conundrum might be explained by desynchronized cell 
signaling with Pyk2-wt overexpression resulting in apoptosis. It has been 
demonstrated by overexpression of GTPase-deficient Gα16 that desynchronization of 
distinct signaling pathways emanating from a ligand-bound receptor may perturb 
receptor-regulated mitogenic signaling leading to the inhibition of SCLC cell growth 
(Heasley 1996). Another explanation would be that the duration of the Pyk2 signal 
after overexpression is different from the one engaged by short-term neuropeptide 
stimulation. This situation would lead to a different temporal pattern of Pyk2 action 
resulting in an altered cellular response. It has been obvious for quite some time that 
potent inducers of cell proliferation such as c-myc also possess proapoptotic 
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activities. Initially this observation was explained with oncogenes forcing cells into 
“unprepared cell cycles by overridding cell cycle checkpoints and inducing mitotic 
catastrophe”. Since then, however, it was revealed that cell proliferation and cell 
death are molecularly distinct mechanisms and so far the precise mechanism how 
oncoproteins promote apoptosis remain elusive. It is hypothesized that one of the 
main mechanisms by which the above mentioned balance of survival and death is 
achieved is by coupling cellular proliferation to apoptosis. In the case of c-myc the 
mitogenic and proapoptotic properties seem to be genetically inseparable (Cox 2003, 
Evan 1998). The clarification of the mechanism underlying Pyk2-mediated induction 
of apoptosis will be the subject of further investigations.  
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6. SUMMARY 
Neuropeptide hormones are a family of structurally and functionally diverse signaling 
molecules. Their cognate receptors are usually classified as primarily Gq/11-coupled 
receptors. Activation of Gq/11 proteins results in activation of PLCβ. PLCβ catalyzes 
the hydrolysis of PIP2 thereby producing the two second messengers IP3 and DAG. 
IP3 regulates rises of [Ca2+]i which are realized by releasing Ca2+ from intracellular 
stores or by influx of extracellular Ca2+ through Ca2+-channels. DAG directly activates 
PKC isoforms. By activating different downstream target proteins, [Ca2+]i and PKC 
stimulate distinct signaling pathways. As most neuropeptides hormone receptors 
interact with overlapping portfolios of G proteins, rigorous conclusions pertaining to 
specific signaling pathways are often impossible. In gonadotropic cells, the GnRHR is 
an exclusively Gq/11-coupled receptor and GnRH challenge leads to rapid activation of 
the ERK/MAPK cascade with the time course being regulated by EGFR 
transactivation. Since GnRH-mediated ERK activation in gonadotropic αT3-1 cells is 
strictly reliant on PKC activity, the GnRHR in gonadotropic cells was henceforth used 
as a model system to study PKC-dependent ERK activation. To compare a strictly 
PKC-dependent ERK activation pathway with one strictly dependend on [Ca2+]i, we 
resorted to the galanin- and bradykinin receptors in SCLC cells. Since neuropeptide-
mediated ERK activation in these cells is solely dependent on [Ca2+]i, Ca2+-
dependent ERK activation was studied in SCLC cells. 
 
1. EGFR transactivation proceeds via a “triple membrane-passing signal 
mechanism”. Herein a variety of different metalloproteinases have been identified to 
cleave EGFR ligand precursors. To identify proteolytic enzymes involved in GnRH-
mediated signaling events, we primarily focussed on an involvement of gelatinases 
since MMP2 and MMP9 are highly expressed in pituitary tumors and normal pituitary 
tissue. By using a specific gelatinase inhibtior, Ro28-2653, GnRH-elicited ERK 
phosphorylation was abrogated. To confirm the prominent role of MMP2 and MMP9 
in GnRH-induced ERK activation, a more specific ribozyme-based transfection 
approach was applied. By transiently transfecting αT3-1 cells with ribozymes directed 
against MMP2 or MMP9, ERK phosphorylation after GnRH challenge was inhibited. 
We extended our study to another gonadotropic cells line, LβT2 cells. In these cells, 
GnRH-elicited ERK phosphorylation was dependent on EGFR transactivation and 
gelatinase activity.  
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2. Each of the known mammalian EGF-like gene products is synthesized as a 
precursor protein subject to proteolytic cleavage to release a soluble growth factor. 
ADAM10, ADAM12 and ADAM17/TACE have been shown to participate in RTK 
transactivation with various EGFR ligand precursors as substrates. To examine their 
contribution to proteolytic cleavage after GnRH challenge, we first chose a 
pharmacological approach and applied a specific ADAM17/TACE inhibitor, Ro32-
7315, to αT3-1 cells. Ro32-7315 pretreatment did not have any inhibitory effect on 
GnRH- as well as TPA-elicited ERK phosphorylation. RT-PCR of total αT3-1 RNA 
using primer pairs for ADAM10 and ADAM12 revealed ADAM10 expression. 
Downregulation of ADAM10 by ribozyme-targeting did not have any influence on 
GnRH-mediated ERK phosphorylation. However, scavenging of soluble HB-EGF with 
neutralizing antibodies completely prevented GnRH-elicited ERK phosphorylation. 
 
3. To characterize the role of gelatinases in GnRH-induced signaling events 
leading to ERK activation in gonadotropic cells, their involvement in the cross-talk 
between GnRHR and EGFR was studied. By inhibiting MMP2 and MMP9 with Ro28-
2653, GnRH-dependent EGFR transactivation was abrogated. In order to strengthen 
the notion that gelatinases are specifically involved in GnRH-induced EGFR 
activation, the expression of MMP2 and MMP9 was targeted by transient transfection 
of αT3-1 cells with ribozymes. GnRH-mediated EGFR phosphorylation was 
substantially blocked in response to transfection with ribozymes directed against 
MMP2 or MMP9. Again we extended our investigation to LβT2 cells. Pretreatment of 
cells with the gelatinase inhibitor resulted in a decline of GnRH-induced EGFR 
activation.  
We have shown that HB-EGF is the pivotal ligand mediating ERK activation 
emanating from the agonist-occupied GnRHR in αT3-1 cells. To test whether HB-
EGF serves to induce EGFR phosphorylation in response to GnRH stimulation, HB-
EGF was trapped with a neutralizing anti-HB-EGF antibody. Neutralization of HB-
EGF inhibited GnRH-induced EGFR phosphorylation. To study the role of 
ADAM17/TACE or ADAM10 in EGFR transactivation, Ro32-7315 was applied or cells 
were transiently transfected with ribozymes targeting ADAM10, respectively. Both 
measures did not affect GnRH-mediated EGFR phosphorylation.  
 
4. GnRH challenge furthered the release of active MMP2 and MMP9 and 
increased their gelatinolytic activities within 5 min. In this context, αT3-1 cells were 
stimulated with GnRH and detection of MT1-MMP in cell lysates and conditioned 
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culture media was performed. GnRH challenge resulted in a decline of MT1-MMP in 
cell lysates with increasing amounts in culture media. Ribozyme-targeted 
downregulation of MT1-MMP or MMP2 inhibited rapid release of MMP2 or MMP9, 
respectively.  
 
5. We addressed the role of Src kinases in GnRH-mediated EGFR activation 
by applying the Src specific inhibitor PP2 or the EGFR specific inhibitor AG1478 to 
αT3-1 cells. Both inhibitors induced a decline of GnRH-mediated EGFR 
phosphorylation whereas the EGFR inhibitor did not change Src phosphorylation 
elicited by GnRH challenge. To assess the contribution of gelatinases in GnRH-
induced Src activation, αT3-1 cells were pretreated with Ro28-2653 which caused 
the inhibtion of GnRH-induced Src phosphorylation. Transfection with ribozymes 
against MMP2 or MMP9 confirmed the pharmacological approach. Specific inhibition 
of Src kinases and EGFR activity did not yield any effect on activation of gelatinases 
after GnRH challenge. In LβT2 cells, GnRH-induced EGFR phosphorylation was 
circumvented by specific inhibition of Src kinases. Inhibition of gelatinases resulted in 
a decline of GnRH-induced Src activation.  
GnRH- as well as short-term phorbol ester treatment resulted in GTP-loading of Ras 
in αT3-1 cells. GnRH-stimulated Ras activation is dependent on PKC- and Src kinase 
activities. Furthermore, pretreatment of cells with Ro28-2653 inhibited GnRH-
mediated GTP-loading of Ras. 
 
6. GnRH stimulation of αT3-1 cells leads to phosphorylation of JNK and 
p38MAPK within 15 min. Activation of JNK and p38MAPK by GnRH was unaffected 
by EGFR- or gelatinase inhibition. 
 
7. EGFR transactivation in αT3-1 cells is of physiological relevance since 
gelatinase activation and subsequent EGFR transactivation are necessary 
intermediate steps required for induction of transcription factors c-jun and c-fos. 
 
8. Ca2+-dependent non-RTK Pyk2 has been shown to be an intermediate in 
GPCR-induced ERK activation. Since Pyk2 is abundantly expressed in neuronal 
tissue, we examined the expression of Pyk2 in SCLC cells and were able to amplify 
two specific DNA fragments. Furthermore, Pyk2 expression was verified at the 
protein level. Neuropeptides represent the major growth factors for proliferation and 
metastasis of SCLC cells. Galanin- or bradykinin stimulation induced rapid tyrosine 
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phosphorylation of Pyk2 in SCLC cells. This effect could be fully mimicked by 
treatment of the cells with the calcium ionophore ionomycin. In response to 
neuropeptide stimulation Pyk2 associates with Src tyrosine kinases and the 
regulatory p85α subunit of PI3K. Pretreatment of SCLC cells with the specific Src 
kinase inhibitor PP2 or the specific PI3K inhibitor LY294002 prevented neuropeptide-
induced Pyk2 phosphorylation. To directly monitor Src kinase activity in SCLC cells, 
an in vitro Src kinase activity assay was performed. Galanin stimulation or elevation 
of [Ca2+]i produced enhanced Src kinase activity in SCLC cells.  
 
9. Neuropeptide stimulation led to GTP-loading of Ras which is reliant on 
[Ca2+]i and Src kinase activity in SCLC cells. To test the involvement of Ca2+-
dependent RasGEFs in neuropeptide-induced Ras activation, their expression in 
SCLC cells was tested by RT-PCR. Amplification products were obtained with 
oligonucleotides specific for RasGRF2. To elucidate the role of RasGRF2 in 
neuropeptide-induced GTP-loading of Ras in SCLC, RasGRF2 was indirectly 
inhibited by the calmodulin inhibitor calmidazolium. Calmidazolium pretreatment did 
not decrease neuropeptide-mediated Ras activation.  
 
10. Galanin- or bradykinin challenge led to stimulation of ERK activity in 
SCLC cells which was assessed in an in vitro ERK activity assay. Neuropeptide-
elicited ERK activation depended on Src kinase activity.  
 
11. The ability of cells to grow anchorage-independent is a well characterized 
marker for their transforming potential and can be monitored by colony formation in 
semisolid medium. Neuropeptides stimulated growth of SCLC cells in soft agar. 
Anchorage-independent growth of SCLC cells is dependent on Src kinase activity. 
For further characterization of the involvement of Src kinases in anchorage-
independent growth of SCLC cells, cell growth was monitored in a liquid culture 
assay. Neuropeptide challenge elicited increased cell numbers with inhibition of Src 
kinase activity resulting in decreased cell numbers.   
 
12. Overexpression of wild type Pyk2 induced apoptosis of SCLC cells as was 
visible in characteristic features of programmed cell death like membrane blebbing, 
cell swelling and apoptotic bodies. Furthermore, cell death was apparent after 
transfection of kinase-dead Pyk2 or Pyk2 impaired in autophosphorylation and Src 
family SH2-binding (Pyk2-Y402F). SCLC cells transfected with Pyk2 mutants 
disrupted either in the first- (Pyk2-P717A) or in the second proline-rich domain (Pyk2-
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P859A) behaved differently. While Pyk2-P859A overexpression induced cell death, 
Pyk2-P717A overexpressed did not alter SCLC cell viability. Pyk2 has been linked to 
the JNK pathway by complex formation with p130Cas/Crk via proline 717. Since our 
data indicate an involvement of the JNK pathway in Pyk2-induced cell death, SCLC 
cells were treated with neuropeptides and JNK phosphorylation was detected. 
Galanin-stimulated JNK activation started within 5 min and declined after 15 min of 
stimulation with basal JNK phosphorylation not apparent. In contrast, SCLC display 
high basal levels of ERK phosphorylation.  
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7. ZUSAMMENFASSUNG 
Mitogene Signalwege Gq-koppelnder Rezeptoren 
 
Neuropeptide bilden eine Gruppe von strukturell und funktionell verschiedenartigen 
Signalmolekülen, die an heptahelikale Rezeptoren der Zellmembran binden. 
Heptahelikale Rezeptoren leiten nach Interaktion mit einem heterotrimeren G-Protein 
die Information über Signaltransduktionskaskaden ins Zellinnere weiter. Man ist sich 
heute darüber im klaren, daß heptahelikale Rezeptoren und G-Proteine eine wichtige 
Rolle bei der Regulation von Wachstum und Differenzierung, aber auch von 
zellulären Transformationsprozessen spielen. Einen wichtigen mitogenen Signalweg 
stellt die Aktivierung der extracellular signal-regulated kinase/mitogen-activated 
protein kinase (ERK/MAPK)-Kaskade dar, die klassischerweise durch Wachstums-
faktoren wie epidermal growth factor (EGF) oder platelet-derived growth factor 
(PDGF) initiiert wird. ERK/MAPKs können auch über G-Protein-gekoppelte 
Rezeptoren aktiviert werden, deren Signale auf unterschiedlichen Ebenen der 
Wachstumsfaktor/Ras/Raf/MEK/ERK-Kaskade einmünden. Neuropeptidhormon-
rezeptoren bewirken über eine Kopplung an Gq/11-Proteine eine ausgeprägte 
Aktivierung der ERK/MAPK-Kaskade. Gq/11-Proteine führen durch Stimulation der 
Phospholipase Cβ (PLCβ) zur Erhöhung der intrazellulären Calciumkonzentration 
([Ca2+]i) und zur Aktivierung von Proteinkinase C Isoformen (PKCs). Aufgrund der 
Aktivierung unterschiedlicher Effektorproteine, stimulieren PKC und Ca2+ 
voneinander abgrenzbare Signalwege. 
Im Rahmen dieser Arbeit sollten die Unterschiede eines streng PKC- mit einem 
streng Ca2+-abhängigen Neuropeptid-induzierten ERK-Aktivierungsmechanismus für 
das Wachstum von Tumorzelllinien untersucht und verglichen werden.  
In gonadotropen αT3-1-Zellen präsentiert sich der Gonadotropin-releasing hormone-
Rezeptor (GnRHR) als ein solitär Gq-koppelnder Rezeptor. Weiter führt die 
Stimulation mit GnRH zu einer raschen Aktivierung der ERK/MAPK-Kaskade, wobei 
die Aktivierungskinetik von der GnRH-induzierten EGF-Rezeptor (EGFR)-
Transaktivierung abhängig ist. Da die ERK-Aktivierung in αT3-1-Zellen strikt PKC-
abhängig ist, fungierte der GnRHR im Rahmen dieser Arbeit als ein Modellsystem, 
um die PKC-vermittelte ERK-Aktivierung durch Gq/11-koppelnde Rezeptoren 
aufzuklären. Neuropeptide stellen die wichtigsten mitogenen Stimuli für kleinzellige 
Lungenkarzinom (small cell lung cancer, SCLC)-Zellen dar und die Neuropeptid-
induzierte ERK-Aktivierung in diesen Zellen ist strikt abhängig von der Erhöhung der 
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[Ca2+]i. Zu Beginn dieser Arbeit war der molekulare Mechanismus der Neuropeptid-
induzierten ERK-Aktivierung in SCLC-Zellen unbekannt und sollte im Rahmen dieser 
Arbeit aufgeklärt werden.  
 
1. Die EGFR-Transaktivierung verläuft über einen triple membrane-passing 
signal Mechanismus, der die Aktivität von Metalloproteinasen und das proteolytische 
Spalten von EGF-ähnlichen Liganden involviert. Im Rahmen dieser Arbeit konnten 
erstmalig Mitglieder der Matrixmetalloproteinasen (MMPs) als proteolytische Enzyme 
in G-Protein-gekoppelter-Rezeptor- (G protein-coupled receptor, GPCR)- vermittelter 
EGFR-Transaktivierung identifiziert werden. Mit Hilfe eines spezifischen Gelatinase-
Inhibitors, Ro28-2653, konnten MMP2 und MMP9 als proteolytische Enzyme in der 
GnRH-vermittelten Signaltransduktion in αT3-1-Zellen identifiziert werden. Die 
pharmakologisch-generierten Ergebnisse wurden durch einen transienten 
Transfektionsansatz mit MMP2- oder MMP9-spezifischen Ribozymen untermauert. 
Eine 5-minütige GnRH-Behandlung setzte in αT3-1-Zellen aktive MMP2 und MMP9 
ins Kulturmedium frei und führte zu einer Erhöhung ihrer Gelatine-spaltenden 
Aktivität. Weiter kam es nach GnRH-Stimulation zu einer Zunahme von membrane 
type (MT)1-MMP im Kulturmedium, wobei der Gehalt von MT1-MMP in Zelllysaten 
abnahm. Die Herunterregulation von MT1-MMP oder MMP2 durch spezifische 
Ribozyme verhinderte die Freisetzung von MMP2 bzw. MMP9. Mittels 
pharmakologischer- sowie biochemischer Daten konnte Heparin-binding epidermal 
growth factor (HB-EGF) als EGFR-Ligand im cross-talk zwischen GnRHR und EGFR 
in αT3-1-Zellen identifiziert werden.  
 
2. Es konnte mittels pharmakologischer und biochemischer Daten aufgeklärt 
werden, daß die GnRH-induzierte GTP-Beladung von Ras-Proteinen und die ERK-
Phosphorylierung in αT3-1-Zellen von Gelatinase-aktivierter EGFR-Transaktivierung 
abhängig ist. Weiter bewirkte GnRH-Stimulation eine Gelatinase-vermittelte 
Phosphorylierung von Src-Kinasen, die nicht EGFR-abhängig war. Aus diesen Daten 
kann geschlossen werden, daß Src-Kinase-Phosphorylierung in αT3-1-Zellen der 
EGFR-Aktivierung vorgeschaltet ist und diese reguliert.  
Die Stimulation von αT3-1-Zellen mit GnRH führte zu einer Phosphorylierung von c-
jun N-terminal kinase (JNK) und p38MAPK, jedoch waren diese Ereignisse 
unabhängig von Gelatinase- und EGFR-Aktivitäten. 
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3. Der cross-talk zwischen GnRHR und EGFR ist von physiologischer 
Relevanz in αT3-1-Zellen, denn es konnte gezeigt werden, daß es nach GnRH-
Stimulation zu einer Induktion der Transkriptionsfaktoren c-jun und c-fos kommt, die 
von Gelatinase-vermittelter EGFR-Transaktivierung reguliert wird. Auch in einer 
weiteren gonadotropen Zelllinie, LβT2-Zellen, konnte die Beteiligung von Gelatinasen 
und EGFR-Transaktivierung in der GnRH-vermittelten Signalweiterleitung gezeigt 
werden. 
 
4. Für die Neuropeptid-vermittelte Signaltransduktion in SCLC-Zellen konnte 
im Rahmen dieser Arbeit die Ca2+-abhängige Nichtrezeptortyrosinkinase Pyk2 als ein 
bedeutendes Intermediat identifiziert werden. Sowohl in RT-PCR-Experimenten als 
auch in Western Blot-Analysen konnte Pyk2 als in SCLC-Zellen hoch exprimiert 
gezeigt werden.  
Die Stimulation mit Galanin oder Bradykinin sowie die Erhöhung der [Ca2+]i durch ein 
Calciumionophor bewirkten eine verstärkte Tyrosinphosphorylierung von immun-
präzipitiertem Pyk2. Neuropeptid-Stimulation oder die Erhöhung der [Ca2+]i führten zu 
einer gesteigerten Src-Kinase-Aktivität in in vitro Src-Kinase-Aktivitäts-Assays und zu 
einer Pyk2/Src-Kinase-Assoziation. Weiter kam es zu einer Neuropeptid-abhängigen 
Komplexbildung von Pyk2 mit der regulatorischen p85α-Untereinheit der 
Phosphatidylinositol 3-Kinase. Mit Hilfe eines GST-RBD-Fusionsproteins, bestehend 
aus der minimalen Ras-Bindungsdomäne (RBD) von Raf-1 und Glutathion-S-
Transferase (GST), konnte in einem Ras-Aktivierungs-Assay erstmalig in SCLC-
Zellen die Neuropeptid-vermittelte GTP-Beladung von Ras-Proteinen gezeigt 
werden, die sich [Ca2+]i- und Src-Kinase-abhängig präsentierte. Anhand von RT-
PCR-Experimenten und pharmakologischen Daten konnte der Einfluß von Ras-
Austauschfaktoren ausgeschlossen werden, so dass die Daten auf eine direkte 
Pyk2/Src-Kinase-vermittelte Ras-Aktivierung schließen lassen.  
Die Neuropeptid-stimulierte Erhöhung der ERK-Aktivität stieg in Abhängigkeit von 
Src-Kinase-Aktivität, was in in vitro ERK-Kinase-Aktivitäts-Assays gezeigt werden 
konnte. In Soft-Agar- und Liquid-Growth-Assays wurde die biologische Bedeutung 
des Pyk2/Src-Kinase-Signalweges für das Wachstum von SCLC-Zellen 
unterstrichen. Die Inhibition der Src-Kinase-Aktivität führte zu einer drastisch 
verminderten Koloniebildung nach Galanin- oder Bradykinin-Stimulation im 
semisoliden Medium und einem verringerten Wachstum im Flüssigmedium. 
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5. Überraschenderweise induzierte die Überexpression von Pyk2 in SCLC-
Zellen Apoptose, die an Membranblasenbildung, Zellschwellung oder apoptotischen 
Zellkörperchen sichtbar wurde. Weiter kam es nach Überexpression einer Kinase-
defizienten- (Pyk2-PKM) sowie einer Autophosphorylierungs-beeinträchtigten (Pyk2-
Y402F) Pyk2-Mutante zu programmiertem Zelltod. Zwei weitere Pyk2-Mutanten, die 
in der ersten- (Pyk2-P717A) oder zweiten (Pyk2-P859A) Prolin-reichen Region 
Mutationen aufweisen, zeigten bezüglich der Induktion von Apoptose ein 
unterschiedliches Verhalten. Während es nach Überexpression von Pyk2-P859A zu 
einem Absterben von SCLC-Zellen kam, verursachte die Transfektion mit Pyk2-
P717A keine Apoptose. Es ist gezeigt worden, daß Pyk2 via Prolin 717 einen 
Komplex mit dem Adaptorprotein p130Cas ausbildet und so in die JNK-Kaskade 
einmündet. Nach Neuropeptid-Stimulation kam es in SCLC-Zellen zu einer Erhöhung 
der Phosphorylierung von JNK, wobei eine basale Phosphorylierung nicht apparent 
war. Im Gegensatz dazu, zeigte die ERK-Phosphorylierung in diesen Zellen eine 
hohe basale Phosphorylierung.  
 
Zusammenfassend läßt sich sagen, daß in Abhängigkeit vom untersuchten 
Zellmodell das Neuropeptid/Gq/11-initiierte Signal auf unterschiedlichen Ebenen in die 
Ras/Raf/MEK/ERK-Kaskade einmündet. In gonadotropen αT3-1-Zellen kommt es auf 
Ebene des EGFR zu einer Einmündung des GnRHR/Gq/11-induzierten Signalweges in 
den ERK/MAPK-Signalweg. GnRH-Stimulation bewirkt in diesen Zellen eine erhöhte 
Gelatinase-Aktivität, was über die proteolytische Spaltung von HB-EGF zur 
Aktivierung des EGFR führt. Die EGFR-Transaktivierung besitzt in diesem Zellmodell 
eine physiologische Relevanz, da es in Abhängigkeit von Gelatinase-induzierter 
EGFR-Aktivierung zu einer Induktion von Transkriptionsfaktoren kommt. In SCLC-
Zellen kommt es über die Neuropeptid-vermittelte Erhöhung der [Ca2+]i zur 
Phosphorylierung der Nichtrezeptortyrosinkinase Pyk2. Pyk2 stellt in diesen Zellen 
ein zentrales Regulationsprotein dar. Einerseits kommt es über Assoziation mit Src-
Kinasen zu einer Aktivierung des Ras/Raf/MEK/ERK-Signalweges, der für das 
Wachstum dieser Tumorentität von entscheidender Bedeutung ist. Andererseits 
kommt es nach Überexpression von Pyk2 zu einer erhöhten Apoptoserate. Diese 
Ergebnisse identifizieren Pyk2 als neue, interessante therapeutische Zielstruktur für 
die Behandlung des kleinzelligen Lungenkarzinoms.  
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